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Ab st ract

This study evaluated existing In Vitro educational
materials in qualitative and quantitative parameters that
currently exist to educate potential clinicians of
nationally accredited Nuclear Medicine programs.
A review of over 3 00 articles, texts, and manuals
pertaining to In Vitro Nuclear Medicine procedures clearly
demonstrated that no In Vitro laboratory manual for
undergraduate students presently existed.
Every Nuclear Medicine program director in the United
States was surveyed.

They were asked for their overall

philosophy in terms of developing an In Vitro manual and
requested to evaluate the significance of 22 general
principles/concepts and 34 specific laboratory testing
procedures.
From the responses to the survey, an In Vitro Nuclear
Medicine manual was created and appended to the study.
manual consists of lecture and study material, chapter
reviews, and laboratory assignments and exercises.

The
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Chapter 1

THE PROBLEM

Introduction to the Problem
Health care, with all its interrelated manifestations,
is America's second largest industry, and it promises to
soon become number one.

Many diverse allied health

professionals, including those trained in Nuclear Medicine
technology, are needed to meet the every-changing needs of
this complex and rapidly developing segment of our economy.
To demonstrate this transition, the evolvement of all
allied health professions in this century has been nothing
short of phenomenal.

Around 1900, one of every three people

engaged in health care was a physician.

By 1967 the ratio

was reported to have changed to approximately one physician
to ten allied health personnel.
one in twenty (Kirby, p. 88).

The ratio now is closer to
The education of health

professionals has become a major concern to physicians,
administrators, and to the general public.
Historically, the education of nuclear medicine
education professionals took place in a hospital or in the
office of a doctor and was devoted primarily to the
practical aspects of patient care; theoretical or background
subjects were taught only as they were directly pertinent to
practice.

Under this arrangement, the cost was borne by
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hospitals or physicians.

In some cases, students received

pay or stipends (Master Plan for Radiologic Technology
Programs).
As complexity of health care increased and as nuclear
medicine technologists became responsible for more
sophisticated duties, hospitals and physicians recognized
that colleges and universities were the appropriate sites to
provide the background in science, mathematics, and
communications needed for new responsibilities, frequently
demanding new knowledge, inferential thinking, and decision
making.

Clinical education with its patient-contact

emphasis continued to be offered in hospitals and
practitioners' offices.

However, it has been found that

many subjects directly related to professional goals of the
students could often be more appropriately taught in
colleges and university classrooms or laboratories as in the
clinical facilities.

Thus the trend in Nuclear Medicine

education has moved toward universities and community
colleges from the hospital setting.
Over the past 2 5 years development of new
radiopharmaceuticals, gamma-ray cameras, advanced laboratory
techniques and equipment have dramatically changed the field
of nuclear medicine.

Consequently, the educational

requirements of those students training in the field have
constantly been revised to keep pace.
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Nuclear medicine technology applies the uses of tracer
amounts of radioactive materials to visualize and measure
regional function in living biologic systems.

This non-

invasive procedure has in the last two decades brought about
significant improvements in basic understanding of disease
processes as well as in medical diagnoses.
Throughout this tremendous growth in Nuclear Medicine,
two major areas have developed within the field: In Vitro
and In Vivo Nuclear Medicine.
In Vitro Nuclear Medicine may be define as that area of
nuclear medicine in which the results may be expressed in a
quantitative fashion.

These testing procedures are

performed in test tubes utilizing tracer amounts of
radioactive material.

In vitro laboratory procedures have

made possible direct assays of many physiologic substances
present in minuscule concentrations including hormonal,
blood, and drug levels.
In Vivo Nuclear Medicine has become a more dominant
component in the educational process of students.

This

aspect involves the use of gamma-ray cameras and scanners to
make interpretations on a qualitative (subjective) basis.
Though all educational Nuclear Medicine programs
require both In Vitro and In Vivo studies, most students do
not acquire adequate training in the In Vitro laboratory
areas.

A recent survey by the Joint Review Committee on

Accreditation of Nuclear Medicine Programs cites the need

for more emphasis on the in-vitro aspects of Nuclear
Medicine Technology (Nuclear Medicine Technology Essentials
Questionnaire).
They are approximately 7 0 accredited Nuclear Medicine
Technology Programs, either at the Associate of Science, or
Bachelor of Science level.

Many of these programs have had

problems in their recent accreditation applications due to
their lack' of In Vitro laboratory education.

Statement of the Problem
Although In Vitro Nuclear Medicine has been an integral
part of the education of students in the field, there is at
this time NO educational In Vitro laboratory manual for
training students.

This has been detrimental to the proper

training and understanding of Nuclear Medicine's graduating
students in regard to becoming qualified technologists.
There is a need to develop an In Vitro Nuclear Medicine
laboratory manual for the training of students in these
programs.

The purpose of this research was to identify

through documentation this need through a nationwide survey
of Nuclear Medicine program directors and review of the
literature in the field.

The research resulted in the

development and writing of an In Vitro laboratory manual to
meet the deficiencies cited.
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Questions
This research resulted in answers to the following
questions:
1.

Was there a need for an In Vitro laboratory
manual for students in Nuclear Medicine
Technology?

2.

What general principles/concepts of In Vitro
studies must be included in this student
manual?

3.

What were the types of testing methodologies
and procedures that must be included in a
comprehensive student In Vitro manual.

4.

What aspects of In Vitro Nuclear Medicine are
most commonly overlooked that need to be
taught to graduating Nuclear Medicine
students?

Significance of Study
Fundamentals of In Vitro Nuclear Medicine.

Prior to

I960, substances present in small amounts in blood and other
body fluids were exceedingly difficult to measure.

Until

then, chemical and bioassays of these substances, usually
hormones, were somewhat crude.

This led to considerable

inaccuracy in the measurement of such small amounts, and
results were difficult to reproduce in other laboratories.
In addition, rather large samples were usually needed for
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the determinations.

In 1960, Yalow and Berson reported a

method for the quantitative measurement of insulin based on
a new technique of competitive binding assay (Rothfeld,
1985, p. 91).

This was the beginning of numerous

breakthroughs in the use of In Vitro laboratory techniques
today.
Through the use of In Vitro Nuclear Medicine laboratory
procedures, biologically active molecules present in the
blood in concentrations as low as 1 part in 50 million can
be accurately measured.

Until recent years, the problem of

measuring these proteins and sorting them out as specific
entities from numerous basically similar molecules seemed
virtually impossible (Chard, p. 43-45).

Now the capability

for measuring clinically significant substances such as
hormones, drug levels, and blood components at levels of
picograms or nanograms per milliliter is available to almost
any In Vitro laboratory that has the appropriate equipment.
There have been numerous books, journals, and articles
written describing Nuclear Medicine In Vitro's capability
for precise and accurate measurement of tracers in clinical
diagnosis, pharmacology, and biochemistry, and in estimable
values in hematology and hormonal, metabolic, infectious,
and inflammatory disorders.

The impact of these Nuclear

Medicine methodologies on progress in medicine should not be
underestimated.

In Vitro laboratory advances have greatly

enhanced the field of Nuclear Medicine and its ability to
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diagnose minute amount of substances in the human blood
system.
Even though there is a sufficient quantity of material
on In Vitro laboratory procedures in the literature, there
is no definitive laboratory manual, text, or guide written
to meet the needs of Nuclear Medicine Technology students.
Many texts discussed in the literature review pertain to
theoretical constructs, while others devoted to practical
applications are written at a highly sophisticated level not
intended for undergraduate students.
On October 19, 1987, letters were written to a number
of highly regarded professionals in the field, requesting
their professional assessment of the need for a student In
Vitro laboratory ma n u a l .
One of these professionals, Sheila Rosenfeld (1987), a
member of the Joint Review Committee on Accreditation of
Nuclear Medicine Programs and Program Director of Nuclear
Medicine at St. Louis University, replied to this letter.
After discussing texts commonly used to teach In Vitro
studies in Nuclear Medicine programs, Rosenfeld states,

"I

personally feel that there is a definite need for a student
laboratory manual1
" (Ltr. , Nov., 1987).
Wynn Harrison,

Director of the Nuclear Medicine Program

at Weber State University in Utah writes,

"I have taught In

Vitro procedures for the past four years in the Weber State
College Nuclear Medicine Program, there has been no suitable
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textbook or laboratory material in this area.

It would be a

service to the profession to have such materials"

(Ltr.,

Dec., 1987).
Allen West, Director of the Nuclear Medicine Program at
the University of Alabama Birmingham writes, "It is a shame
that most programs cannot provide the necessary In Vitro
laboratory procedure due to the lack of quality text or
manuals to train students properly"

(Ltr., Dec., 1987).

Anthony Snow, Director of a San Francisco Hospital's
Nuclear Medicine Department writes, "Most students enter the
work force not sufficiently trained in In Vitro Nuclear
Medicine procedures, due to the lack of materials written at
the undergraduate level"

(Ltr., Sept., 1988).

Further telephone conversations with Henry Ernstal,
Director of the Society of Nuclear Medicine,; Virginia
Pappas, President of Technologist Section of the Society of
Nuclear Medicine; Craig Harris, Nuclear Medicine Program
Director at Duke University; and Marsha Boyd, Director of
Baptist Memorial Hospital and President of the Technologist
Section of the American Registry of Radiologist
Technologists; all reiterated the need for a student In
Vitro Nuclear Medicine laboratory manual.
A recent questionnaire sent to 1,122 registered Nuclear
Medicine technologists by the Joint Review Committee on
Nuclear Medicine Technology identified the fact that
graduating technologists were not receiving the proper
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educational requirements and did not receive sufficient
experiences in In Vitro laboratory procedures.
Therefore, the purpose of this research was to survey
all Accredited Nuclear Medicine Program Directors in order
to gather information pertinent to:
1.

Identifying the need for a student Nuclear
Medicine In Vitro laboratory manual,

2.

Identifying those aspects or concepts

that

must be included in a student manual, and
3.

Identifying the types of testing
methodologies and procedures that must be
included in a comprehensive student In Vitro
manual.

From the information gathered in the research and the
content analysis of the literature, a Student Nuclear
Medicine In Vitro Laboratory Manual to meet this need was
developed.

Premises
The first premise is that developing an In Vitro
student laboratory manual is desireable and in the best
interest of Nuclear Medicine Technology education.

In

support of this premise, the majority of Nuclear Medicine
program directors believe that a student manual is needed.
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The second premise is that a student manual can be
developed to meet the overall In Vitro needs of many diverse
educational Nuclear Medicine programs.
The third premise is that constructing a laboratory
manual was possible based on data collected.

Furthermore,

there was enough congruence between the directors of
accredited programs in their responses that an overall
consensus can be derived.
The fourth premise is that directors of accredited
programs are expert enough in the field of In Vitro
laboratory procedures to

make intelligent decisions

pertaining to its future

needs.

The last premise is

that a review of the literature

and

a content analysis of In Vitro material reveal a gap or a
need for a student In Vitro manual for prospective
graduating Nuclear Medicine Students.

Delimitations
The survey itself was delimited by the relatively small
number of accredited Nuclear Medicine programs in the United
States

(approximately 70).

This researcher made extensive

efforts to elicit responses from all universities/colleges
surveyed.
Another possible delimitation pertaining to the small
number of existing Nuclear Medicine Programs is that
extraneous variables may enter into the evaluation process.
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These include restrictions in different universities
pertaining to core requirements for graduation and the
attempt of some program directors to protect their existing
program and set In Vitro curriculum.

There may also be an

attempt by certain directors to hide their program's In
Vitro laboratory weaknesses and possibly deny the need for a
student manual.
Many Nuclear Medicine Program Directors may themselves
have limited backgrounds and work experiences in In Vitro
laboratory procedures.

Others may be removed from the

clinical setting by their current administrative duties and
have not kept pace with the changing In Vitro laboratory
field.
Finally, some universities may not employ a Nuclear
Medicine program director.

The dean or administrative head

of that sector were asked to assume the responsibility of
completing the survey.

This delimitation might impact the

number of questionnaires received and interpretations
expressed.

Method of Research
The first step in the study was to develop a
questionnaire based on content analysis of current
literature which provides information the researcher
desires.

Secondly, the field test of the questionnaire was

distributed to a small group of authorities in Nuclear
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Medicine.

Once the field test questionnaire was received,

the survey was revised accordingly.
The final questionnaire was distributed to all
accredited Nuclear Medicine Program Directors or their
representatives.

Follow-up contact was made until a

representative sample of the survey is attained.

Due to the

limited numbers in the study (70), every effort was made to
obtain a 100 percent response rate.
Next the questionnaire was categorized and the data
analyzed based on the respondent's answers.

Another content

analysis was developed based on the questionnaire.

This

information was then utilized to:
1.

Compare the assessments of Nuclear Medicine
program directors with the content analysis
of the current literature,

2.

Categorize through general principles
concepts and specific types of In Vitro
testing procedures seemed most essential to
students entering the field of Nuclear
Medicine, and

3.

Develop a student In Vitro laboratory manual
based on the overall needs indicated by the
review of the literature and the national
survey.
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Definition of Terms
AART.

The American Registry of Radiologic

Technologists.

This association develops policies and sets

standards for radiologic technologists.

It also provides a

written test of competence in the field of radiologist
technology.

This examination is nationally accepted.

Accreditation of Nuclear Medicine Program.

A formal

process in which a school applies for and has a site
visitation of their program by an Agency that has the
authority to evaluate the appropriateness of their studies.
Accuracy.

Closeness to true or real value.

Advanced Radiologic Technology.

Generally considered

more sophisticated forms of radiology, such as nuclear
medicine, C.T. scanning, nuclear magnetic resonance.
Affinity.

Strength (energy) of binding to the

receptor.
Analvte.

The patient sample.

Antigen fAb).

A protein formed as part of an

immunologic response to foreign substance.
Antigen fAg).

A substance capable of including

formation of antibodies.
Antiserum.
Avidity.

Measure of the strength of the bound Ag.

Measure of the strength of the bound Ag.

B.S.R.T. Program.
Technology.

Bachelor of Science, Radiologic

Usually upper-level curriculum only.
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CAHEA.

Committee of Allied Health Education and

Accreditation.
Competencies.

Specialized area in which individuals

are trained in radiological sciences.
Competitive Binding Assay.

A type of In Vitro testing

procedure that is commonly used to analyze blood components.
Controls.

May be a standard or any known concentration

c-f testing material that serves as a comparison between
successive test runs.
Cross Reactivity.

Similar structured Ag that interfere

with analysis of a given assay.
Equilibrium Saturation.

Competition between labeled

and unlabeled ligand is allowed to occur simultaneously
until equilibrium is reached between the ligand and the
binder.
Freud's Adjuvant.

An emulsifier that enhances the

immune response and allows for slow absorption into an
animal's system when producing antiserum.
Hapten.

A substance that is not immunogenic in itself

but becomes immunogenic when complexed with another
compound.
Hematocrit.
Immunogen.

Formed elements divided by whole blood.
A substance capable of inducing an immune

response.
Immunoqlobulins.

A group of serum proteins

(antibodies) that specifically bind the antigens.
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Inflammatory Disorders.

Reaction of the tissues to

injury; the essential process, regardless of causative
agent.
In Vitro Nuclear Medicine.

Testing procedures

performed in test tubes utilizing tracer amounts of
radioactive material.

Usually involves direct diagnostic

assays of physiologic substances present in minuscule
concentrations including hormonal, blood, and drug levels.
In Vivo Nuclear Medicine.

The use of gamma-ray cameras

and scanners to make interpretations on a qualitative basis.
Commonly referred to as scans such as bone, liver, brain
scans, etc.
JCAH.

Joint Commission on Accreditation of Hospitals.

This is the accrediting agency for all U.S. hospitals.
Joint Review Committee on Accreditation of Nuclear
Medicine Programs.

A committee that is granted its

authority by the Committee of Allied Health Education and
Accreditation, which grants accreditation to all Allied
Health programs.
Laboratory Manual.

A working guide to help an

individual understand the application of theory into a
practical nature.
Ligand.

The substance that is bound.

Milliliters.
Modalities.

10‘3 liters.
Various types of technical areas in

radiological sciences such as radiation therapy,
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radiography, nuclear medicine, ultrasound, and C.T.
scanning.
Nanoarams.

10'9 grams.

Non-invasive Procedures.

Diagnostic procedures that do

not cause harm or pain to the patient receiving it.
Non-Specific Binding.

When labeled Ag and Ag free

serum (without Ab's) are put into the same test tubes.
Nuclear Medicine Program Director.

The individual who

directs, supervises, and administrates the individual
Nuclear Medicine program.
Nuclear Medicine Technologist.

An individual who

performs diagnostic and therapeutic procedures utilizing
radiopharmaceuticals.
Picoarams.

10’12 grams.

Precision.

Degree of agreement of repeated measurement

of a quantity (usually expressed as coefficient of
variance).
Prototype Curriculum.

Course work designed to be

implemented in any radiological sciences program.
Quality Control.

Ensure that the results of assays are

reliable and representative of true concentration.
Radioimmunoassay.
receptor is an antibody.

Radioligand assay in which the
The use of radioactive tracers to

evaluate blood components, hormonal levels, or drug levels.
Radiographer.

One who is responsible for actually

performing the x-ray procedure on the patent.
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Radiologic Technologist.

A generic term to describe

any technologist that works in the field of radiology,
including radiographer, nuclear medicine, ultrasound,
radiation therapy, and C.T. scanning.
Rank Order.

A chronological listing from top to bottom

of certain items based on an assessed value.
Receptor.

A substance (protein) that specifically

binds a certain compound (ligand).
Sensitivity.

Minimum quantity detectable.

Society of Nuclear Medicine.

A national society of

physicians, scientists, and technologists whose desire is to
promote the field of Nuclear Medicine and maintain up-todate material.
Specific Activity.

Activity, usually expressed as

uci

mass.
Specific Gravity.

Materials’ weights are being

compared to that of water.
Specificity.

Capacity to discriminate antigens of

similar structure.
Standard.

A substance that is added to certain

reference tubes to serve as a yardstick for quantitation of
the contents.
Standard Curve.

A curve of dilutions of known amounts

of substance to which the unknown may be compared.
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Technical Education.

Those aspects of training

involving hands-on experience and less emphasis on
theoretical thought-provoking ideas.
Technologist Sections.

A group designed to meet the

group needs of technologists of a specific discipline.
Titer.

Measurement of antibody concentration— the

dilution of antiserum that will bind 50 percent of added
radioligand.

Organization of Study
In order to develop a strategy which ultimately results
in adding to the body of knowledge in Nuclear Medicine
Technology education, this study must first seriously
examine the literature pertinent to the field.

Secondly,

develop a method of collecting relevant information related
to the researcher's stated problem.

Thirdly, analyze data

and synthesize results in order to bring about meaningful
change in Nuclear Medicine In Vitro Laboratory education.
A thorough review of the literature includes historical
perspective of Nuclear Medicine education, its growth,
development, recent trends, and all literature pertinent to
the development of a Nuclear Medicine In Vitro Laboratory
manual.

It was vitally important to establish the need for

this study by discussing previously related endeavors and
other research which may be peripheral or corroborated to
this study's eventual findings.

Based on the supportive
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literature findings, a well-conceived questionnaire was
developed which provided research information desired.
This survey questionnaire was field-tested for
reliability and validity by sending it to five established
experts in the field of Nuclear Medicine,

identified by the

Society of Nuclear Medicine, for their input and
evaluations.

When returned to the researcher, questions

were reconstructed to conform with the group's criticisms.
Those who do not respond were contacted by follow-up.
The results were analyzed and the data used to develop
an In Vitro Laboratory Manual identified as being needed in
Nuclear Medicine Technology education.

This laboratory

manual was based on the information gathered in the national
survey and currently lacking in the literature.
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Chapter 2

REVIEW OF THE LITERATURE

Development of Nuclear Medicine Technology Education
This chapter provides a literature review of many
important aspects within the field of Nuclear Medicine.

In

order to develop an appreciation for Nuclear Medicine, three
major areas are discussed and analyzed.

These include:

Nuclear Medicine Technology Education, an overview of
historical changes in Nuclear Medicine, and a content
analysis of In Vitro Nuclear Medicine literature.
The first section concentrates on the development of
Nuclear Medicine education.

This discipline emerged through

Allied Health concept which emphasizes the training,
certification, and how professional practices of specialized
fields developed.

Other aspects contributing to Nuclear

Medicine education including task analysis, credentializing,
movement toward baccalaureate-level curriculums, Nuclear
Medicine Associations, and advancement in technology.
The chapter continues with a fairly in-depth look at
the historical development of the field of Nuclear Medicine.
The discoveries and inventions that revolutionized our
society's concept of diagnostic and therapeutic treatment of
people using radioactive material beginning in the early
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1920s to the late 1980s.

Special emphasis is given to the

development of In Vitro Nuclear Medicine, including
radioimmunoassay principles.
The final thrust of the review of the literature
centers on the content analysis of over 300 texts, articles,
and manuals written on the subject of In Vitro Laboratory
Procedures.

The tables that were developed characterize

these written works into the level of material, type of
material, and whether they provide laboratory exercises.

Development of the Allied Health Concept.
For hundreds of years, medicine was practiced in
conjunction with religion.

During this time, many health-

related decisions were based upon faith and superstition.
With the Twentieth Century, there began a new era in
medicine.

The turn of the century marked the science age.

Soon, the superstitions which served as the basis for
medicine were replaced by scientifically founded facts.
The advent of new technological discoveries led to a
rapid increase in the demands for health care services.
One-to-one doctor-patient care became a thing of the past.
These new technologies became so complex that their proper
operation required specially trained personnel.

As these

health technologies began to develop individual autonomies,
the people within the specific fields began to form their
own professional societies.
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The establishment of technological societies resulted
in the identification of specific education requirements for
each technology.

This led to the process of accrediting

educational institutions for each respective health field by
the American Medical Association (AMA).

Currently AMA has

defined 23 allied health fields or professions based
principally on technology (Amer. Society of Radiologic
Technologists, 1972, p. 1).

These include the following:

Assistant to the Primary Care Physician
Cytotechnologist
Electroencephalographic Technician
Electroencephalographic Technologist
Histologic Technician
Medical Assistant
Medical Assistant in Pediatrics
Medical Laboratory Technician (Associate Degree)
Medical Laboratory Technician (Certificate)
Medical Records Administration
Medical Records Technician
Nuclear Medicine Technologist
Occupational Therapist
Operating Room Technician
Ophthalmic Medical Assistant
Physical Therapist
Radiation Therapy Technologist
Radiologic Technologist
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Respiratory Therapist
Respiratory Therapy Technician
Specialist in Blood Bank Technology
Surgeon's Assistant
Each profession is autonomous in matters of training,
certifying, and setting standards of professional practice.
Although the arrival of the scientific age played an
important role in the development of allied health
professions, there were also other factors which assisted in
its development.

These factors include the Allied Health

Act of 1966; pressures from professional societies;
increases in the number of community colleges, and their
attempt to meet the needs of the community; and the
establishment of schools of health-related sciences (Amer.
Society of Technologists,

1972, p. 1).

Use of Task Analysis for Program Development in Allied
Health, such as Nuclear Medicine Technology
Professional allied health societies evolved for a
number of reasons.

Some of the reasons were to prevent

incompetent people from practicing, to standardize the
training of personnel, to reduce the competition in the job
market, and to protect technologists' positions.

One major

outcome of the professional societies was the establishment
of registries and/or certification.
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Originally, professional societies were responsible for
the development and implementation of registries and/or
standards of certification.

As time progressed, the

American Medical Association (AMA) became involved in
accrediting allied health education programs.

Eventually,

in order for an individual to become eligible to write a
specific registry or qualify for certification, allied
health personnel had to graduate from a school accredited by
the AMA.

Currently, school accreditation is contingent upon

the institution complying with the "essentials" or
guidelines established by the AMA for allied health (AMA,
1978).

As technology continues to advance, the list

"essentials" continues to increase.
In 1970-71, the Association of Schools of Allied Health
Professions and the AMA sponsored a "Study of Accreditation
of Selected Health Education Programs"
238-240).

(JAMA, 1971, 218, p.

The objective of the study was to evaluate the

current accreditation process for various allied health
fields.

The results of the study demonstrated that

accrediting agencies, including the AMA, require a multitude
of accreditation criteria.

The criteria include a variety

of specific courses, course credits in terms of credit
hours, and hours of supervised clinical practice.
In essence, the committee defined many of these
criteria as meaningless.

As a result, the theory of

"essentials" has been scrutinized by Ruhe and Kuhli, staff
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members of the AMA.

They perceive that the future criteria

of allied health was stated in meaningful and measurable
behavioral terms.
The World Health Organization supports the concept of
defining behavioral objectives and has gone on record as
stating tat the failure to define goals is one reason which
has prevented significant advances in the quality of health
care (McBride, 1977, p. 14).
One method of defining goals is through task analysis.
Task analysis involves the identification of tasks
associated with a specific job.

There are several

approaches that may be employed to identify tasks.

One

approach is to have a group of "experts" in a particular
field list the tasks associated with a job.

A second method

is to survey the population involved in performing the
tasks, and allow the population to identify the relevant
tasks.

Probably the best method of task identification is

to allow the "experts" to identify the tasks, they survey
the population that performs the tasks to confirm or alter
the task list established by the "experts".
The process of task analysis should include the
identification of the frequency the task is performed, the
amount of knowledge required to perform the task, and the
importance of the task.

Identification of tasks in

accordance with their frequency, knowledge, and importance
enables the development of an educational program.

For
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example, the tasks identified as requiring basic knowledge
would represent the basic or elementary program course work
and the tasks identified as requiring advanced knowledge
would represent the advanced program course work.
The development of specific course content and unit
objectives would require a further analysis of the task.
The further analysis of the task would serve to identify the
"steps" or "work activities" which would result in producing
the identifiable task output (Bosissoneau, 1983, p. 155).
Because of the current public concern over quality
health care, the state and federal governments have begun to
mandate that goals and objectives be established for allied
health.

Some states require that allied health personnel

obtain licenses in order to practice their respective
specialty.

This is of particular importance in Nuclear

Medicine in which technologists prepare and administer
radioactive materials to patients.

Proponents of mandating

minimum educational standards at the federal level are
Senator Edward Kennedy (National Health Insurance Bill), the
National Advisory Commission of Health Manpower, and the
Secretary's Commission of Medical Practice.
The actions of these proponents indicate that in order
for allied health personnel to have a voice in their own
futures, it is important that the members of the allied
health professions actively pursue the defining of their
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goals and purposes in educating future individuals in their
fields.

Credentialina in Nuclear Medicine Technology
Credentialing is a term used to describe how graduates
of accredited Nuclear Medicine Programs become eligible to
take a national registry in their chosen fields.

A number

of national organizations and committees helped to develop,
coordinate, and implement what is today a national
credentialing examination accepted throughout the country.
Its brief history began only 25 years ago.
In the early 1960s, the growing importance of
radioisotopes as diagnostic and therapeutic tools of
radiology and a correspondent need to develop and identify
individuals with the specialized skills necessary to assist
physicians in the practice of Nuclear Medicine became
apparent to the Board of Trustees of The American Registry
of Radiologic Technologists (ARRT).

Consequently,

in 1962,

the Board moved to begin the examination and certification
of radioisotope technologists the following year.
Recognizing the need for standardization of education in the
new allied health specialty, the ARRT also proposed to the
Board of Chancellors of the American College of Radiology
(ACR) that the Council on Education of the American Medical
Association be requested to consider the establishment of
minimal educational standards for a one-year program for
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radioisotope technologists.

An interim curriculum was

provided by the American Society of Radiologic Technologists
(ASRT) as a basis for the first examination which was held
on November 2, 1963.

The 148 technologists who passed that

examination were certified on December 1, 1963, to become
this country's first credentialed Nuclear Medicine
Technology Specialists

(Lam, 1980, p.52).

The following year, the American Society of Clinical
Pathologists (ASCP) in collaboration with the American
Society of Medical Technologists (ASMT)

implemented a

program to examine and certify medical technologists in its
nuclear medicine subspecialty.

Subsequently, both the

ASCP/ASMT and the ARRT organizations continued to separately
examine and certify nuclear medicine technologists.
Although there was some overlap, the ARRT generally
attracted candidates who had worked and trained under
radiology with emphasis on imaging procedures, whereas the
ASCP/ASMT operated on a smaller scale primarily serving
candidates with medical laboratory training and experience
emphasizing wet laboratory procedures.

However, with the

advent of formalized education in Nuclear Medicine
technology, these differences gradually became less
pronounced.
In 1977, the ARRT and ASCP/ASMT registries cooperated
as members of an ad hoc committee to draft essentials for
educational programs in Nuclear Medicine technology.

The
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work of that committee led to the approval of the first
"Essentials of an Accredited Education Program for the
Nuclear Medicine Technologists" by the AMA House of
Delegates in 1979.

Included in the "Essentials" was a

provision for a "Board of Schools" to serve as a review body
for educational programs in Nuclear Medicine technology.
The "Board of Schools" later became the Joint Review
Committee on Educational Programs in Nuclear Medicine
Technology.
As a step toward further cooperation between
organizations in 1979, the ASRT Board of Directors proposed
that the ARRT establish reciprocity of certification with
ASCP/ASMT Board of Registry.

Subsequently, the ARRT Board

of Trustees authorized correspondence with other parties
affected by the ASRT proposal and appointed representatives
to develop a mutual exchange of information with the ASCP,
ASMT, and the Society of Nuclear Medicine (Seibert, 1981, p.
346) .
In March, 1981, the president of the ARRT met in
Washington, DC, with representatives of the Registry of
Medical Technologists (ASCP), the American Society of
Medical Technologists and the Technologist Section of the
Society of Nuclear Medicine to explore the possibility of
forming a conjoint registry for Nuclear Medicine technology.
A task group was formed "to prepare a draft of guidelines
for training and certification in nuclear medicine
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technology" to be considered at the annual meeting of the
Society of Nuclear Medicine (Seibert, 1981, p. 52).
Later in 1981, representatives of the Joint Review
Committee on Educational Programs in Nuclear Medicine
Technology met with ARRT representatives at the Registry
office in Minneapolis over a mutual concern with
fragmentation of certification in nuclear medicine
technology.

Eligibility requirements, examination

questions, and administrative procedures of the ARRT and
ASCP/ASMT examinations were compared and discussed at
length.

It was agreed that it would be desirable to have a

common examination in Nuclear Medicine technology.

It was

the consensus of those present that a conjoint committee
should be established to make up future examinations using a
common pool of questions.
Finally, it was concluded that the organizations should
work toward a single certificate of registration in nuclear
medicine technology with appropriate notations of interested
parties to the certification (Seibert, 1981, p. 52).
Today, through the combined efforts of these
organizations, the examination and credentialing of
certified nuclear medicine technologists is accepted as
proof of qualifications in all 50 states and many countries
abroad.
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Recent Trends in Nuclear Medicine Technology Education
The Movement Toward Baccalaureate Level Curriculum for
Nuclear Medicine Programs.

Nuclear medicine is generally

credited with being the second largest radiological science.
It has significantly changed its curricula from two-year
programs to four-year baccalaureate-level degrees.
There is a little doubt that the baccalaureate degree
is valuable both to an individual and to the profession to
which he belongs.

In a study of allied health graduates,

Broski and Ballinger found that those from baccalaureate
programs enjoyed higher levels of professional
responsibilities, higher salaries, better geographic
mobility, and greater job satisfaction than their associate
degree counterparts (Broski, 1980, p. 51-485) .
In that study, it was also demonstrated that
baccalaureate decreed Nuclear Medicine graduates are
assuming responsible positions with relatively high
frequency.

The positions assumed most frequently by

graduates in that survey were in educational settings,
administration, and in advanced or alternate imaging
modalities.

These findings confirm what has been revealed

by a survey of Nuclear Medicine technology program directors
in 1975, that there was a need for advanced training in
specialized areas, administration, and educational
techniques.
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Growth in advanced Nuclear Medicine technology
education has been affected to a large extent by the
preponderance of the 24-month curriculum.

In 1966, programs

of two years in duration proliferated as a result of the
ARRT policy requiring 24 months of formal education for
examination eligibility.

However, in recent years,

educators have questioned whether the two-year curriculum
can be the primary mode of meeting traditional as well as
specialty personnel requirements in Nuclear Medicine
technology.

For example, in 1977, as a result of an

international survey that analyzed the length of educational
programs in Nuclear Medicine technology in 25 countries,
Ohnysty (1978) found that basic curricula of two years in
duration were in the minority, and he observed that "Based
on the development of new imaging procedures, laboratory
tests, variations in equipment in Nuclear Medicine and
increased responsibilities of the technologists, two-year
programs have proven to be inadequate to train the caliber
of technologist necessary in current practice"

(p, 448).

Many factors have influenced the education of Nuclear
Medicine technologists to higher levels of education.

In

the past ten years, the shift in accredited Nuclear Medicine
programs nationwide has been toward increased higher levels
of educational qualifications and a reduction in the overall
number of programs that provide training.

Some of this

reduction has been due in part to lack of adequate In Vitro

33
laboratory education.

In 1974, the total number of

accredited Nuclear Medicine programs in the United States
was 177 with only 28 of those requiring two years or more to
complete.

In 1984, a marked reduction in the number of

overall programs is noted at 110, with 70 of these programs
now providing at least two years or more to complete.

The

trend has definitely evolved toward a higher level of
education, requiring background courses that allow for a
more sophisticated, career-minded Nuclear Medicine graduate.
The three most important phenomena that have helped to
advance educational levels higher are: Nuclear Medicine
technologist associations, advancement in technology, and
national accreditation agencies.

It is important to examine

each individually to see how they have influenced Nuclear
Medicine education.

Nuclear Medicine Associations
The development of strong state Nuclear Medicine
associations have helped foster higher levels of
qualifications for employment in radiology and have mandated
higher levels of education in certain states.

Such

associations have been highly correlated to states that
provide highly qualified technologists, the highest level of
education and generally demand the highest salaries
nationwide.

States such as California and Florida are

excellent examples.

Florida has laws regarding personnel
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licensure employees that use radioactive materials and
equipment.

Furthermore, it has state competency

examinations in many different specialty classifications—
such as radioassay, technician, technologist, and
radiological administrator.

The prerequisites for taking

examinations include educational requirements that enhance
the movement toward higher levels of sophistication of
knowledge and understanding of new modalities in theoretical
terms in order to be employed at that respective position.
Strong, unified state organizations have used their
political clout to muster the energy to convince lawmakers
that only specially-trained individuals should be allowed to
use radioactive materials for diagnostic and therapeutic
means.

This has had the effect of elevating radiological

education requirements and fostering higher levels of
training and specialization.

Advances in Technology
No one can deny the massive and impressive advances in
health care technology over the past few decades.
Individuals that enter the medical field need to be trained
on highly sophisticated, diverse computerized systems of
diagnostic and therapeutic medicine.

Students of Nuclear

Medicine sciences are entering a dynamically growing
increased specialized field including digital subtraction
imaging, nuclear cardiology, radioimmunoassay, and nuclear

medicine resonance.

Each of these testing procedures need

specific didactic and clinical educational experiences
associated with them.

further these students must possess

basic understanding in chemistry, biology, physics, and
computers.

These advances in Nuclear Medicine technology

have pushed the emphasis of education to higher levels in
which individuals would be required to have many preliminary
courses in order to fully comprehend these new modalities.

National Accreditation Agencies
The Joint Commission on Accreditation for Allied Health
programs has helped foster standards of educational
proficiency.

JCAH has placed great emphasis on updating

educational curricula and providing students with
theoretical and practical experiences that assure quality in
job performance.
Ficken, a medical physician with over 15 years as a
member of Nuclear Medicine programs joint review inspection
teams, believes that such programs need to be placed at
four-year level universities.

He reasons that there is

increased intellectual demands on technologists and that a
university setting can provide overall better facilities,
more qualified teachers, and prerequisite courses needed in
order for students to fully comprehend new advances in
Nuclear Medicine technology (1985).

These comments and

actions by JCAH have helped push the education pendulum back
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toward higher educational levels for potential Nuclear
Medicine technologists.

History of the Field of Nuclear Medicine
Before the Early 1920s, discoveries of Roentgen,
Betquerel, Curie, and Rutherford began to revolutionize the
concept of radioactivity and its biological effects and
potential usefulness.

But not until 1923, when Hevesy

employed a natural radioisotope of lead to investigate the
metabolism of lead in plants was the field of Nuclear
Medicine born.
When Hevesy and Paneth used radioactive "indicators,"
they relied mainly on the gold-leaf electroscope.
Measurement of the tracer's radioactivity provided
thousandfold increases of sensitivity and accuracy over
existing chemical assays, which Hevesy exploited 10 years
later in following the movement of a tracer in living
systems.

By measuring the radiolead accumulated in various

portions of the plant, he was able to quantify the uptake of
lead in them.

So sensitive was his gold-leaf electroscope

that he could use the radiolead in quantities so minuscule
as to avoid the toxic effect of lead, an important basic
principle in tracer methodology.

This first use of a

"radioindicator" in biomedicine presaged things to come
(Aebersold, 1956, p. 1027).
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The foundation and basic rationale of much of nuclear
medicine stem from Hevesy's realization that the state of
radioactivity of radioelements in no way affects their
biochemical properties.

More than anyone, Hevesy deserves

the designation "grandfather of Nuclear Medicine."

He

visualized that a radioactive atom might be used as a
"representative" tracer of stable atoms of the same element
whenever and wherever it accompanied in biologic systems.
His studies in this "classical period" were limited, of
course, to the few available naturally radioactive
materials.

These were comprised of radioisotopes of

uranium, thorium, radium, polonium, bismuth, and leadelements that were not of great biologic importance.
Radium, in its transmutations into radioactive isotopes of
bismuth and lead, he found most feasible for developing his
tracer method of analysis (Aebersold, 1956, 1027).
Blumgart and co-workers conducted the first clinical
studies with radioactive tracers in the '20s in Boston.
They injected solutions of radium C(214Bi) into one arm and,
with a cloud chamber, detected the appearance of highly
penetrating gamma rays in the other.
the "velocity of the circulation."

Their aim was to study
In these pioneering

studies, the mean normal arm-to-arm circulation time was 18
seconds, which was prolonged in patients with heart disease.
Using a forerunner of the Geiger counter with platinum
needle electrodes over the right atrium and left elbow, they
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were able subsequently to calculate pulmonary circulation
time and pulmonary blood volume and to study effects on them
of various heart and lung lesions, thyroid disorders,
anemia, polycythemia, and drugs.

Such classical studies

illustrate that minds and method were fully prepared to
exploit the eventual appearance of radioactive isotopes of
physiologic elements (Moss, Dalrymple, & Boyd, 1976, p. 48).
The growing understanding of the nature of the atom and
of the behavior of its radiations made it a practical
certainty that there would soon emerge a means to produce
radioactive tracers of many elements.

Among the most

important was the discovery by Rutherford,

in 1919, that the

structure of matter could be changed by bombarding elements
with alpha particles from radium.
In the 193 0s, the development by Lawrence of the
cyclotron made it possible to produce radioactive materials.
This was the beginning of the first uses of artificial
radioisotopes employed for therapeutic and diagnostic value
in man.
The metabolism of phosphorus in animals and in man
quickly was delineated further in a series of studies made
possible by the availability of large amounts of the
cyclotron-produced tracer 32P.

Hevesy, Chiewitz, Aten,

Chaikoff, Cohn, Cook, Greenberg, Hahn, Jones, Lawrence,
Perlman, and Scott were among the investigators pursuing
this trail.

The great efficiency with which the body
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absorbed inorganic phosphorus and preferentially utilized it
in hematopoietic tissues and in rapidly multiplying cells,
such as those associated with malignancies, was observed.
John Lawrence was the first to seize upon the therapeutic
implications of these findings, and on Christmas Eve of
1936, he first used 32P as phosphate in the treatment of
leukemia, thus inaugurating the therapeutic employment of
artificial radioisotopes (Chiewitz & Hevesy, 1935, p. 754).
In the
thyroid and

1940s, relative uptake of radioiodine in the
in distant metastases was

being portrayed by a

prototype "scanner" consisting of a shielded directionalized
Geiger counter used for manual "point-by-point counting"
over areas of interest.

With careful and laborious

charting, a

map could be constructed of the distribution of

uptake, and

isocount lines drawn.

It

first occurred to

Benedict Cassen, a physicist, that the scanning pattern
could be refined mechanically by means of a motorized dector
moving in a raster fashion over the area to be charted.

The

output of the detector then could be used to activate a
moving pen, which could thus depict with ink dots an "image"
of the relative numbers of gamma rays emanating from the
area so scanned.
In the development of this important approach, several
problems had to be solved.

At the dector end, the Geiger

counter had serious deficiencies.

It was notoriously

inefficient in its reactions with the penetrating gamma
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photons used for external detection, and this shortcoming
necessitated large doses of 131I.

It was necessary to find a

detector more sensitive to gamma radiation to make it
possible to use smaller doses of this radioisotope for
diagnostic purposes (Hamilton, 1942, p. 541).
The answer came from the field of crystallography.
Certain crystals of high density and transparency have the
power to absorb the gamma photon and produce a flash of
light called a scintillation.

Fluorescent phenomena had

been known for some time, and indeed, Rutherford had relied
on fluorescence in many of his early studies of particles.
In 1947, Kallmann devised a scintillation detector by
utilizing organic crystals of naphthalene attached to the
face of multiplier phototube, which had the capacity to
transduce the flashes of light into amplified surges of
electricity.

Kallmann's first detector, crude by present

standards, still was much more efficient for gamma rays than
the Geiger counter tube (Anger, 1958, p. 27).
In the 1950s, Cassen developed the Gamma Scanner.
Cassen's first rectilinear scanner in 1951 used inorganic
calcium tungstate detector crystals, which were even much
more efficient than naphthalene.

Detector efficiency was

improved further by Hofstadter when he activated highdensity sodium iodide crystals by adding small amounts qf
thallium.

An especial advantage of these crystals is that

they may be grown from molten salt into the enormous sizes
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currently being used in Nuclear Medicine.

Not only do they

interact highly efficiently with gamma rays to give large
scintillations but the sizes of many of these light flashes
are proportional to the energy of the absorbed gamma photon.
Consequently, the voltage pulses triggered by the multiplier
phototube may be sorted electronically to discriminate among
gamma ray emissions of various energies to select only the
ones of primary interest.

This facilitates the localization

of sources of direct emissions because one may "turn out"
irrelevant off-axis, low-energy secondary photons resulting
from degrading scatter of some of the primary gamma rays
within the patient, improved images of the spatial
distribution are the result (Anger, 1958, p. 27).
Cassen's scanning machine displayed the results as a
picture by applying the amplified detector's pulse to a pen
that contacted the paper by a carrying arm that moved in
parallel with the directionalized scintillation detector.
Response of the pen involved considerable mechanical inertia
and the writing process was subject to jamming.
In the early 1960s, Hal Anger, embodying in a single
person a "convergence" of nuclear physics, electronics,
optics, and information handling, pursued a completely
different path at the Donner Laboratory of Medical Physics
of the Lawrence Berkeley Laboratory.

He sought a means of

utilizing gamma rays to build an image rapidly, camera-wise,
in contrast with one built up over long intervals of time
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with a moving scanner based on a raster principle.

Gamma

rays cannot be refracted with lenses, like light, or bent in
magnetic fields, like charged particles and thereby
"focused" (Anger, 1963, p. 56).
Besides Cassen and Anger, many other developers and
manufacturers added to the body of knowledge and improved
the scintillation camera.
When the camera finally caught on, and it became
readily available commercially in 19 64, it fairly
"revolutionized the practice of clinical Nuclear Medicine."
It accentuated the significance of such radioisotopes as 123I
and 99mTc, whose low-particulate and gamma-ray emissions are
so appropriate for camera use (Wagner, 1978, p. 121).
The development of the gamma-ray camera included
multihole collimators, ever larger sodium iodide crystals,
the use of larger banks of improved detector phototubes,
tomographic applications, and highly sophisticated linkages
with computers that has resulted in an explosion in new
measurement technology.
Through this technology of gamma cameras and scanners
developed in to what is referred to as In Vivo Nuclear
Medicine.

In the 1970s and 1980s, the ability to detect and

accurately diagnose different diseases in man continued
through the improvement of gamma camera.
Increases crystal diameter in gamma cameras has
permitted a larger field of view in camera application; it
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has also improved some aspects of scanning by allowing the
geometric efficiency of the detector to be increases.

With

focused collimators, more emissions from a source of
radioactivity can be collected on a broader crystal surface.
In effect, this raises sensitivity to nuclear emissions much
as a widened lens aperture increases the sensitivity to
light in a camera.

More emissions are collected per unit of

time; thus, shorter exposures are required for detecting and
recording enough events to form a statistically significant
image, and the speed with which the scanning head can move
on its path may be increased significantly.

A crystal with

a diameter of 5 inches provides roughly a threefold gain,
and an 8-inch crystal an electric circuit can be made that
will accept only desired pulse amplitudes— those
characteristic of direct, unscattered gamma rays from the
specific radioisotope used.

This process is called pulse-

height selection.
The result is a scintillation counter with energy
specificity, or, in other words, a counter that
discriminates against gamma rays from radioactive isotopes
of different energy.

It produces electrical pulses that can

be quantified in terms of counts per second, which is
important in estimating the amount of the radioactive tracer
at different sites within the body (Wagner, 1978, p. 121).
Two other factors need to be discussed in relate to the
growth of both In Vivo and In Vitro Nuclear Medicine in the
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1970s and 1980s.

They are computers and

radiopharmaceuticals.
The technology of Nuclear Medicine permits direct
measurements to be made of body processes in man that in the
past could only be examined in experimental animals.

Such

study often produces large amounts of data, often in the
form of quantities of radioactivity distributed in specific
sites within the body, often changing over a period of time.
The instrumentation utilized presents the data either as
quantities that can be plotted and analyzed or as image
analogues that allow the clinician to visualize the
distribution of radioactive tracer materials within an organ
or lesion (Natarajan, 1969, p. 823).

the full diagnostic

potential of nuclear data cannot be realized without
computer assistance.
Today, throughout the nation there are very few Nuclear
Medicine departments that do not fully utilize a dedicated
Nuclear Medicine computer system.

A highly trained

technologist must set up the computer with proper perimeters
and carefully analyze the image received in order to
evaluate the lesion correctly.
In order to study the intrinsic contrast between the
amount of radioactivity within a lesion as compared with
that in the surrounding tissue, it is frequently necessary
to use contrast enhancement to make the lesion readily
visible.

The technologist adjust the contrast in much the
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same manner as he would with a television set.

Should he

adjust for high contrast, he achieves a dramatic gross
differentiation between area of activity, but possible
important subtleties in the blacked-out or bleached-out
areas are lost to him.

In short, he makes a deliberate

decision to exclude certain data that the machine is capable
of providing.

Should he adjust for low contrast over a wide

range of values, he runs the risk of overlooking
diagnostically important variations that greater contrast in
narrower ranges would show him.

Although remarkable in

capacity for spatial resolution, the human eye and brain are
notoriously poor in memory and ability to quantify,
precisely those attributes in which computers excel

(Anger,

1983).
The second major factor in the development of Nuclear
Medicine is radiopharmaceuticals.

During the past 2 5 years,

clinical applications of radioactive materials have become a
major branch of medicine.

The growth rate of such

applications is still progressing exponentially and is now
estimated at from 2 5 to 4 0 percent annually, as measured in
terms of persons involved in these applications and of the
industry developed to support them.

Already, most hospitals

contain or are developing a Nuclear Medicine facility.
While nuclear procedures may never be available in every
physician's office, there is scarcely a practitioner in any
field whose understanding of physiology and pathophysiology
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is not increases through the application of radioisotopes to
the study of man (Anger, 1983).
The development of both the nuclear reactor and the
cyclotron has allowed for the inexpensive production of
radiopharmaceuticals for medical use.
The nuclear reactor generates power through controlled
nuclear fission which introduced a new dimension into the
production of artificial radioisotopes.

It was appreciated

that the nuclear reactions occurring in a nuclear reactor
result in a high flux of neutrons that could be used for the
generation of radioisotopes.

Almost any material could be

lowered into the reactor and subjected to neuron
bombardment, producing "neutron-excess" radioisotopes
(MacRae, 1974, p. 497)).
The cyclotron utilized the concepts developed at
Lawrence Laboratories of particle acceleration to provide
radionuclides.

In cyclotron, the particles are repeatedly

accelerated through intermediate voltages to achieve high
energy.

Protons are commonly used as a bombarding material.

It has the advantage over a nuclear reactor in providing a
wide variety of radionuclides.

Another advantage is that it

is capable of producing certain useful radionuclides,
preliminary short lived, that are not produced in
significant quantities in nuclear reactors.

Development of In Vitro Nuclear Medicine
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Nuclear Medicine's capacity for precise and accurate
measurement of tracers has made possible a variety of
laboratory assays of great importance in clinical diagnosis,
pharmacology, biochemistry, and many other fields.

The

studies of blood ferrokinetics, volume determinations, and
vitamin B-12 absorption have been of inestimable value in
hematology.

Other radioassays have sharpened diagnosis in a

host of hormonal, metabolic, infectious and inflammatory
disorders.

All of these testing procedures that utilize

tracer amount of radioactive material in test tube sampling
analysis have become commonly referred to as either In Vitro
Nuclear Medicine or Radioimmunoassay.
Radioimmunoassay is a term that describes the use of
radioactive tracers to assay or analysis of an unknown
quantity.

Radioimmunoassay (RIA) came into being not by

directed design but as a fallout from what might be
considered an unrelated study.

Prompted by the suggestion

of I. Arthur Mirsky that maturity-onset diabetes might not
be due to an absolute deficiency of insulin secretion but
rather to its abnormally rapid degradation by an enzyme
which Mirsky called insulinase (Thorell, 1984, p. 4),
Solomon A. Berson attempted to study the metabolism of 131iinsulin following intravenous administration to diabetic and
non-diabetic subjects (Thorell, 1984, p. 4).

He observed a

slower rate of disappearance of the 131I-insulin from the
plasma of insulin-treated subjects than from the plasma of
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untreated subjects.

He postulated that the slower

disappearance was a consequence of the binding of labeled
insulin to antibodies that had developed in response to
treatment with foreign proteins— i.e., animal insulins.
The use of radioisotopic techniques for studying the
primary reaction of antigen with antibody and analyzing
soluble antigen-antibody complexes initiated a revolution in
theoretical immunology, and it is now generally appreciated
that peptides as small as vasopressin and oxytocin are
antigenic in some species and the equilibrium constants for
the antigen-antibody reaction can be as great as 10u L/mol.
(Rothfeld, 1985, p. 14).

Radioimmunoassay Principle
The principle of RIA is quite simple.

The

concentration of the unknown, unlabeled antigen is obtained
by comparing its inhibitory effect on the binding of
radioactively labeled antigen to specific antibody with the
inhibitory effect of known standards.

It should be

appreciated that there is no requirement for standards and
unknowns to be identical chemically or to have identical
biologic behavior.

A properly validated assay is one in

which the concentration in the unknown sample is independent
of the dilution at which it is assayed.

As described later,

some assays have proven to be properly validated due to lack
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of immunologic identity between standards and the sample
whose concentration is to be determined.
The RIA principle need not be limited to immune systems
but has been extended to other systems in which, in place of
the specific antibody, there is a specific reactor of
binding substance.

Herbert and associates (Herbert, et a l ,

1959, p. 433; 1960, p. 160) first demonstrated the
applicability of competitive radioassay to the measurement
of vitamin B12 in a liver receptor assay using 60Co-vitamin
B12 and intrinsic factor as the binding substance.

However,

it remained for Rothenberg (1961, p. 45) laboratory and
Ekins (1960, p. 453) to develop assays for serum vitamin B12
using this principle.

Ekins and later Murphy (1964, p. 679)

employed thyroxine binding globulin as the specific reactor
for the measurement of serum thyroxine.
In the 1950s, when bioassay procedures were in the
forefront, the first presentation of the potential of
hormonal measurements by RIA went virtually unnoticed (Yalow
& Berson, 1960, p. 1157).

Somewhat more interest was

generated by the demonstration of the practical application
of RIA to the measurement of plasma insulin in man.

It

became evident that the sensitivity and simplicity of RIA
permitted ready assay of hundreds of plasma samples, each as
small as a fraction of a milliliter.

It made possible

measurement not only of single blood samples (as had been
performed on occasion with In Vivo bioassay) but also of
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multiple samples, thus permitting study of dynamic
alterations in circulating insulin levels in response to
physiologic stimuli.
In the 1960s, results of numerous studies were
consistent with the assumption that immunologic activity
reflected biologic activity and that the behavior of
endogenous hormone in plasma resembled that of exogenous
purified hormone added to plasma.

Thus, plasma ACTH

paralleled plasma cortisol throughout the day, responded
appropriately to a variety of stressful stimuli, was
elevated in patients with adrenal insufficiency not
receiving steroids and was suppressed by steroid therapy,
etc (Yalow & Berson, 1960, p. 1157).

There were many

similar studies with other peptide hormones measured by RIA.
RIA was initially employed primarily for the assay of
peptide hormones since its exquisite sensitivity was
required to permit their measurement in plasma in the
unstimulated state in which the concentrations may range
from 10 13M to 10'1°M.

However, the specificity and

simplicity of RIA methodology soon led to its application to
the measurement of non-peptidal hormones as well.

Chopra

(1972) first described RIAs for tyrosine (p. 938) and
triiodothyronine (T3).

The sensitivity and specificity of

the RIA for the thronines and the ability to measure
thyrotropin (TSH)

(Chopra, p. 938) have made possible a

nationwide screening program for neonatal hypothyroidism, a
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disease that must be treated shortly after birth to avoid
irreversible mental retardation (Chopra, p. 938).
By 1969, a sensitive solid-phase RIA for plasma
estradiol-17 beta had been described.

Soon thereafter the

number of applications of RIA to the measurement of steroid
hormones grow very rapidly.

Within five years, in a review

of the field, Abraham (1969) indicated that RIA had been
applied to the measurement of every known hormonal steroid
and to many other steroids without known biological activity
(p. 866).

RIA in Pharmacology
Although RIA appeared to belong almost exclusively to
endocrinology during the first decade after its description,
the rediscovery of the work of Landsteiner (1945) on
production of antibodies by low molecular weight haptens
coupled to proteins led to the realization that RIA could be
adapted to the measurement of drugs.

At the end of that

decade Oliver, et al (1968), published a classic paper
describing the measurement of digitoxin in human serum by
RIA (p. 1035).

At present, commercial kits for the

measurement of the cardiac glycosides are routinely employed
in hundreds of laboratories.

A particularly important

application in toxicology is the assay in plasma of the
concentration of antibiotics for which there is a very
narrow range between efficacy and toxicity.

Microbiological
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essays for these drugs are time consuming and expensive.
The introduction of the RIA for gentamicin (Oliver, 1958, p.
1035). led the way, and commercial kits soon became
available for assay of many antibiotics.

RIAs for the host

of other drugs are now available; many are in simple kit
form.

RIA in Infectious Diseases
The first application of RIA to the field of infectious
disease began with the development of an assay for hepatitis
B antigen, then known as Australia antigen (Purcell,
Holland, Walsh, et al, 1969, p. 383).
Over the past few years the incidence of acquired
immunodeficiency syndrome (AIDS) due to infection with a
tretovirus has skyrocketed, and the incidence rate is
increasing yearly.

Although an enzyme-linked immunoassay

for detection of antibody to this virus contributes to the
safety of blood used for transfusion, a test for the virus
itself is urgently required.

It is evident that there are

infected persons without antibody, either because it is too
early in the course of infection for antibody to have
developed or because compromise of the immune system may
decrease antibody production.

It is not unreasonable to

hope that an RIA for the virus will be developed that will
permit improved safety of bank blood.
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It can be predicted that RIA and related techniques
will be applied increasingly to the detection of active
infectious disease.

Straus, et al (1981), have reported an

RIA for a tuberculoprotein that can make the diagnosis of
active tuberculosis more rapidly and in a much less
expensive, simpler, and far safer fashion than with the use
of classic microbacteriologic methodology (p. 3214).

Even

were this technology applicable only to the diagnosis of
tuberculosis,

it would remain a major breakthrough.

However, it should serve as a model for the development of
assays for proteins associated with other slow-growing
organisms, the diagnosis of which may be difficult with
standard microbiologic methodology.

Future of RIA
This review of the development of a small sampling of
applications of RIA emphasizes the fact that in science new
truths become evident when new tools become available.

For

more than a quarter century, RIA has been an important tool,
fruitfully employed in diverse areas of biomedical
investigation and clinical medicine.

Can we predict what

the relative usage of radioactive and non-radioactive labels
in immunologic methods for diagnosis (immunodiagnostics)
will be in the future?. A Wall Street investment concern has
attempted such a prediction (Dunne, 1981).

They have

estimated that in 1980 the market segment for RIA in
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immunodiagnostics was $332 million, for non-radioisotopic
therapeutic drug monitoring $43 million, and for all other
non-radioisotopic immunoassays $28 million; in 1990, they
predict markets of $785 million, $625 million, and $838
million respectively for these three methodologies.

Thus,

from a commercial point of view RIA usage is expected to
more than double during the decade of the 1980s, but its
fraction of the total immunodiagnostics market is expected
to drop from over 80 percent to about 35 percent.

Why?

First of all, many of the new applications simply do not
require the exquisite sensitivity of RIA.

For instance, in

therapeutic drug monitoring the concentrations being
determined are generally a million-fold higher than the
concentrations of peptide hormones.

Furthermore, assays for

drugs generally need not be quantitative over a multiple
hundredfold range.

It is often necessary only to determine

whether the concentration is high enough to be efficacious
and not so high as to be toxic.

In the field of infectious

diseases, where immunodiagnosis will play a major role, the
choice between radioisotopic and non-radioisotopic
methodology again would depend on the sensitivity required;
in the presence of massive infection, the massive infection
the sensitivity of RIA is not likely to be necessary.
However, in a number of instances, those promoting nonradioisotopic labels are not necessarily suggesting that
these have any technical advantage, but rather that
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regulatory procedures and fear of radiation at any level
would make radioisotopic label less desirable.

Nonetheless,

RIA is likely to remain the method of choice for what has
been its first application, the measurement of peptide
hormones in plasma and other body fluids, since their
concentrations are well below 10*1°M, and the sensitivity of
RIA is essential (Dunne, 1981).
RIA and related methodologies have opened new vistas in
science and medicine.

RIA is now used in thousands of

laboratories around the world to measure hundreds of
substances of biologic interest.

Even now, a quarter

century after the introduction of RIA, there remain many
additional fields that can be explored with its help.

Review of In Vitro Literature
A selective review of the nuclear medicine In Vitro
literature was performed on over 300 articles, text books,
and manuals.

This researcher examined the literature and

categorized the materials into a content analysis chart.
The five areas were: Level of Material, Type of Material,
Possibility of Providing Laboratory Exercises, General
Principles, Concepts Discussed, and Specific Testing
Procedures Mentioned.
The following is presented as a content analysis chart
and a summary of resultant values obtained.
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Content Analysis of In Vitro Nuclear Medicine
Literature.

Column indexes and abbreviation conventions:

Column 1, Bibliography
Column 2, Level of Material
under = undergraduate
grad = graduate
tech = technical
Column 3, Form of Material
Column 4, Laboratory Exercises Provided
Column 5, Concepts Discussed
Column 6, Specific Testing Procedures
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Summary of Resultant
Level of Material.

In order to evaluate the need for a

student laboratory In Vitro manual, it was necessary to
examine the literature content and categorize in terms of
(NOTE: The numbers following each section relate to the
total frequency of occurrence for that topic mentioned
within the literature:
Undergraduate Level: Understandable to beginning
students in field or general public (13).
Technical Level: Written for individual in field
(206).
Graduate Level: Highly sophisticated; for advanced
educational-level individuals (91).
Tvne of Material.

This is the form the material was

written in, either an article, text, or manual.
Article: Categorized as in a journal or presented
as a paper in a symposium (262).
Textbooks: Larger volumes covering numerous area
and topics of In Vitro material (48).
Manuals: Written as a guide to students to work
through problems and exercises (4).
Providing Laboratory Exercises.
of In Vitro literatures
exercises included.

Of the over 300 types

examined only seven times were any

The types of exercises were: basic RIA,

concepts, separation techniques, calculation of results,
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labeling, basic reactions, basic immunology, and blood
components sampling procedures.
General Principles and Concepts Discussed.

The

literature was categorized in 11 overall principles and
concepts, each different type were placed into one of these
areas:
Basic Principles/Concepts: This included materials
that discussed elements, standards, structures, basic TIA
properties and methodologies and typical RIA examples (62).
Basic Reactions: Concepts included concentrations,
components of RIA, equations, chemical properties,
physiology, interfering substances (65).
Radiolabelinq: Labeling of radioactive materials,
production and purification of labeled isotopes (29).
Basic Procedures: Techniques, evaluation of
techniques, applications, calibrations (13).
Kit Evaluation: Assessment of basic manufacturer
RIA testing kits (12).
Separation Techniques: Separation of bond-free
(26) .
Calculations of Results: Measurement, assessment,
evaluations (54).
Preparation; Patient sampling, binding properties,
receptors, Ag-Ab preparation (18).
Quality Control: RIA laboratories, equipment, kits
(19) .
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Alternative Immuno Blood Testing; Enzyme,
luminescence, fluorescent excitation testing (24).
Specific Testing Procedures.

A review of the In Vitro

literature reveals numerous types of testing procedures
discussed.

The following is a list in descending order of

the most commonly mentioned testing procedures (NOTE:
Numbers correspond to frequency distribution of test
procedures mentioned within literature):
thyroid T3, T4 - (56)
blood volumes - (18)
schilling testing - (15)
vitamin B12 - (13)
red blood cell survival - (11)
WBC labeling - (10)
peptide (protein hormones) - (10)
insulin - (9)
iron (Fe) recovery - (8)
drug testing - (8)
TSH - (7)
thyrotropin - (7)
CEA - (7)
estradiol, estrone - (7)
folic acid - (6)
alpha-feto protein - (6)
3 — 5
corticol

testosterone
FSH
HCG
LSH
PTH
creatine kinase
renin, aldosterone
aminoglycoside
ACTH
gonadotropin
steroid testing
IGE
angiotension
monoclonal antibodies
norepinephrine
TBG
LH
digoxin
In summary, this chapter attempts to review those
aspects most influencial on the development of In Vitro
Nuclear Medicine education.

This review of the literature

exposes the reader to many reasons for the development of
Nuclear Medicare Technology education, the historical
changes influencing the field of Nuclear Medicine and
finally the tabulated content analysis of over 3 00 articles,
texts, and manuals written within In Vitro Nuclear Medicine.
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This content analysis of the review of In Vitro
literature is used as the basis for the development of the
nationwide survey sent to all Nuclear Medicine program
directors.

The general principles/concepts, testing

procedures and laboratory exercises cited in the literature
are evaluated by the program director as to their relative
importance in the educational process of nuclear medicine
students.
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Chapter 3
METHODOLOGY

Introduction
Chapter III is concerned with the methods and
procedures that were used in this study.

Information was

provided regarding the selection and description of the
subjects, and description of the development and
administration of the instruments.

Settincr and Subjects
Based on the content analysis of the Nuclear Medicine
In Vitro Laboratory literature a questionnaire was
developed.

Before any nationally accepted survey could be

sent out to all Nuclear Medicine program directors the
validity and reliability of the questionnaire had to be
established.
Five authorities in the field of Nuclear Medicine
technology were identified to evaluate the initial surveys
contents.

A letter was sent to the Joint Review Committee

on Accreditation of Nuclear Medicine Program and the Society
of Nuclear Medicine asking these groups to choose
individuals they deem as experts in the field.
suggested list of individuals,

From the

five were selected at random

and received by mail the researcher's initial survey.
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The final sampling population consisted of all
Accredited Nuclear Medicine Technology Program Directors in
the United States (approximately 7 0).

A list of accredited

programs were supplied by the Joint Committee on Education
in Radiologic Technology (1988 listings).
Directors of each accredited degree program were
selected not so much for their educational and professional
experience, but because they may have the most dominant
voice in the actual implementation and future use of this In
Vitro Student Manual into their curriculums.
Since there may not be a Nuclear Medicine program
director for a given university, the person directly
responsible for the program (dean, chairman, etc.) were
asked to complete the questionnaire.
designated on the form.

Their title was

No differences were analyzed

between various titles as long as they have direct
responsibility for the Nuclear Medicine technology program.
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The following Procedural Chart outlines the basic
sequencial steps undertaken that ultimately lead to the
development of an In Vitro laboratory manual.
PROCEDURAL CHART
Content analysis of literature is used to develop basic
questionnaire on the needs of In vitro Nuclear Medicine
procedures.
ii
ii

V

Letter to Joint Review Committee on Accreditation of
Nuclear Medicine Program and Society of Nuclear Medicine
asking them to choose individuals they deem as experts in In
Vitro Laboratory procedures to evaluate questionnaire.
i i
i i

V
Five experts randomly selected from list provided.
tt
i i

V
Questionnaire was revised and necessary changes made
based on criticisms of experts.
i i
i i

V
Survey is sent to all Nuclear Medicine Programs
Directors nationwide (approximately 70 schools).
i i
i i

V

Data is collected and analyzed.
i i
i i

V
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In Vitro Laboratory Manual is written to meet education
needs cited.
ii
ii

V

Manual is sent to experts for their critique and
comments about how well manual will meet needs in Nuclear
Medicine In Vitro Laboratory.

Procedure
A letter was developed and sent to the Joint Review
Committee on Accreditation of Nuclear Medicine Programs and
the Society of Nuclear Medicine asking them to identify
experts in the field of Nuclear Medicine education.

A

random selection of five names were used to validate the
researcher's initial questionnaire.
The five individuals chosen randomly were:

Wynn

Harrison, Director of Nuclear Medicine, Weber State
University, Utah; John Hamlett, Director of Nuclear
Medicine, Temple University; K. McEnerney, Director of
Nuclear Medicine, California State University, Berkeley;
Sheila Rosenfield, Director of Nuclear Medicine, St. Louis
University; John Rollins, Director of Nuclear Medicine,
University of Alabama, Birmingham.
A cover letter and questionnaire was mailed to these
Nuclear Medicine Technology authorities in the field of
Nuclear Medicine technology.

The cover letter explained the
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purpose of the study and the importance of their input.
They were requested to respond by a certain date.

Telephone

calls followed to three experts who did not return a
questionnaire asking or reminding them for their response.
A second letter and questionnaire was sent with appropriate
follow-up contact made until all five authorities did in
fact complete and return the questionnaire.
From the five authorities responses an overall review
and necessary changes were made to adjust to the criticisms
of these individuals.

The final survey was sent to all

Nuclear Medicine Program Directors from the University of
Nevada, Las Vegas with a self-addressed,
for easy return.

stamped envelope

In hopes of increasing participation the

participants were asked whether they wished to have the
results of the research sent to them.
Again, due to the relatively small number of accredited
Nuclear Medicine programs, any director that did not respond
was contacted by phone and reminded to please make every
effort to respond to the survey.

A second cover letter and

questionnaire was sent to those who had not responded.
Every attempt was made to receive an overall response rate
of 70 percent or better.
From all Nuclear Medicine Program Directors that did
respond the data was analyzed and a In Vitro Laboratory
Manual was developed by this researcher.
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Finally a cover letter and the In Vitro Laboratory
Manual developed was sent to two of the original five
experts for their overall evaluation and commentary.

Instrumentation
Each Nuclear Medicine program director (or person
responsible for program) throughout the United States was
asked to complete a questionnaire for this survey research.
This instrument was designed to develop a nationally
accepted In Vitro Student Laboratory Manual based on data
collected.
The survey was first field tested by five authorities
in the field of Nuclear Medicine education, identified by
either the CAHEA or the Society of Nuclear Medicine.

The

surveys were returned to this researcher and questions were
reconstructed to conform with the overall groups'
criticisms.
The follow-up questionnaire was designed to have
program directors evaluate the appropriateness of general
principles, concepts and specific testing procedures
essential to a quality Nuclear Medicine Student In Vitro
Laboratory Manual.

A cover letter sent to all those

surveyed explaining the purpose of developing an In Vitro
Laboratory Manual for their curricula.
The survey first asked the respondent to identify the
school's name, their name and their title.

Initially four
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yes/no type questions are asked of the respondent.

These

relate to the individuals philosophical perspective of the
projected In Vitro Laboratory Manual.
The questionnaire is then broken down into two major
sections.

The first section includes a series of statements

dealing with components of basic principles and theories to
be discussed within the laboratory manual.
twenty-two

A list of

(22) general principles and concepts are provided

to be evaluated for their relative importance in In Vitro
Nuclear Medicine education.
The second section relates the testing procedures which
need to be part of a successful Nuclear Medicine In Vitro
Laboratory Manual.

A list of 34 specific testing procedures

associated with In Vitro testing were supplied.

These lists

for both sections were derived from the content analysis in
the In Vitro literature review.
In both section I and section II the participants were
asked to evaluate the significance or importance of general
principles, concepts and specific tests listed by each
selecting the appropriate option described.
1.

Must be part o f :

should be thoroughly discussed

or reviewed.
2.

Must be part o f :

does not need thorough

discussion.
3.

Should be part o f :
Vitro education.

some aspects are vital to In
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4.

Could be part o f :

5.

Is irrelevant.

nice to know.

The survey respondents are then asked to please add
general principles, concepts or specific testing procedures
they feel have been omitted that are essential to an In
Vitro Laboratory Manual of prescribed lists.
This chapter examined the overall methodology and
process which was undertaken for this research.

Discussion

included the setting for the investigation and the subjects
utilized.

A procedural chart attempted to simplify the

sequencial steps.

An indepth look at procedure followed,

along with a comprehensive analysis of the questionnaire
utilized in the national survey.
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Chapter 4
COLLECTION AND ANALYSIS OF DATA

Introduction
This chapter will discuss how the research was
collected and analyzed.

The entire population of accredited

Nuclear Medicine programs in the United States were surveyed
for this study.

The questionnaire was sent from the

Univcersity of Nevada, Las Vegas, with return envelopes.
Based opn the 74 percent response rate, the average values
for all questions and statements were tabulated and
analyzed.
The sampled population consisted of all Nuclear
Medicine Program Directors in the United States
(approximately 70).

This group was selected because they

have the strongest influence on the development and future
implementation of an In vitro Student Manual into their
curricula.

Therefore, any valid study of future changes

regarding In vitro education must include the perceptions of
these individuals.
The survey was designed to have the Program Directors
assess the need in the development of an In vitro Student
Manual.

Then if such a need exists, evaluate the

appropriateness of particular general principles, concepts
or specific type of tests in an In vitro Student Manual.
The questionnaire was mailed out from the University of
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Nevada at Las Vegas with a cover letter explaining the
purpose of the survey.

Telephone calls followed, and

follow-up surveys to those directors that did not initially
respond, asking or reminding them of the importance of their
input of the 70 Nuclear Medicine programs surveyed
nationwide. Fifty-Two responded to the questionnaire.

One

of the schools reported back that they had dropped their
Nuclear Medicine program.

Therefore, the actual number of

completed surveys were 51 out of a possible population of
69; this represents 74% of the total Nuclear Medicine
programs in existence in the United States.

The study

achieved its goal of at least seventy percent (70%) response
rate.
The large overall collection of questionnaires clearly
demonstrates the meaningfulness and importance to the
Nuclear Medicine educational community the need for an In
vitro Laboratory Manual to be developed.
The Nuclear Medicine Program Directors surveyed were
first presented with four (4) yes/no type questions and
asked to please circle the answer that best represents their
philosophy in terms of the projected In vitro Laboratory
Manual.

1.

The overall raw data results follow each question.

Do current texts, workbooks or laboratory manuals meet
the needs of your nuclear medicine students with
respect to In vitro procedures? '
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Yes

No

9

41

Eighty-two percent (82%) of these surveyed felt that
the current literature do not meet the needs of the Nuclear
Medicine students.

This fact seems to support the review of

the literature which reveals no laboratory manual was
currently available to educators that provided a thorough
examination of In vitro procedures in Nuclear Medicine.
2.

Do you believe an In vitro Nuclear Medicine
Undergraduate Level Manual is needed to properly train
your students?
Yes

No

43

6

In response to this question eighty-eight percent (88%)
of the Nuclear Medicine educators felt that a manual was
needed.
3.

Does a laboratory In vitro Manual need to be written to
meet this need?
Yes
40

No
8

The overwhelming response was affirmative by the
various educators surveyed.

Eighty-three percent (83%)

felt

strongly enough to indicate that a laboratory manual needed
to be written.
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4.

Should such a manual provide both a discussion of
theoretical constructs and laboratory exercises for
students?
Yes
41

No
9

In this question the surveyor was attempting to see if
the Nuclear Medicine educators felt that a manual needed to
in fact integrate the theory and practical work concepts.
Again, the overwhelming number of participants were
convinced, with a response rate of 85 percent that an In
vitro Manual was needed both theoretical constructs and
laboratory exercises.
The next two sections of the survey asked the Nuclear
Medicine experts to evaluate the importance of various basic
principles, theories and testing procedures which need to be
a part of any successful In vitro Nuclear Medicine
Educational Manual.

Each respondent was asked to place a

numerical value on each item listed in both sections.
The numerical values were as follows:
1.

Must be part o f :

should be thoroughly discussed

or reviewed.
2.

Must be part o f :

does not need thorough

discussion.
3.

Should be part o f :

some aspects are vital to In

vitro education.
4.

Could be part of:

nice to know.
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5.

Is irrelevant.

Section I included statements dealing with components
of basic principles and theories.

The average results of

all participants follows each item.
Elements of R.I.A. antibody-antigen reaction.

1.3

Growth development, historical changes in In vitro
Laboratory Technology.

3.2

Properties and methodologies of typical R.I.A. tests.

1.4

Components of R.I.A. equations of equilibrium,
chemical properties, physiology.

1.2

Basic blood components and interfering substances.

1.3

Separation of free from bound techniques.

l .6

Calculations of results, assessment and evaluation of
resultant values.

1.6

Evaluation of different techniques and kits.

2.8

Quality control on instrumentations, equipment in
laboratory.

1.5

Typical R.I.A. testing procedures.

1.3

Labeling of radioactive material.

2.6

Production and purification of labeled isotopes.

2.7

Preparation of patient samples, blood and urine.

2.2

Gamma well counters and liquid scintillation.

l .3

Alternative immune testing procedures, enzyme,
luminescence, gas spectroscopy.

l .7

Proper intravenous injection techniques.

l .9

Statistics and computer data.

l.5

Presentations in R.I.A.
Blood volumes.

l .9

W.B.C. labeling.

2 .1
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R.B.C. labeling.
B-12 absorption testing,

1.4
Schilling testing.

1.7

Iron recovery.

2.8

All basic principles and concepts described were
classified by evaluators as (3.2) or numerically lower.
This would seem to indicate that every principle and theory
listed needed to be at least some part of the In vitro
Manual.
Of the 22 statements and numerical values that followed
three (3) categories were developed to evaluate the extent
that these items would appear in the Nuclear Medicine
Laboratory Manual.
1.6 or lower - thoroughly discussed and reviewed.
2.2 - 1.7 - discussed, but not in great detail.
3.5 - 2.3 - needs to be part of, briefly analyzed and
discussed.
This scale was developed and utilized because almost
all general principles/concepts listed were considered by
educators as at least in the range of should be part of In
Vitro education.

The educators were asked to please add any

principle or theory not included in this list.
item was listed on more than 5 returned surveys.

Only one (1)
This was

the concept of dilution principles listed 12 separate times.
It was therefore included into the laboratory manual overall
concepts discussion and analysis.
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Section II of the survey asks the Nuclear Medicine
Program Directors to evaluate the appropriateness of
different types of testing procedures.

Using the same scale

utilized in section I f the experts selected numerical values
(1-5) for each item on the list of 34 testing procedures
provided.
The final total averaged results for the national
survey for section II was as follows:
Thyroid

1.2

Angiotensin

3 .4

Blood Volume

1.4

Drug Testing

1.4

Iron Recovery

1.8

I.G.E.

2.8

Cortisol

3.0

Monoclonal Antibodies

2.1

Testosterone

2.1

Norepinephrine

4 .5

Estradiol, estrogen 2.1

Digoxin

2.6

CEA

1.6

LH

2.2

Peptide

4.2

TBG's

1.4

RBC Survival

1.6

Folic Acid

1.6

LSH

1.9

Alpha-feto Protein

1.9

Insulin

3.8

HCG

2.6

TSH

1.4

Vitamin B-12

1.5

PTH

2.9

Schilling Test

1.6

WBC Labeling

1.5

Thyrotropin

4.2

Renin, aldosterone

2.7

Creatinine

3.4

ACTH

3 .6

Aminoglycoside

4.2

Gonadotropin

3.4
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Again, the respondents were asked to add any other
testing procedures that could enhance Nuclear Medicine In
vitro education.
The following testing procedures were named as
important enough to be part of the developed laboratory
manual.
Hepatitis Testing
Gastrin
Myoglobin
Calcitonin
Gentamicin
Phenytoin
Theophylline
Of these responses only hepatitis testing appeared on
more than three (3) separate surveys.
different survey responses.

It was added to seven

This the researcher felt was

significant and is thoroughly discussed in the laboratory
manual.

The other tests are only briefly reviewed.

Summary of Resultant Values of 51 Nuclear Programs
Nationwide

The following basic principles, concept or

testing procedures were ranked (1.6 or lower) and are
thoroughly discussed and reviewed in the developed Nuclear
Medicine In vitro Manual.
Elements of R.I.A., antibody-antigen reaction.

101
Components of R.I.A. equations of equilibrium, chemical
properties, physiology.
Basic blood components and interfering substances.
Separation of free from bond techniques.
Calculations of results, assessment and evaluation of
resultant values.
Quality control on instrumentations, equipment in
laboratory.
Typical R.I.A. testing procedures.
Properties and methodologies of typical R.I.A. tests.
Proper intravenous injection techniques.
Statistics and computer data presentation in R.I.A.
Blood volumes.
W.B.C. labeling.
R.B.C. survival.
Gamma well counters and liquid scintillation.
Vitamin B-12.
Schillings.
CEA.
Thyroid.
Blood volumes.
TSH.
Drug Testing.
RBC survival.
T B G 's .
Folic Acid.
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WBC labeling.
* Hepatitis testing.
* Dilution principles.
(*

Added to list by respondents.)

The following basic principles, concepts or testing
procedures were ranked between (2.2 - 1.7) and are
discussed, but not in great detail:
Evaluation of different techniques and kits.
Labeling of radioactive material.
Production and purification of labeled isotopes.
Preparation of patient samples - blood or urine.
Alternative immune testing procedures, enzyme,
luminescence, gas spectroscopy.
Monoclonal antibodies.
LH.
Alpha-feto protein.
Iron recovery.
Estradiol, estrogen.
Testosterone.
FSH.
LSH.
The following basic principles, concepts or testing
procedures were ranked between (2.3 - 3.5) and are briefly
discussed and analyzed in the In vitro Laboratory Manual.
Growth, development, historical changes in In vitro
Laboratory Technology.
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I.G.E.
Digoxin.
Cortisol.
HCG.
PTH.
Creatinine.
Ren in, Aldosterone.
Angiotensin.
* Gastrin.
* Myoglobin.
* Calcitonin.
* Gentamicin.
* Phenytoin.
* Theophylline.
(*These testing procedures were added by the Nuclear
Medicine Program Directors surveyed.

None of these tests

appeared on more than three (3) separate respondent
surveys.)
Three categories were developed based on the overall
average values assessed to each general principle/concept or
testing procedure by the Nuclear Medicine program directors.
Items ranked (1.6 or lower) are thoroughly discussed and
reviewed the the Nuclear Medicine student In Vitro manual.
This section included 27 properties.

The next category

included principles/concepts or tests which ranked between
1.7 to 2.2 and were discussed in the In Vitro manual, but

not in great detail.

This section encompassed 13

principles/concepts or testing procedures.

The final

category incorporated basic principles/concepts or testing
procedures ranked 2.3 to 3.5 and was briefly analyzed in the
In Vitro manual.

This group included 14 such items.

Items

with a numerical value greater than 3.6 was not included in
the manual.
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Chapter 5
SUMMARY, CONCLUSIONS, RECOMMENDATIONS,
AND RECOMMENDATIONS FOR FURTHER STUDY

This chapter briefly reviews the problem, summarize the
results, and identify the conclusion based on the research.
The major emphasis focuses on examining how well the four
initial questions raised in Chapter 1 were answered by the
research data.

Then suggest alternative ways of solving the

problems raised and provide recommendations for further
research.

Restatement of the Problem
The purpose of this study was to examine the necessity
for development of an In Vitro student laboratory manual to
be used by accredited nuclear medicine technology programs.
A review of the literature reveals through a content
analysis that such a manual is not in existence.
A questionnaire was developed and distributed to all
accredited nuclear medicine program directors nationwide.
The survey elicited responses pertaining to general
principles, concepts, and specific testing procedures they
deemed essential to an educationally sound In Vitro
laboratory manual for graduating students.

106
Summary
Based on the responses from the questionnaire, this
section discusses the overall findings of the study.

The

initial questions posed which the basis of all the research
was formulated is discussed, and analyzed.
The research attempted to answer four initial questions
posed by the researcher.
1.

Is there a need for an In Vitro laboratory manual

for students in nuclear medicine technology?
First, through an extensive content analysis of In
Vitro nuclear medicine literature it was clear that no such
manual existed.

There is no undergraduate level of material

that provides laboratory exercises, conceptual discussion,
and analysis of specific testing procedures vital to
educating successful nuclear medicine technology students.
Secondly, 82 percent of the nuclear medicine program
directors responding

to the national survey felt that

current texts, workbooks, or laboratory manuals did not meet
the needs of their nuclear medicine students with respect to
In Vitro procedures.

Furthermore, 88 percent of the nuclear

medicine educators felt that a manual was needed.
2.

What general principles/concepts of In Vitro

studies must be included in this student manual?
Through the extensive content analysis of the In Vitro
literature, 22 general principles/concepts were cited.
these lists the national survey asked nuclear medicine

From
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program directors to assess the importance of each item and
add to this list whatever was in their view missing.
3.

Identify the types of testing methodologies and

procedures that must be included in a comprehensive student
In Vitro manual.
Again, through the content analysis of the literature
and the national survey 34 predominant testing procedures
merged as important enough to be part of a comprehensive
nuclear medicine In Vitro laboratory man u a l .
4.

What aspects of In Vitro nuclear medicine are most

commonly overlooked that need to be taught to graduating
nuclear medicine students?
This question, though not specifically asked of the
national survey respondents,
collected.

can be deduced from the data

A number of general principles, concepts and

testing methodologies not mentioned in the literature were
sighted by nuclear medicine program directors as essential
to this developed manual.

Conclusion
All of the data collected from both the review of the
nuclear medicine literature and the national survey clearly
indicates a need for development and future implementation
of an In Vitro laboratory manual in nuclear medicine
programs nationwide.

This researcher has analyzed this data

by developing and writing a student In Vitro manual at the
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undergraduate level to meet this need.

This laboratory In

Vitro manual consists of nine chapters discussing general
principles, concepts and specific testing procedures
performed in nuclear medicine.

The manual also provides 12

laboratory exercises for students to have hands-on
experiences.
This laboratory manual will be made available to CAHEA,
the Society of Nuclear Medicine, and nuclear medicine
programs nationwide.

The information gathered from this

study can also be used by program directors in assessing
their current In Vitro curricula and identify deficiencies.
One limitation that must be cited, is that due to time
constraints and a tremendous amount of nuclear medicine
materials, certain aspects may not have received the full
extent of discussion they warranted.
Based on the data collected from this study further
research in this area and other such texts, manuals need to
be developed.

Clearly there is a tremendous need not being

met by the current writings in the field of nuclear medicine
education.

Future research may wish to utilize this

research data and emphasis in greater detail general
principles/concepts or specific testing procedures.

Others

may desire to devote their energies on laboratory exercises
for students.

It is quite obvious that much more can be

researched and developed to foster nuclear medicine In Vitro
education to a higher level.
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QUESTIONNAIRE FOR
UPDATE OF THE NMT
ESSENTIALS
The JRCNMT would appreciate a moment of your time to respond
to the enclosed questionnaire, relevant to the education and
practice of Nuclear Medicine Technology.
The information
derived from this and future assessemtns will guide us in
our review of education programs and future revisions of the
Essentials and Guidelines.
Please indicate in the space provided, your answers to the
following questions.
Demographic Data
1.

Present Position(s), Check all which apply to you
Staff Technologist
Physician
Senior Technologist
Scientist
Chief Technologist
Radiation Safety Officer
Administrator
Clinical Instructor
Educator
Radiopharmacy Technologist
Student
Other

2.

Training and education in nuclear medicine
OJT
CAHEA
ADV. DEGREE
RT
BS/BA
M.S.
MT
AS/AA
M.D.
RN
Certificate
Ph.D.
HS Certificate

2a.

Years in Practice:

3.
Type(s) of institution where presently employed: Check
all which apply
Private Hospital
University Hospital
Community Hospital
Government (Federal or State)
Private Practice
Mobile Service
4.

What is the size of your principal institution:
Over 100 beds
101-200 beds
201-500 beds
over 800 beds
Does not apply

5.

Location:

Large City
Suburb
Small City
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6.

Zip Code:

7.

Where is nuclear medicine practiced in your
institution?
Nuclear Medicine
is separate department
Nuclear Medicine
is part of Radiology
Nuclear Medicine
is part of Pathology
Nuclear Medicine
is part of Internal Medicine
Other ____________
Specify ____________

8.

Does the Nuclear Medicine Department at your
institution perform: Check all that apply
Imaging procedures
In Vitro procedures
In vivo non-imaging procedures

9.

How many nuclear imaging procedures does your
institution perform each month:
Under 100
1 0 1-200

201-400
401-600
601-800
801-1000
Over 1000
10.

How many immunoassays does your institution perform
each month:
Under 100
100-500
501-1000
1001-5000
5001-10,000
Greater than 10,000

11.

How many nuclear medicine technologists are currently
employed at your institution?
Nuclear Medicine Practice

RADIOPHARMACY
12.

Where are radiopharmaceuticals prepared?
in your institution's Nuclear Medicine Department
in your institution's Pharmacy Department
outside commercial centralized pharmacy
other_____
Specify ________
Do you anticipate any changes?
yes
no
Comment:
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13.

What is the professional background of the principal
individual responsible for radiopharmaceutical
preparation?
nuclear medicine technologist
radiographer
medical technologist
other Specify ________

14.

Who is responsible for radiopharmaceutical quality
control procedures?
nuclear medicine technologist
radiographer
medical technologist
radiopharmacist
radiochemist
other Specify _______

IMMUNOASSAY
15.

Have you performed immunoassay prcedures in the last
two years?
_____ yes
______
no

16.

Where are radioassays performed at your institution?
nuclear medicine
pathology
outside commercial lab
do not do

17.

Which of the following methods are used for
immunoassay? (indicate % of tests done by each method)
RIA _____ %
EIA _____ %
Fluorescent _____ %

18.

Do you anticipate any changes in the involvement of
Nuclear Medicine Technologists in Immunoassays at your
institution?
_____ yes
_____
no
If yes, please comment:
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School's Name____
Individual's Name
Title________________________________
Please Circle the answer that best represents your philosophy in
terms of the projected In vitro laboratory manual.

Yes/No

1. Do current teHts, workbooks or laboratory manuals meet

Yes/No

the needs of your nuclear medicine students with
respect to In Vitro procedures?
2. Do you believe an In Vitro nuclear medicine under
graduate level laboratory manual is needed to properly
train your students?

Yes/No

3. Does a laboratory In Vitro manual need to be written
to meet this need?

Yes/No

4. Should such a manual provide both a discussion of
theorical constructs and laboratory exercises for
students?

Section 1 :

The following series of statements deal with components
of basic principle and theories to be discussed within
laboratory manual.
(Please write the appropriate
numerical value in the space provided for each item
mentioned.)

1.
2.

Must be part o f :should be thoroughly discussed orreviewed
Must be part o f : does not need thorough discussion

3.
4.

Should be part o f : some aspects are vital to In Vitro education
Could be part o f : nice to know

5.

Is irrelevant

______

Elements of R.I.A., antibody -antigen reaction.

______

Growth, development, historical changes in In Vitro
laboratory technology.

______

Properties and methodologies of typical R.I.A.

tests.
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______
______
______
______
______
______
______
______
______
______
______
______

Components of R.I.A. equations of equalibrium, chemical
properties, physiology.
Basic blood components and interferring substances.
Separation of free from bond techniques.
Calculations of results, assessment and evaluation of
resultant values
Evaluation of different techniques and kits.
Quality control on instrumentations, equipment in
laboratory.
Typical R.I.A. testing procedures.
Labeling of radioactive material.
Production and purification of labeled isotopes.
Preparation of patent samples - blood or urine.
Gamma well counters and liquid scintillation.
Alternative immune testing procedures, enzyme,
liminescency, gas spectroscopy.

______
Proper intravenous injection techniques.
______
Statistics and computer data presentations in R.I.A.
______
Blood volumes.
______
W.B.C. labeling.
______
R.B.C. survival.
______
B-12 absorption testing, schilling testing.
______
Iron recovery.
Please add any principle or theory not included in this list:

Section I I :

The rest of the data collection relates to the testing
procedures which need to be part of a successful
nuclear medicine In Vitro laboratory manual. (Please
write the appropriate numerical value in the space
provided for each item mentioned.)

1.
2.

Must be part o f : significant, thoroughly discussed or reviewed
Must be part o f : but not have to be thoroughly discussed
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2 . Should be part o f : some aspects are vital to In Vitro educatio
4. Could be part o f : but not vital to In Vitro education
5. Can be excluded from: In Vitro nuclear medicine manual

Thyroid
Blood volume
Iron recovery
Corticol
Testosterone
Estrodiol, estrone
CEA
Peptide
RBC survival
FSH
LSH
Insulin
TSH
PtH
WBC labeling
(Fe) recovery
Renin, aldosterone
ACtH
Angiostensin
Please add any other testing procedure that
medicine In Vitro education.

Drug testing
CEA
I .G .E .
Monoclonal antibodies
Norepinephrine
Digoxin
LH
TBG' S
Folic acid
Alpha feto protein
HCG
Vit. B -12
Insulin
Schilling test
Thyrotropin
Creatine
Aminoglycoside
Gohadotropin
could enhance nuclear

I wish to have results reported to me.

nn
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Chapter 1
INTRODUCTION TO
RADIOIMMUNOASSAY
Objectives
The student should
• be able to understand the basic advantages of
radioimmunoassay over other tests;
• comprehend basic antigen-antibody reactions;
• be able to identify the 4 basic steps in a R.I.A. reaction;
• understand the purpose of RIA, including percent
bound antigen concentration relationship;
• define and describe standards, labeled antigen, ligands,
cross-reactivity, haptens, antigen production;
• describe a typical RIA exam, including controls;
• be familiar with isotopes used, binders (Ab), titer,
affinity, iodination;
• give an example of basic RIA procedure;
• understand the concept of non-competitive assay.

Introduction
Prior to 1960, certain substances in the blood and other body
fluids were extremely difficult to measure. This was to soon
change and a new world of medicine would soon flourish. Two
researchers, Yalow and Berson, reported a method for the
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quantitative measurement of insulin in the bloodstream. The
technique was known as “competitive binding assay”.
The technique they developed made use of an insulin binding
protein using 1-131 and guinea pig antibodies.
Before “RIA”, substances in biological fluids were measured
by chemical analysis or bioassay. These methods, however,
lacked sensitivity, specificity, and accuracy. The methods
were laborious, expensive and time consuming. Radioim
munoassay techniques became widely used for measuring
many substances, particularly hormones. Much of the
progress in endocrinology during the past decade has oc
curred because of the availability of RIA techniques.
In the 1970’s and 1980’s, much of the invitro laboratory pro
cedures’ rapid growth and development were due to:
•
•
•
•
•
•

production of more and better antibodies;
different labeling techniques;
solid phase techniques;
new methodologies;
new instrumentation;
and more accurate data reduction protocols.

The advantages of RIA over other systems include greater
sensitivity, accuracy, specificity, and precision. RIA is
synonymous with these other terms in principle: “saturation
analysis”, “competitive radioassay”, “competitive binding
assay”, “displacement analysis”, and “radiosteroassay”.
RIA is based on the principle that antibodies are produced to
specifically interact with foreign substances which enter the
body. They are the main basis of the body’s immune system.
RIA is based on the concept that certain substances to be
measured, antigens, will react with these specific antibodies.
This reaction is outlined as follows:
ki
Ag + Ab

AgAb

*'
k2

where ki represents the rate constant or association con
stant, k2 represents the rate constant or dissociation con
stant. At the start of the reaction with free Ag and free Ab,
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the rate of association is high (ki). Until the rate is equal in
both directions, the reaction will continue until equilibrium
is reached and no further changes in concentration will result.
K can be demonstrated as follows:

AgAb = k (equilibrium or affinity concentration)
[Ag][Ab]

Low concentrations of an antigen can be detected by deter
mining the ability of these antigens to be bound by a specific
antibody. Competition of a non-labeled hormone or antigen
(Ag) with a radio-labeled antigens for the same binding sites
on an antibody (Ab) causes a depression of the amount of
bound, labeled material in the final solution.

(* radioactive Ag)
Ag *Ab

By studying a series of labeled antigens as standards, known
amounts of unlabeled hormone (in unknown patient serum)
can be measured because it offers similar competition with
labeled hormone molecules for the antibody. In other words,
the labeled and unlabeled antigens will compete equally.
The antigen to be measured is known as a “ligand”. The
antibody is a gamma-globulin protein with receptor sites for
the antigens. The radioactive tracer is known as a
“radioligand”.

THE STEPS IN THE REACTION ARE AS FOLLOWS:

(*)labeled antigen
antibodies
unlabeled antigen
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[Stepi]
where both labeled and unlabeled antigens, again, are al
lowed to interact with the antibody in solution. The result is
two more substances, namely bound labeled antigen and
bound unlabeled antigen.
[Step 2j
Incubation period - this time allows the process to reach
equilibrium (the constants are equal).
[Step 3j
The separation of bound and free or unbound antigens.
[Step 4!
Determining the amount of radioactivity present using the
appropriate instrumentation.
Adding4arger amounts of known quantities of the original
antigen will result in the formation of less of the labeled
bound. The excess unlabeled form competes successfully
against the small amount of labeled antigen for the binding
sites on the antibody.
After the free and bound substances are separated, the
amount bound can be measured.
100
% bound 60

400

800 1200 1600
antigen or ligand
concentration

This chart demonstrates the reaction principle that the greater
the amount of ligand or patient antigen present, the lower the
percent bound of the added radioactive antigen or ligand.
Antigens, in more detail, are specific types of ligands. Ligands
may be purified from natural or synthetic materials and an
ample supply of these purified ligands must be used to gain
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the desired reaction. One of the most important qualities of
a ligand is that it be identical to the endogenous ligand being
measured (the patient sample). If they are dissimilar, the
assay’s specificity, sensitivity, and accuracy will be affected.
The ligand is capable of stimulating an antibody response and
must consist of the following properties:
© it must be foreign to the host;
® must have a molecular weight of 5000 or greater;
• must be pure;
e and again, must be identical to the endogenous ligand.
Elements used in RIA reaction are incubated to allow the
reaction to occur. The competition between labeled and
unlabeled ligands is allowed to occur simultaneously until
equilibrium is reached the ligands and the binder. This is
known as “equilibrium saturation”. The sensitivity obtained
by the RIA reactions as a whole depend somewhat on the
specificity of the antibody as well as the antigenicity of the
antigen, but depends primarily on the equilibrium constant or
affinity constant. The higher the affinity, the greater the
sensitivity of the antibody and the more rapid the attainment
of equilibrium. The greater the affinity, the greater the con
centration of antigen-antibody complex formed and the
smaller the dissociation constant.
Separation of bound from free reactants once equilibrium is
reached is determined by making use of the procedure which
will give the greatest amount of separation with the least
amount of effort, but in the meanwhile not sacrificing sen
sitivity. Procedures such as gel filtration, chromatography,
precipitation of the bound form (double antibody technique)
and absorption of the free phase by charcoal are a few of the
methods used. Regardless of the technique used, there
should be no effect on the antigen-antibody reaction.
Determining the amount of radioactivity present is done by
using gamma counters for traces of 1-125 and 1-131, for ex
ample, and liquid scintillation is used for H-3 and C-14 and
other beta em itting radionuclides. The radioactivity
measured reflects the relative amount of radioactive bound
fraction and radioactive unbound fraction. The results are
usually reported as a dose-response curve.
The dilution of antiserum binding in a predetermined percent
of tracer which is usually equal to the concentration to be used
on the assay is called titer. The dilution is that amount which
will bind 50% if the antigen.

APPENDIX C-6

IN VITRO NUCLEAR MEDICINE LABORATORY M A N U A L

The term immunogen is used synonymously with the ligand.
Also, the patient sample (antigen or ligand) can also be
termed analyte.
Certain characteristics of the labeled antigen must also be
present. It must be highly purified, it must be able to be
radiolabeled without loss of immunoreactivity. Many an
tigens are polypeptides which contain tyrosine residues that
are fairly easy to label with iodine. Often 1-125 is used as the
tracer, since a higher specific activity (act/mass) can be
gained.
Antigens are produced from an antiserum. This antiserum is
usually from guinea pigs or rabbits in sufficient amounts for
RIA purposes. The actual antibody used in testing usually
represents a high dilution of the original sera; the final dilu
tion may be 1:1,000,000 and 1ml of the antiserum will suffice
for 2,000,000 assays.
The labeled antigen can be labeled with not only 1-125, but
also 1-131, C-14, H-3, P-32, Se-75, Fe-59, Co-57. These
isotopes are several of the more historical substances. More
widely used today is 1-125, though Co-57, Fe-59, Se-75, and
H-3 may be used. The ideal radionuclide must conform to the
following characteristics:
•
•
•
•
•

high abundance;
high counting efficiency;
moderately long half-life;
be bound easily to the antigen;
and consist of a low or negative radioactive risk.

The shorter the half-life and the greater the specific activity,
the greater the sensitivity.
The tagging process as performed by the manufacturers of the
“kits,, are done by several methods. When labeling with H-3,
this process is completed via invivo or invitro H-3-lab precur
sors, neutron activation, chemical synthesis, and the Wilzbach
technique (an exchange reaction where H-3 is substituted for
stable H on the molecule).
The iodination of an antigen is accomplished directly or in
directly by conjugation of a prelabeled tyrosine molecule to
an antigen. The 1-125 is substituted for H in the aromatic
chain of tyrosine residues by conversion of unreactive I- to a
highly reactive I + state.
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For large protein molecules, direct labeling is usually not a
problem since they contain a tyrosine residue. The amount
of labeling depends on the specific activity of iodine or the
number and location of tyrosine residues.
The most popular method of iodination is called the
“chloramine-T” method. It is useful in the iodination of
peptides and proteins. Chloramine-T is found to oxidize I125-labeled Nal for reactions with tyrosine residues.
Conjugation labeling makes use of haptens or bridges. First
coupling of iodine to a carrier molecule is followed by con
jugation to an antigen by the hapten. Conjugation labeling is
successful for several reasons:
• it does not expose the ligand to chemical damage;
• it can be applied to ligand without tyrosine residues;
• and it is a simple procedure.
Quality assurance regarding these radiolabeled ligands or
antigens include:
• radiochemical purity—chromatography is used to
check the maximum binding or nonspecific binding;
• immunoreactivity—checked by the use of excess
antibody and a small amount of labeled ligand (if a
significant amount of label does not bind it denotes
nonimmunoreactivity);
• specific activity—measurement of the curves
containing radioactive isotope/weight of both labeled
and unlabeled ligand—the degree of specific activity
can affect assay sensitivity;
• stability—this category includes half-life, storage,
chemical breakdown, and loss of immunoreactivity.
The stability of the antigen used as the standard is particularly
important because they are used in assays over a long period
of time. Of importance in the maintenance of stability is an
awareness of interfering substances. These substances may
prevent nonidentity of the standard and include urea, heparin,
bilirubin, buffers, and the effects of temperature and pH.
There are three types of binders common in RIA. They are
the antibody, circulating binding protein, and cell receptors.
The most important characteristics of binders include affinity
capabilities, specificity, and availability.
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The antibody, again, is an immunoglobulin produced in
response to an antigen or immunogen. The proteins are
categorized as albumin, alpha, beta, or gamma globulin.
There are five distinct classes of globulins, all of which have a
common structure but a different function. They are known
as IgG, IgA, IgD, and IgE. The IgE, for example, is respon
sible for allergic reactions, while IgM is present at the onset
and eventually disappears. Specificity of the antibody for an
antigen interaction is influenced by the heterogeneity of an
tibodies for the same antigen; that is, the cross-reactivity for
similar substances. The RIA system depends on the Ag-Ab
reaction and not upon the biological activity of the antigen or
ligand. A specific concentration of the antibody must be used,
and the dilutionis often chosen which will be sufficient to bind
50% of the labeled antigen, with the resultant bound to free
ration (B/F) being 1:1.
Certain substances, called haptens, are used in the production
of antibodies for use in RIA. They are relatively small
molecules unable to initiate an antibody response by themsel
ves, but which can combine with larger molecules to produce
an antibody response.
Polyclonal antibodies are produced in response to a variety of
antigenic determinants on an immugen which is injected into
an animal. Each antigenic determinate produces an antibody
with its own affinity and specificity. This is the antiserum.
Small amounts of immunogen are used at regular intervals
and booster shots are given. The immunogen must be as pure
as possible and given in a combination of mycobacteria,
minerals, and emulsifiers that enhance the immune response
and allows for slow absorption into the system, known as
Freud’s adjuvant. The route of administration is usually
subcutaneous and the selection of host animal depends on a
variety of variables: volume of antisera needed, foreignness
of the immunogen and the availability of the animal. After
the booster injections are given, usually every 6-8 weeks, the
antiserum gained is purified.
The antibody gained is a fairly specific three dimensional
configuration. Certain portions of the molecule are exposed
or are available to react with other molecules, known as the
lock and key phenomenon. Cross-reactivity becomes impor
tant at this point; the antibody may have a low avidity for the
antigen resulting in the inability to discriminate different
antigens because of their structural similarities. The greater
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the specificity of an antibody, the less likely the chances of
cross-reactivity.
Binding proteins, the second type of binder mentioned, are
used in assays for thyroid hormones, cortisol, estrogens, and
progesterone. The disadvantages of binding proteins are:
•
•
•
•

a low affinity constant (less sensitive);
poor specificity;
temperature dependency;
and high concentration of binder.

Cell receptors, the third type of binder, are important when
dealing with protein hormones. The effects of many protein
hormones are exerted by first coupling specific receptor sites
on cell membranes. The receptor activity measured ultimate
ly becomes a measurement of biologic activity. Difficulties
arise due to:
•
•
•
•

diverse tissue;
low concentration present;
unstableness;
and can be easily damaged.

Because of the reasons stated above, antibodies remain the
major choice of binders available.
The ideal competitive radioassay should consist of the follow
ing criteria:
• nonradioactive and radioactive ligands or antigens
should be chemically and immunologically
indistinguishable;
• the reaction should continue until equilibrium is
reached (ki= k 2);
• antigen and antibody binding sites should react in a 1:1
ratio;
® the antibody should be specific for a single antigen;
• the amount of antigen should be in excess of the
antibody;
• and antibody binding sites should be independent of
one another.
In review, the purpose of binding assays is to determine the
concentration of the antigen in patient serum or plasma or
other body fluids. Tb perform this function, a dose response
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curve must be constructed using serial dilutions of a known
standard, known as a standard curve.
For an example of a typical RIA procedure see laboratory
exercise section.
In non-competitive assays, the antibody is usually labeled
instead of the ligand. This method is particular useful when
the ligand cannot be easily labeled, as is the case with
hepatitis-associated antigen or other viruses.
The receptor preparation is incubated with the sample con
taining the ligand to be assayed until all ligand present is
bound to the receptor. Now, a second set of receptors is
added, which are soluble but have a radioactive tracer labeled
to their outer end. The radioreceptor adheres to any bound
ligand present in the sample.
The ligand must be sufficiently large to have two or more
molecular regions that can act as combining sites (divalent or
polyvalent). Following the incubation with radioactive recep
tors, the matrix is washed and all non-bound radioactivity is
removed.
The radioactivity remaining bound to the matrix is now
measured. The activity bound to the solid phase is propor
tional to the amount of non-radioactive ligand present:

% bound
ligand
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REVIEW
Section 1
1-10 Matching
__ 1. pt. sample
__
__
__
__
__
__
__
__

a. in RIA it is considered the incuba
tion period
2. antigen
b. minimum quantity detectable
c. capacity to discriminate (Ag)
3. affinity
4. accuracy
d. reference tubes that react withAb
similarly to patient sample
5. ligand
e. the substance that is bound
6. precision
f the substance capable of inducing
formation o f (Ab)
7. sensitivity
8• repeatability o f measured quantity
h.
8. specificity
i. closeness to true or real value
9. standard
10. equilibrium / substance that is interpolated into
standard curve
k. substance that is not immugenic it
self

Section 2
VERY briefly describe or explain the following questions:
1. List and describe the 4 basic procedural steps in any RIA
test.
a.
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C.

d.

Section 3
Multiple Choice
1. RIA has become a widely used technique for measuring
many substances because
.
a. high specific activity
b. wide range of isotopes available
c. ability to detect small quantities
d. very fast process (less than 15 min.)
e. all o f the above
2.

Antibodies are

.

a. receptor sites
b. usually gamma-globulin protein
c. bivalent or polyvalent molecules
d. all of the above
3. Competitive protein binding is inversely related to ligand
present, why?
a. the titer is at 75% dilution
b. Ab receptor sites are saturated
c. *Ag, Ag (pt. sample) compete for binding sites on
Ab
d. only the Ag (pt.) is labeled and can be measured

IN VITRO NUCL E A R MEDICINE L ABORATORY M A N U A L

APPENDIX C-13

4. The principle of radioimmunoassay is based upon the fact
that
.
a. both labeled and unlabeled antigens will combine to
form a measurable entity
b. only labeled antibody and labeled antigen will com
bine to form a measurable entity
c. only unlabeled antigen will compete with the
labeled antibody to form a measurable entity
d. both labeled and unlabeled antigen will compete
with a known amount of antibody to form a
measurable entity
5. The term radioimmunoassay is synonymous w ith

.

a. saturation analysis
b. competitive-binding analysis
c. displacement analysis
d. all of the above
e. a and c only
6. In general, the basic components of an RIA reaction are_
a. labeled antibody, unlabeled antigen
b. antibody, labeled antigen
c. antibody, labeled antigen, unlabeled antigen
d. labeled antibody, unlabeled antibody, antigen
7. Which one doesn’t belong: haptens are substances
a. foreign in origin
b. sm. molecules
c. can induce Ab formation
d. linked to larger molecule
8. The isotope most commonly used in RIA procedures is
a. 1-131
b. C-14
c. H-3
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d. 1-125
9. Antiserum used to produce (Ab) in R IA

.

a. come from sm. animals such as guinea pigs and rab
bits
b. used in a final dilution of 1:1,000,000
c. used in a final dilution of 1:500
d. a and b
e. a and c
10. The titer of the antibody is a term which refers most
specifically to
.
a. avidity
b. affinity
c. concentration
d. stability
11. An example of non-competitive assays is _____ .
a. digoxin
b. T-7
c. HCG-B
d. hepatitis (virus)
e. a and b only
12. Non-competitive binding is different than competitive
because
.
a. radioactivity is labeled to Ab
b. radioactivity to bound ratio is 1/2
c. radioactivity labeling is to Ag
d. a and b
13. In non-competitive binding the ligand is
a. directly related to % bound
b. indirectly related to bound
c. inversely related to amt. of counts recorded
d. dependent if its solid phase

.
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14. In order for (Ag) to induce (Ab) it must be of foreign
origin and relatively high molecular weight.
a. true
b. false
K1

15. Ligand + Ab ----- ►LI + Ab - K1 is
K2

a. overall rate of reaction
b. association constant
c. dissociation constant
d. dependent on amount of tyrosol residues
16. In a competitive binding radioassay, competition exists
between
.
a. a ligand and an antigen
b. an antigen and an antibody
c. a ligand and a radiolabeled ligand
d. a ligand and an analyte
17. After the ligand, radioligand, and binder are given time
to equilibrate
.
a. the radiolabeled ligand must be separated from the
binder
b. the radiolabeled ligand must be separated from the
nonbinder
c. the bound ligands must be separated from the free
ligands
d. all of the above

Section 4
TorF
1. A hapten is defined as the substance to be bound.
2 In a competitive assay between Ag and Ab the
greater the amount of ligand or patient antigen
present, the lower the percent bound.
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3. Patient (Ag) or ligand must be identical to other
(Ag) and have a molecular weight o f500.
4. The measure of the strength of the bound antigen is
called affinity.
5. In non-competitive assays such as hepatitis-as
sociated antigen or other virus, the labeled molecule
could be either theAg or Ab.
6. Inproducing antiserum, freud’s adjuvant is used to
enhance the immune response and allow for slow ab
sorption into the animal’s system.
7. In non-competitive assays, the antibody or the an
tigen are labeled as count rates increase and con
centration decreases.

Chapter 2
ASSAY CHARACTERISTICS AND
PROCEDURAL EVALUATION
Objectives
• Understand the uses and meanings of: total counts
tubes, blank tubes, standards and controls.
• Be able to describe the differences between pooled and
commercial serum sources of controls.
• Develop a working knowledge and purpose of the
College of American Pathologists, American College
of Nuclear Physicians, and the ‘Center for Disease
Control.
• Be able to define accuracy, sensitivity and specificity
and how they are measured in RIA testing procedures.
• Describe other considerations to be considered when
evaluating testing procedures.

Assay Characteristics
The following is a discussion of the components of a typical
RIA test and their function in determining final resultant
values.

Total Activity or Total Counts TUbes
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Usually the first tubes utilized in any test. These tubes contain
only the radioactive tracer and are used as a comparison to all
other tubes.

Blank TUbes - 2 Types:
• Standard “O” Tubes
• NSB-Non-Specific Binding Tubes
Blanks: Blanks, or solutions containing only portions of the
assay system, are often necessary in the assay. An antibody
blank contains labeled ligand (Ag*), antibody, and antigenfree serum. Its use allows assessment of the antibody - labeled
antigen interaction as well as the efficiency of the separation
step. A second blank consisting of labeled ligand and antigenfree serum (without antibody or unlabeled ligand) gives infor
mation about the non-specific precipitation of labeled
hormone and the trapping of “free” ligand in the bound
fraction.

S tandards or Calibrators
Known amounts of different concentrations used to analyze
and compare with pt. unknowns and controls.
The purposes of standards are 1) to establish a curve of
dilutions on known amounts of substances to which the un
knowns may be compared, 2) to ensure a stable interassay
comparison, and 3) to compare the results obtained with other
laboratories or established quantities in other assay systems.

Controls
A control may be a standard or any known concentration of
test material that serves as a comparison between successive
runs (inter-assay), whereas the usual standard involves vary
ing concentration used to evaluate individual samples within
a single run (intra-assay). Controls may vary in concentration
ranges so that high, medium, and low ranges are covered.
Controls and standards are solutions that contain known
amounts of material, but their end uses may differ.
The manufacturers recommend levels of control Sera for each
different type of RIA assay. This is commonly referred to as
target values.
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These controls are used as a means of setting individual
precision limits of reproducibility from day to day on specific
tests being performed.
Sources of Control
• Pooled Serum—Manufacturers may send a laboratory
a serum containing many different Ag (Antigen) which
are to be used for numerous RIA assay procedures,
e Commercial—A serum containing only one specific
type of control assay.
External Surveys used as control measures for laboratory
assay quality control.
College of American Pathologists and the American College
of Nuclear Physicians help laboratories establish and main
tain quality control. JCAH of hospital may waive a formal
evaluation of an RIA if they are accredited by either organiza
tion.
The laboratory receives monthly unknown control serum
from these bodies and reported their results quarterly. A
composite answer from all reference labs that comply will
provide verifiable information pertaining to controls used.
If the laboratory is significantly off composite control answer,
they will have to document corrective actions to alleviate the
problem.

C enter for D isease Control
can be utilized as stop-gap for new procedures or new kits.
Example: Can provide positive (negative) serum samples for
new AIDS tests on the market.

Pt. Unknown Sam ple
These are the serum from the patient. One wants to find their
actual value of antigen in body. These values are determined
by interpolating counts from patient test tubes and comparing
them with counts of known standard values of concentration.
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Procedure Evaluation and Validation
Accuracy
Closeness to true or real value
In our RIA tests the true values are the standards or calibrators
provided to labs by the manufacturer of these kits.
These reference standards are weighted and measured by the
National Board of Standards which defines what calibrators
are acceptable and will be allowed to be used.
The National Institutes of Health and the World Health Or
ganization manufactures some standards that are used as
reference standards. Kits produced by RIA manufacturers
need to meet the criteria and specifications set up by one of
these bodies.

Recovery Studies
When a manufacturer sends a laboratory a known amount of
an antigen or reagent. The RIA lab does not know the true
value and must test for the amount of antigen and recover the
quantity. They then send in their analysis to the manufacturer
to see how close they were to the “true value.”

Precision
Degree of agreement of repeated measurement of a quantity
or “reproducibility.” Two types:
• Within Assay R un-In any particular RIA test, all
reagents are run in duplicate tubes. A coefficient of
variance value of less than 10% is acceptable.
• Between Assay Runs—A comparison of standard curve
from one assay run to another. Secondly, a cumulative
data collection of all high, medium and low controls run
on that type of assay.

Sensitivity
Minimum quantity detectable
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The manufacturer in his packet insert will describe and
analyze the smallest value that can be accurately interpreted
and reported out for a particular assay. This is usually
described in terms of some value (B) compared to the stand
ard “O” value (Bo) - B/Bo.

Specificity
Capacity to discriminate antigens of similar structure Can be
described and analyzed in terms of:
• Dilutional Parallelism—when a laboratory dilutes the
pt. samples and attempts to see if and/or where the ratio
of resultant values changes significantly.

Cts

Example: Dilution 1:1 - 10,000
1 :2 -will cts be cut in half?
1:3 - will cts be cut by one-third?
1:4 - will cts be reduced by one-fourth?

• Cross Reactivity—asks the question: What other
similarly structured antigens will interfer with analysis
of a given assay?
• Non-Specific Binding—NSB tubes when labeled
ligand (Ag*) and antigen-free serum (without antibody
or unlabeled ligand) are put together in the same test
tubes. The lab is looking for information about the
non-specific precipitation of labeled hormone and the
trapping of “free” ligand in the bound fraction.
Other Considerations when evaluating procedures include:
• Cost—Is it too expensive to run this kit in your
laboratory?
• Personnel Time—Do you have the workers that have
sufficient time to run this testing procedure?
• Equipment Required—Do you have all the necessary
materials available?
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• Manufacturers—Are they reliable, established,
reputable?
• Service—Can they supply the kits and materials
needed?
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REVIEW
Section 1
1. Discuss the purpose of:
a. Recovery study b. Dilutional parallelism c. Cross-reactivity 2. Explain why these components are utilized in an RIA test.
a. Tbtal counts tubes____________________________
b. Blanks______________________________________
c. Standards___________________________________
d. Controls____________________________________
e. Pt. unknown________________________________

Section 2
1. The property of antisera whereby antibodies react with two
or more antigens of similar structure and which reduces the
specificity of the assay is known as
a. sensitivity
b. cross-reactivity
c. avidity
d. antigenicity
2. Controls need to
a. be part of standard curves
b. set laboratory acceptable levels of reproducibility
c. be able to induce formation of (Ab) or (Ag)
d. all of the above
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3. Cross-reactivity results from some (Ab) molecules low
avidity for (Ag) and being unable to discriminate between
different (Ag) because of their structural similarities.
a. True
b. False
4. Cross-reactivity is
a. not desirable in RIA
b. similar to haptens
c. used as reference standards
d. all of the above
5. When running a standard RIA test, what goes into the
total count tubes?
a. standard O only
b. tracer and Ag-free serum
c. tracer and standard O
d. tracer only

Section 3
SftrSSSSSSS&SS

TorF

1. The total cts tubes are the second blank tubes con
sisting of labeled ligand and antigen-free serum.
2. Calibrators can be used to ensure a stable inter
assay comparison and compare results obtained with
other laboratories.
3. Two sources for control are the pooled serum and
the Centerfor Disease Control.
4. The College of American Pathologists work as a
stop-gap for new procedures or new kits. (Example:
provide positives for new AIDS tests)
5. A precision test within assay run is a comparison of
standard curves from one assay run to another.
6. Sensitivity can be analyzed by comparing some
valve (b) to the standard “O” valve.
7. Non-specific binding is analyzed by using dilutional
parallelism.
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8. Cross-reactivity is when similar structures interfere
with analysis of a given assay.
9. Non-specific binding are test tubes that have only
labeled Ag and antibody.
10. Most hospitals using RIA procedures send their
results to the National Institute of Health for evalua
tion.
.11. Precision is the capacity ofAg to discriminate.
.12. Affinity is closeness to true value.
13. In most testing procedures, the order of analysis of
test tubes is unimportant as long as the technologist
knows which is which.
.14. Controls are used to establish a curve of dilutions
on known amounts of substances to which the un
knowns may be compared.
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Chapters
SEPARATION TECHNIQUES IN RIA
Objectives
• Understand the overall purpose and usefulness of any
separation technique.
• Demonstrate a knowledge and understanding of the
purpose and methodology of:
° the absorption technique
° non-specific precipitation
° immunoabsorbent technique
° sandwich technique
° double antibody technique
0 magnetic separation method
• Be able to recall the uses of electrophoretic method
and gel filtration separation techniques.

Separation Methods in Radioimmunoassay
There are two basic methods of isotopic dilution performed
in the presence of specific binding agents. Radioimmunoas
say utilizes techniques that employ the principle of isotopic
dilution of labeled antigens and unlabeled antigens in the
presence of specific antibodies, with the desired end being the
separation of bound, labeled ligand (Ag) from the unbound,
free, labeled ligan (Ag). Radioassay utilizes specific binding
proteins instead of specific antibodies.
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The selection of a suitable separation procedure is based upon
the properties of the antigen and nature of the biological
material to be assayed. Successful separation techniques
should be rapid, inexpensive and simple. Also, common
available reagents should be used and there should be a
minimal margin for error in the procedure.
There are a number of separation techniques available, each
of which is discussed in the following paragraphs:
Absorption Techniques are based on the removal of the un
bound, labeled ligand (Ag) from the system after the con
clusion of the reaction. Many physical and chemical factors
determining the absorption, including size, charge of antigen,
cimposition and concentration of other proteins present pH
and ionic strength of the solution. The advantage of this
technique is the reduction of the concentration of free an
tigens to zero very quickly, thus eliminating kinetic influences
that would cause dissociation of the complex.
Some common absorbents are charcoal, talc, and silicates. A
common characteristic shared by all of the absorbents is rapid
binding of unbound Ag/*Ag. Silicates specifically are of value
because of their ability to absorb peptide hormones. Silicates
with high silica content are added to the incubation period or
phase. The absorption is rapid and centrifugation is simple,
the end result of centrifugation being the packing of silica on
the bottom of the test tube.
Ag*—Ab
(add

Ag —Ab

silica

supern
atant

+ Ag
Ab

Ab

fuge)

counted

Ag Ag* Ag
Ab
Sample

Incubate

bound Ag is absorbed
to the surface of the
added silica
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Separation of bound from free labeled Ag is the process
known as the Electrophoretic Method. This method uses
differential migration in an electric field to accomplish the
separation of labeled Ag from the Ag-Ab complex.
Chromatoelectrophoresis depends initially on placing a
sample containing 1) undamaged, free hormone, 2) bound
hormone, and 3) damaged hormone on a paper strip that
demonstrates selective preference for the absorbent of the
labeled, undamaged hormone.
The labeled, undamaged hormone is returned at the origin,
while other components migrate under the influence of buffer
flow of evaporation and the electric field on the strip. The
entire process, though, has some major disadvantages: it is
too complex and time consuming, needs a high voltage, and
must be performed under cold temperatures.
Non-Specific Precipitation is based on the principle that at
critical concentration of inorganic salt or organic liquid, the
Ab (globulins) become insoluble, while free Ag remains in
solution. The procedure precipitates all Ab present including
labeled Ag and Ab attached.
Separation of both free fraction of labeled Ag and bound can
be achieved by filtration or centrifugation.
either

^(NK.feSa,

ethanol

Ag*—Ab
A g-A b

centrifuge

Ag*
Ag

unbound

Patient/
Standard

Incubation

A g-A b

(or equilibrium)

Ag*—Ab
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What does precipitated mean? It means to cause a substance
to settle (heavier particles) in solid particles.
Gel Filtration, another separation technique, separates
materials according to size by the elution of these materials
through beds of porous beads. The adjustment of various
sizes and types of molecules can be done by correcting the
pore size distribution of the beads.
The incubated mixture can pass through the column in such a
way that the bound portion of the Ag-Ab complex is eluted,
leaving the unbound Ag in the resin.
The immunoabsorbent technique is similar to the solid phase
technique; the test tubes are manufactured labeled with Ab.
In the immunoabsorbent technique, an insoluble polymer is
coupled to an Ag binding agent. A polymer is a compound of
high molecular weight derived either by a combination of
smaller molecules or by condensation of small molecules
(eliminating the OH- molecule).
Longer

* Ag*Ag

Incubation
/
Ag*

X

"

Ag

X

Incubate
---- ►

Ag

X

Ag*Ab

4

disc is

Ag

removed

Ag*

& counted

Ag

X

AbAb

x=

coated

un labeled

disc

antigen

tube

add I g *

% bound
Ag ligand concentration
(High count rates reflect low unlabeled Ag concentration.)
The Ab is absorbed on polyethylene or polypropylene tubes.
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Another useful method is known as the Sandwich Technique
and is used for the detection of hepatitis B and viruses. A
plastic tube is pre-coated with a specific antibody. A standard
or unknown sample is added to the Ab coated tubes and
allowed to incubate. If the antigen is present, it will react with
the specific antibody sites. After incubation, the labeled Ag
is added and is followed by a second incubation. The tubes
are then washed and counted and any unbound radioactivity
is washed away. This is an example of a noncompetitive
binding assay.
Ab
Ab

incubate

Ab

A b -A g

+ Ab*

A b-A g

Ab

A b-A g

ad d
radioacti'
antibodi

Ab
Ab-coated
tube

standard
& patient

A b -A g -A b *

Ag concentration
increases, final count
rate will increase.

A b -A g -A b *
Ab

% bound
Ag
(Direct relationship in the noncompetitive binding assay)

The Double Antibody Technique utilizes a second Ab to
precipitate the initially formed Ag-Ab complex.
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Ag

A b-A g
Abi + Ag*

Ag

Ab-Ag

Ag-Abi-Ab 2
Ab 2

Ag*-Abi-Ab 2

A g-A g
specific Ab
competitive
binding assay

double antibody
separation

The second antibody is capable of recognizing the antigenic
sites on the first antibody molecule (Abi).
Abi-from a small animal such as a guinea pig or rabbit
Ab2-from a large animal; uses preparation of immuno-globulin
against those of the small animals

The advantage of the double antibody technique is in its
effective separation of free from bound hormone. This tech
nique differs from non-specific separation in that there is little
precipitation of the free, unbound, labeled Ag in the Ag-AbiAb2 complex.
The Magnetic Separation Method also utilizes two an
tibodies, as well as polymer beads with the capability of being
magnetized. When a magnetic field is introduced, separation
can begin. Antibody A is bound to the Antibody B (which is
attached to the beads), and it is this process which allows the
separation of free and bound Ag to take place. The beads
move to the bottom when the magnetic field is applied.
The advantages of this process are reduced incubation
periods, centrifugation is not longer needed, and it is simple.
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REVIEW
Section 1
1. Briefly describe these RIA separation techniques
(choose only 3 out of 5):
a. Absorption technique:

b. Non-specific precipitation:

c. Immunoabsorbent:

d. Double antibody technique:

e. Magnetic separation technique:

2. From one (1) of the above, draw out the process and dis
cuss each aspect. Is this technique competitive or non-com
petitive and why?
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Section 2
wsmmms

TorF

_
_

1. During non-specific precipitation, the bound por
tion is on the bottom of the tubes.
2. In non-specific precipitation, the principle that at
critical concentrations of inorganic salt or organic liq
uid the (Ab) concentration becomes insoluble while
(Ag) remains in solution.
3. The absorption technique utilizes a paper strip that
demonstrates selective preference for the absorbent of
the labeled.
4. In non-specific precipitation the unbound Ag is on
the bottom of the test tube after separation.
5. The magnetic separation method utilizes a double
antibody technique.

Section 3
mmmmsmsmimmma

Multiple Choice
1. When the final product after separation is Ab-Ag-Ab*
and there is a direct relationship between counts and an
tigen, the separation technique used was
a. double antibody
b. immunoabsorbent
c. sandwich
d. magnetic
2. A technique that utilizes a polymer, removes a disc to
count, and is an indirect measurement of antigen is
a. sandwich
b. absorbent
c. double antibody
d. immunoabsorbent
3. In the absorption technique, the most common
material used is
a. polypropylene
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b. (NH4)2S04
c. silicates
d. peptide proteins
4. Which does not belong? Selection of suitable separa
tion procedure is based upon
a. being rapid
b. inexpensive
c. fairly simple
d. commonly available reagents
e. none of the above
5.
is absorbed to the surface of the added silica
material.
a. Unbound Ab
b. Radioactive Ag
c. Radioactive Ab
d. Unbound Ag
6. The sandwich technique is used for
a. detection of hepatitis B antigens
b. non-competitive binding
c. Ab coated tubes
d. all of the above
7. Chromatoelectrophoresis, solid-phase, double-antibody
immunoprecipitation, filtration, and centrifugation are all
methods used to
a. iodinate the labeled antigen
b. separate bound from free antigen
c. purify the labeled antigen
d. produce antibodies for use in the assay
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Chapter 4
STATISTICS IN IN VITRO
LABORATORY TESTING
Objectives
Know the meaning and uses of:
•
•
•
•
•
•
•
•
•
•
•

the mean
frequency distribution
normal distribution
median
mode
range
standard deviation
percent error
confidence intervals
normal ranges
fitting the standard curve

Statistics Needed
Invitro RIA tests depend upon statistics principles very heavi
ly. Some important questions that need to be considered are:
• How long should a sample be counted?
• What do you do with a sample with low count rates and
high background counts?
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• When is the quality of results compromised?
• How do we know the instruments are accurate and
reliable?
• How long can we use a test kit without compromising
our test results?
Central Tendencies
Mean: the sum of all numbers
number of items

Frequency distribution: examination of all the different in
dividual counts
Normal distribution: resembles a bell-shaped curve, where
the majority of counts are clustered in the middle
Median: middle point
Mode: most frequent occurring value

M easure of Dispersion
Range: difference between largest minus the smallest
Standard deviation:
,(y 7)2
n-1
■msimmmsmsstmmmmsmmmmsmmm

Fitting th e Standard Curve
The standard curve is estimating point value samples of
known concentration of the material under study. Then
under conditions identical to those used by patient samples
from known results, curves can be constructed that allow
estimateion of patient values. The patient values are called
interpolated into the actual known standards.

IN VITRO NUCLEAR MEDICINE LABORATORY M A N U A L

APPENDIX C-39

The Use of the Normal Distribution
Example of its u se in statistics:
Number of Cts
100

(1SD)68%

Range

+ 10

Percent Error

90-110

10%

1.000

+ 32

968-1,032

+ 3.2%

10.000

+100

9,900-10,100

1.0%

100.000

+317

99,683-100,317

+ 0.3%

In routine N.M ., the decision must be made how many cts. be
accumulated to have reasonable confidence that cts. within
acceptable degree of error.
95% confident - within + 2% error
10,000 cts. - represent 68% chance of 1% error
2SD = 95%

3SD = 99%

range
9,800-10,200

2SD
+ 200

percent error
+"235

Regardless of time required, 10,000 cts. should always be
accumulated.
Relationship between number of cts, recent errors, and
desired confidence level:
V = % error

68% confidence N = 10,000 N = # of cts.

V*
95% confidence N = 40,000 V

2

99% confidence N = 90,000 V

2

68% - preliminary studies
95% - routine studies
99% - research studies
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Suppose: We wanted to know + 1% error or 99% confidence.
How many cts. would be needed?
(n) = 90,000 X (1)2 = 90,000 cts.
95%, 2% error
(n)

= 40,000 x(2)2 = 10,000 Cts

As the number of cts. (n) collected increases , the relative
percent error decreases.
Error: The deviation of an observed value from the from
absolute or true value:
• Determinate errors - equipment malfunction
• Indeterminate or random errors - operator has no
control
(See lab exercises on normal distributant percent error)

Quality Control and Normal Ranges
The results obtained in any type of lab must be valid. Proved
Q.C. measures should be routinely used in order to ensure
valid results.
Q.C.: Any and all measures taken to ensure a valid result.
Precision, accuracy, reproducibility, standard
controls, sensitivity, specificity
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REVIEW
Section 1
Based on the following set of count rates, find the mean,
median, mode, 1SD, 2SD, 3SD
1. 10,352
2. 9,681
3. 10,945
4. 11,842
5. 10,369
6. 9,677
7. 10,001
8. 10,356
9. 10,945
10. 10,258

Section 2
Multiple Choice
1. TTie minimum number of counts for any sample testing
in nuclear medicine is
a. 5,000 cts./min
b. 10,000 cts./min
c. 10,000 cts. regardless of the time required
d. depends upon the amount of efficiency one desires
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d. depends upon the amount of efficiency one desires
2. The number of counts needed in routine studies can be
derived from
a. N = 10,000/V squared
b. N = 40,000/V squared
c. N = 90,000/V squared
d. depends upon type of scan one is performing
3. If a technologist is receiving 900/ct./sec on a patient for
a spleen scan, how long must he count to be + or - 2%
error: _____ .
4. As the number of counts in any test increases,
a. the relative percent error increases
b. the relative percent error decreases
c. percent error will not change
5. If a test is performed in nuclear medicine department
with 5,000 ct./sec., how long must the test take in order to
be 95% confident and + or - 2% error:
a. 20 seconds
b. 2 minutes
c. 2 seconds
d. 5,000 of x 200 seconds
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Chapter 5
BASIC IN VITRO EQUIPMENT AND
DETECTION INSTRUMENTATION
Objectives
• Have a working knowledge of pipettes, vortexers,
centrifuges, refrigerator, timers, test tubes, and
incubators in a RIA laboratory setting.
• Know the basic principles and concepts of a gamma
well counter and a liquid scintillator, including their
applications and purposes.
• Understand the counting of iodine 1-125 and its many
inherent problems.
• Demonstrate knowledge and understanding of the
various components of gamma scintillation detection
and liquid scintillation.
Basic In Vitro Equipment
•SK3S8383&KS3SSS83

Pipettes
A device which no RIA laboratory can do without is the
pipette. Pipettes are used to withdraw specific quantities of
solution, as a sample or ingredient of an RIA kit. Pipettes are
available in various sizes and volumes or they may be
equipped with a control which can be set to control the
amount of solution to be collected. The tips of the pipettes
also vary in size and are usually made of glass or plastic, and
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most are disposable. Most of these devices are semi
automatic; that is, they are operated by pushing a (button) at
the top of the pipette while in solution and releasing to
remove the pipette. The tip is then placed into the desired
tube and the (button) pushed again to release the solution.
Pipettes are also available which have rubber suction devices
or designed so that the user must use mouth suction, but this
kind is not appropriate for collecting samples or radioactive
materials due to the inherent danger of swallowing or trans
ferring contaminated solutions. Automatic pipettes are also
used in those laboratories which do large quantities of tests.

Vortexers
Since most tests require the mixing of samples and reagents,
electronic instruments called vortexers have become indis
pensable. The test tubes can be placed in the vortexer for a
predetermined time (some require that the tube be held at
the top until the mixing is done) to assure adequate agitation
and to increase the chances of component interaction.

Centrifuges
The centrifuge is used for the separation of elements, namely
the supernate and precipitate. The tubes are placed in the
centrifuge, being careful to balance the weight from side to
side so as not to cause uncontrolled vibration of the instru
ment. Care must also be taken to control the time, tempera
ture (if possible; some centrifuges do not have this capability),
and speed inside. Its principle is based on that of centrifugal
force, with the heavier elements ultimately ending up at the
bottom and the lighter elements on top. Most will have
controls which the operator can set to a desired number of
revolutions per second or minute.

Refrigerators
Refrigeration is essential for the storage of certain kits which
require temperatures below normal room environment in
order to maintain their stability. Certain samples, such as
blood, also require refrigeration to keep them fresh and
usable for a longer period of time. These refrigerators must
be lead-lined (due to the radioactive materials being stored
inside) and should have the capability of being locked for
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safety and protection. Thermometers should also be easily
accessible and monitored to avoid the costly destruction of
samples and kits.
mmmsssm

Timers
The use of timers may be necessary in some laboratories
should some instruments not contain one. Devices such as
vortexers and centrifuges may already have timers; but should
they not or this component is malfunctioning, a timer would
be essential.

Test Tubes
Test tubes come in various sizes and materials. Plastic tubes
are lighter in weight, basically non-destructible, and are less
expensive than glass since disposability can be important.
Test tube holders and racks are also available in various sizes,
materials, and capacities. Tubes and racks should be able to
be identified easily and/or labeled appropriate (by using an
easily removable maker if nondisposable, for example).
mmzsimmmss

Incubators
An incubator is used should the test tube require a constant
temperature.

|In Vitro Detection Instrumentation
• Gamma well counters
• Liquid scintillation
Primary strength of RIA is its ability to measure extremely
small quantities of material because of the presence of
radioactivity. Radiation means spontaneous decomposition
of a nucleus that is accompanied by emission of radiation
types common in RIA, gamma rays, x-ray, beta emissions.
Gamma ( y ) is most desirable, as contrasting with beta radia
tion 1-125,1-131, Co-57 are the most commonly used gamma
radionuclides. Solid scintillation detector (well counter) can
be used.
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For some applications the counting of beta particles must be
performed. The beta emitting radionuclides commonly used
tritium 3H and 14C - liquid scintillation counting is most
frequently used.
Detection of Radiation by NAI System
sample
crystal

Output
Device

Height

Tube

Analyzer
Preamp

This type of detection is considered two (2) jz . It relates the
positioning of the sample within the NAI counter.

NAI Crystal (TL) Thalium Impurities
Gamma Detection System
Iodine is an element of high (Z) number the properties of an
absorption event by photoelectric absorption is greatly en
hanced.
Thalium impurities—When a ( y ) or (x-ray) photon is ab
sorbed, visible light is emitted by the crystal. The amount of
light emitted is proportional to the energy given up to the
photoelectron or the recoil by the incident photon.
The technologist must select the proper window in the pulse
height analyzer for the specific energy range of the
radioisotope one wishes to count. If PHA accepts a pulse, this
pulse is then passed to the output device—commonly scaler.
Simply sums the cts. which have been passed by the PHAs.
The output of the scaler with modem instruments usually
prints the results on some form of hard copy output-coupled
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by computer that will give both total cts. and ct. rate accumu
lated.
If more than one isotope is counted, two PHA are needs.
Example: B-12, folates (C 057,1125)

Instrument should be calibrated separately for each
radionuclide measured. 1251,1311,57CO

Counting of 1-125
Counting iodine 125 has many inherent problems. First, be
cause of its very low energy, it has many self-absorption
problems, which stem from the fact that the energy may be
absorbed in the sample if the sample is too large, if the
container holding the sample is too thick, if its position within
the well is improper. All of these situation may drastically
reduce the count rate. Second, setting up the spectrum has a
unique problem.
When the spectrum of 1251 from a sodium iodide detector is
plotted, the spectrum shows two basic energy peaks. One
peak is at approximately 28 KeV, and the second peak is at
approximately 60 KeV. The first primary energy peak is com
posed of basic characteristic X-rays and the primary 35 KeV
energy peak. Because of the inherent resolving problem of a
sodium iodide detector, the individual peaks from the X-ray
and the primary gamma ray cannot be resolved. Thus a
resulting peak of 28 KeV is observed. The second peak, which
is sometimes called the sum-peak, is the sum of the charac
teristic x-ray from 1251 and radiation from the daughter
product of 1251 (tellurium 125). The resulting sum is ap
proximately 60 KeV. When 1251 is counted, the spectral
settings either can be set to count just the primary peak, which
is a larger peak, or it can be set up to count both peaks.

The Decay Schem e of 1-125 Looks Like:
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The Decay Schem e of 1-125 Looks Like:
Electron Capture: e + p

n +

+ energy

1251
electron capture
125Tb
52Te

ENERGY PEAKS:
Primary peak (larger)
28KeV

60 KeV

Liquid Scintillation Counters
Used for low energy beta emitters, sample is actually dis
solved in the scintillation itself.
Advantage—Excellent geometry. Literally surrounded by
scintillator (4IT) geometry.
Disadvantage—Problem of solubility of material to be
counted. Sample cannot be brought into solution. Counting
by liquid scintillation becomes more difficult.
Four Components:
• Solvent: tolvene and diozane. This is an aromatic
solvent.
• Solubilizer: protosol, hydroxide. This requires
treatment with relatively strong agents. It functions to
dissolve the sample for biological liquid counting.
e Fluor: a primary and secondary. Primary: (PPO) 2.5
diphenyloxazole. Light emitted by primary fluor is a
wavelength not detected by some types of P.M. tubes.
Secondary: (POPOP) 2.5 phenoyloxade benzene.
The second fluor is used to shift the wavelength to emit
light.
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• Radioactive sample: usually H-3 or C-14 Quenching
Problems—Anything that interferes with the
visualization by P.M. tubes of the emitted light.
Chemical Quenching—Scintillation solution absorbs
the energy of radiation without the emission of
detectable light (inorganic adds, organic compounds).
Color Quenching—Samples that are red or yellow, such as
blood or urine, may cause problems. Red color absorbs the
bluish light emitted by fluor, causing reduction in amount of
light reaching P.M. tubes and reducing count rates.
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REVIEW
Section 1
1. List and describe the major components of a gamma
well counter

2. List and describe the 4 components of liquid scintilla
tion counters, including their functions.

3. Compare gamma well counters and liquid scintillation
in terms of geometry, uses, advantages and disadvantages.
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Section 2
1. The principal gamma energy and half-life of 1-125 is
a. 159 KeV, 13 hours
b. 364 KeV, 8 days
c. 173 KeV, 2.8 days
d. 35 KeV, 60 days
2. 1-125 shows two basic energy peaks, 28 KeV and 60
KeV. 28 KeV is based on
a. characteristic X-ray and primary energy peak
b. inherent resolving problem
c. 1-131 interference
d. all of the above
e. a and b only
3. The most common causes for counting failure include
a. high voltage drift
b. cracked Nal crystal
c. preamp to scaler malfunction
d. loss of control of window setting
e. none of the above
4. Geometric factors do not include
a. volume of sample solution
b. type of Nal arrangement (side window)
c. position of sample in counter
d. none of the above
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Section 3
T/F Section
_
1. A gamma counter works in this sequence:
Nal

-*

pre-amp

-*

P.M. tubes

-* PHA

-*

scaler

2. The primary peak (larger) for 1-125 is approximate
ly 60 KeV and decays by electron capture.
3. 1-125 window settings are 25-60 KeV.
4. Liquid scintillation counters are used to count beta
emitting radionuclides such as 1-125,1-131, and C-14.
5. 1-125 has a sum-peak of approximately 35 KeV and
decays by position emission.
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It: can be predicted that RIA and related techniques
will be applied increasingly to the detection of active
infectious disease.

Straus, et al

(1981), have reported an

RIA for a tuberculoprotein that can make the diagnosis of
active tuberculosis more rapidly and in a much less
e x p e n s ive, simpler, and far safer fashion than with the use
of classic microbacteriologic methodology (p. 3214.) .

Even

were this technology applicable only to the diagnosis of
tuberculosis,
However,

it would remain a major breakthrough.

it should serve as a model for the development of

assays for proteins associated with other slow-growing
organisms, the diagnosis of which may be difficult w i t h
standard microbiologic methodology.

Future of RIA
This review of the development of a small sampling of
applications of RIA emphasizes the fact that in science new
truths become evident when new tools become available.

For

more than a quarter century, RIA has been an important tool,
fruitfully employed in diverse areas of biomedical
investigation and clinical medicine.

Can we predict what

the relative usage of radioactive and non-radioactive labels
in immunologic methods for diagnosis (immunodiagnostics)
will be in the future?

A Wall Street investment concern has

attempted such a prediction (Dunne, 1981) .

They h a v e

estimated that in 1980 the market segment for RIA in

immunodiagnostics was $332 million, for non-radioisotopic
therapeutic drug monitoring $43 million, and for all other
non-radioisotopic immunoassays $28 million? in 1990, they
predict markets of $785 million, $625 million, and $838
million respectively for these three methodologies.

Thus,

from a commercial point of view RIA usage is expected to
more than double during the decade of the 1980s, but its
fraction of the total immunodiagnostics market is expected
to drop from over 80 percent to about 35 percent.

Why?

First of all, many of the new applications simply do not
require the exquisite sensitivity of RIA.

For instance, in

therapeutic drug monitoring the concentrations being
determined are generally a million-fold higher than the
concentrations of peptide hormones.

Furthermore, assays for

drugs generally need not be quantitative over a multiple
hundredfold range.

It is often necessary only to determine

whether the concentration is high enough to be efficacious
and not so high as to be toxic.

In the field of infectious

diseases, where immunodiagnosis will play a major role, the
choice between radioisotopic and non-radioisotopic
methodology again would depend on the sensitivity required;
in the presence of massive infection, the massive infection
the sensitivity of RIA is not likely to be necessary.
However, in a number of instances, those promoting nonradioisotopic labels are not necessarily suggesting that
these have any technical advantage, but rather that
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regulatory procedures and fear of radiation at any level
would make radioisotopic label less desirable.

Nonetheless,

RIA is likely to remain the method of choice for what has
been its first application, the measurement of peptide
hormones in plasma and other body fluids, since their
concentrations are well below 10"10M, and the sensitivity of
RIA is essential

(Dunne, 1981).

RIA and related methodologies have opened new vistas in
science and medicine.

RIA is now used in thousands of

laboratories around the world to measure hundreds of
substances of biologic interest.

Even now, a quarter

century after the introduction of RIA, there remain many
additional fields that can be explored with its help.

Review of In Vitro Literature
A selective review of the nuclear medicine In Vitro
literature was performed on over 300 articles, text books,
and manuals.

This researcher examined the literature and

categorized the materials into a content analysis chart.
The five areas were: Level of Material, Type of Material,
Possibility of Providing Laboratory Exercises, General
Principles, Concepts Discussed, and Specific Testing
Procedures Mentioned.
The following is presented as a content analysis chart
and a summary of resultant values obtained.

Content.Analysis of In Vitro Nuclear M edicine
Literature.

Column indexes and abbreviation conventions

Column 1, Bibliography
Column 2, Level of Material
under = undergraduate
grad = graduate
tech a technical
Column 3, Form of Material
Column 4, Laboratory Exercises Provided
Column 5, Concepts Discussed
Column 6, Specific Testing Procedures
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Chapter 6
EQUIPMENT QUALITY CONTROL
Objectives
• Know the three basic parameters of equipment
performance evaluation:
° Counting efficiency
° Statistical bias
° Background cts.
• Be able to demonstrate an understanding of the
purpose of these 3 testing procedures.
• Be able to quantitively analyze and set up these 3
testing procedures.
• Demonstrate a knowledge of normal ranges and their
functions.
° Be able to set up a data reduction system for:
° point-to-point analysis
° log-logit assays
° single-point assays
• Know the different kinds of RIA testing procedures
that match up to the appropriate data reduction
methods.
• Understand how to assess antibodies, labeled ligands,
standards and different RIA testing kits.
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Equipm ent Perform ance Evaluation.
Three parameters can affect overall accuracy and/or
reproducibility of test results:
• Counting efficiency (accuracy)
• Statistical bias (reproducibility)
e Background cts.
Ct. Efficiency: Number of cts. registered compared to the
number of potentially effective emissions from the source.
CPM =

a . Per Min.
Disintegrations
Per Min.

The ratio should be near
ly constant for a given
detector, nuclide, sample
size, base and window
setting, gain and high
voltage.

Ct: A standard having a similar decay scheme. A long halflife and record the results (see lab exercise).
Statistical Bias: The most critical performance test of any
counting equipment is when large number of samples are to
be counted and compared to some standard value.
Test is performed to ensure that variation in a series of in
dividual cts. are likely to be due to random nature of radioac
tive decay and not by other influences.
Using a single source (long - many weeks)
T 1/2 -

ct. a series of 1 min. cts.

This set of cts. is compared to theoretical variation that one
would expect from random sampling:

C hi-Square Test
JU.

= g(X-X)

—Compare result to tabulated P values

X
P values should fall between. 10-.90 if outside these limits, the
most common causes for non-reproducible counting failure:
• High volt, drift
• Cracked Nal crystal
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• Loss of optical coupling between P.M. tubes and crystal
• Loss of control of window setting
B5S«SS3SSSSSSSS3S5S33SSSS3SSSSSS3S3SSSS^SSSSSSK3S3S3SS3

Background C hecks
Observed background to quickly alert for contamination or
other radioactive sources in area.

Sam ple Collection
Most assays are performed on the blood components (plasma
or serum).
Collection must be reviewed by specific assay protocol.
Proper attention to timing of collection of samples TSH and
cortisol is necessary to account for nature of the secretion of
these hormones.
Posture may affect serum secretion, such as plasma renin.
Food intake may affect certain test results. Human growth
hormone is markedly affected by stress.
Collection involves immediate clotting and centifigation and
possible freezing -20C for some specimens.

Normal R anges
For any assay, should be established in each laboratory.
N.R. usually refers to healthy persons. It has become rather
difficult to relate to natural phenomenon, such as aging, ac
tives.
Statistical principles use 95% confidence limits to define
normal population or test results.
Expected measurement for 1 individual in 20 to fall outside
of the normal range.
Fairly large population must be sampled. Population should
be illness-free (by as many criteria as possible) when defining
the normal population.
Other factors: race, age, sex, etc.
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Setting up Your Equipment Parameters
Background
In all cases background is subtracted automatically prior to
print-out of counts or any calculations.

W indow Settings
There are two preprogrammed isotope values which can be
used to set the window, 1-125 and Co-57. Ranges for these
isotope values can be entered in one or two ways. The ap
propriate keys representing the isotope can be entered. Or
the range can be entered by pressing the appropriate numeric
keys. For example, the range for 1-125 equals 15 to 70 KeV.
By pressing the numeric keys then pressing the decimal point,
the range is entered.
These isotopes have these equivalent ranges:
1-125 = 15 to 70 KeV
CO-57 = 45 to 235 KeV

When unknowns are run, the standard deviation and coeffi
cient of variation are calculated as a function of dosage.
Standard Deviation (SD)

Coefficient of Variation (%CV) =
X

Mean =

Sum of Individual Counts
# Replicates

X2 = £ (X-X)2

Chi-square =

~=r

x 100
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Methods of Data Reduction
Protocol: Point To Point
Point to Point assays are entered similarly to log-logit assays:
•
•
•
•

Total count tubes (if any).
Non specific binding (NSB) tubes (if any).
Zero standard (Bo) tubes (if any).
Lowest standard

• Highest standard. Point to Point assays can be run
without:
° Total count tubes
° NSBs
° Bos
Standard values for concentrations other than 0 (zero) must
be entered in ascending order (from lowest to highest).
Respective counts for those standards can be entered in either
a consistently ascending order or descending order. If the
counts are not entered in consistently ascending or descend
ing order, an error message will be printed: RECHECK
STNDS. The assay calculations will revert to the counter
mode and only counts will be printed.
The method of data reduction for Point to Point assays uses
the respective averages from each set of adjacent standards to
plot a series of straight lines.
Average counts from a givenset of unknowns will then be read
from a series of straight lines and the corresponding con
centration is determined.
If an individual unknown tube has a count rate corresponding
to a concentration that is less than the lowest concentration
or higher than the highest concentration, it will be deleted. If
replicates are being run and one or more tubes of a given
sample are deleted, the calculation will continue based only
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on the undeleted tubes. When this occurs the operator should
validate the data.

Protocol: Log-logit (curve Fit) A ssays
Log-Logit assays must include:
• Either a total count tube)s) and/or Bo tube(s) (zero
standard tubes).
® At least three standards other than zero.
Standard values (concentrations other than zero) must be
entered in ascending order (lowest to highest concentrations).
Assays must be loaded and run in the following sequence:
°
°
°
°

Total count tubes (if any).
Non specific binding (NSB) tubes (if any).
Bo (zero standard) tubes (if any).
Lowest standard

° Highest standard
DATA REDUCTION
The following formulas are used in the data reduction
process:
Total counts = Free counts + Bound counts + NSB
Bo = Bound counts at zero - NSB
Logit = In

-1— where y = B/Bo or B/T
1-y

Pipetting Error =

\y

(sd^-t

whore (SD)2! = Variance of total count tubes

The curve fitting procedure is a log-logit transformation using
all data points other than the zero standard.
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Each concentration is converted to its logio. Each standard
count ratio (B/Bo or B/T) is converted to a logit.* A least
squares linear regression is then performed. The unknowns
are determined by converting each ratio to a logit. If more
than one ratio exists per patient, a mean of the patient’s logits
is calculated. The unkinown can be read off the regression
line. The following will be printed:
Concentration of the unknown
SD
% CV If more than one reading/patient
Special checks of the data are performed during data reduc
tion.
• All standards and unknowns must be:
° >NSB
° < Total
° <Bo
If standards do not meet these criteria, the assay must be
re-run. When unknowns do not meet these criteria, they are
deleted.
• When counting bound counts, or when free counts are
converted to bound counts, the counts must decrease
as the standards increase.
Each standard count is compared to the mean of the previous
standard value. If it is not less than the previous mean, an
error message RECHECK STNDS will be printed, identifying
the standards as questionable and the assay will continue.
• Unknowns and controls which are not within the range
of standards enteredare either extrapolated to zero or
reported higher than the highest standard. Such
controls appear as zeros in Q.C. data.

Protocol: Single Point A ssays
A Single Point assay must be loaded and run in the following
sequence:
• Reference control tubes (standards)
o Controls (knowns, unknowns, Q.C. tubes)
• Unknowns
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Single Point assays, such as Triobead, have only one standard
value. If more than one replicate is used of the standard value,
the average count of the replicates is used and a straight line
is plotted through that data point (counts vs. dosage or %
bound, etc.) and the zero concentrations point.
If more than one tube is included for each patient, a mean is
calculated.
Controls and unknowns are read from that line and reported
in the same units as the standard. For example, if the standard
is entered as 100%, each unknown is reported as a percentage
of the standard.
The patient‘s T3 value is then calculated using this equation:
Unknown % = Unknown 00001 Mean X Reference Value in %
Control Count Mean

If multiple replicates of either or both standards and un
knowns are run, the standard deviation and coefficient of
variation are calculated and printed.
Q.C. data stored for each assay includes:
•
•
•
•
•

Date
Lot Tech. No.
Reference Control Counts
Reference Value in %
Control Counts

If a T3 test, such as Triobead, is being run and T7 values are
desired, the respective T4 value for each patient must be
manually entered. The patient’s T3 value, when derived, is
multiplied by the T4 value. The units of T7 value are the same
as T4 value.
If T7 values are desired for some but not all patients, a zero
should be entered in response to the operator prompt asking
for T4 values for those patients whose T7 value is not neces
sary.

A ssessm en t
Binding Agents—Antibodies requirement are specificity of
reaction and sensitivity.
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Actual specificity is determined by comparing known substan
ces that might cross-react with the binder substance that show
identical dose-response curves can be assumed to be immunologically similar, but actually may not be identical com
pounds.
Specificity of a system is usually estimated by adding known
interfering substances and comparing the dose-response cur
ves.
Labeled Ligand—Assessment is concerned with:
• specific act of the substance
• purity of the substance
® identity of the labeled ligand with its corresponding
unlabeled substance (use of chromatography)
Standards—Purposes of standards are:
• establish a curve of dilution on known amounts of
substances to which the unknown may be compared
« ensure a stable interassay comparison
• compare the results obtained with other lab or
established quantities

Kit Evaluation
Some tests are requested by MDs so infrequently that it may
be advantageous to send samples to large commercial labs.
Isotope needed—important consideration:
liquid scint. 3H, 14C and gamma counters - 1251,1311,
57Co
Stability of the reagents (components) will determine the
shelf life of an individual kit. Lyophilized (freeze dried)
agents generally provide the longest shelf life. Frequency and
the number of tests performed influence kit selection.
Reliability of delivery, cost, policy of replacement, ease of
instructions, provisions for free kits.
Type of equipment needed, separation techniques, pipetting,
cting, temperature requirements, time requirement.
Kit should be chosen based on:
• clinical needs
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•
•
•
e

equipment, personnel, and time available
component characteristic of kit
cost
manufacturer’s consideration, reliability, availability

Kit evaluation should include:
• specificity of assay
• sensitivity of assay dose-response curve (shape of
curve)
• inclusion of controls to judge interassay variation and
clarity
• protocol itself, separation technique, equipment, time
required
• components of kit: shelf life, storage, replacement
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REVIEW
Section 1
1. Name at least three (3) quality control measures used
in gamma well counter equipment and their specific func
tions. Please show all work:

2. Calculate efficiency of a given gamma counter based on
the fo lowing data:
CPM of counter = 31,501
CS-137 = T l/2 30 years - calibrated 9/71-1 uci
2.22 x 104 DPM = lu c i

3. Very briefly, describe these data reduction methods
used in RIA testing.
a. Point to point:
b. Log-Logit:
c. Single Point:
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Section 2
Which d o e s not belong?
1. Important components of kit evaluation include:
a. cost
b. clinical needs
c. equipment, personnel, and time available
d. manufacturer’s availability
e. a and b only
f. none of the above
2. The kit itself should include:
a. protocol
b. spedfity of assay
c. components of kit
d. inclusion of control to judge interassay variation
e. none of the above
3. The three parameters that can affect overall accuracy
and/or reproducibility of test results include:
a. counting efficiency
b. gamma absorption test
c. statistical biases
d. background counts

Tirue/False
_
4. The results obtained in any type of lab must be
valid. Proven quality control measures should be
routinely used in order to ensure valid results.
_
5. One o f the aspects o f assessment o f labeled ligand
is concerned with the purity of the substance.
_
6. Counting efficiency is the number of counts
registered compared to potential number of effective
emissions.
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7. A test to measure the variation o f a series of counts

from one source is the background check.
8. Point to point data reduction method allows for the
development o f a nicely uniformed curve.
9. Chi-square test is used to check accuracy o f a
gamma well counter.
10. A coefficient of variance value within assay runs
must be greater than 10% to be acceptable.
11. Point to point assays can be run without total
count tubes, NSBs and Bo.
12. Log-Logit data reduction method is used for one
standard only. Example: HCG-B testing.
13. In single point assays:
Unknown % = UnknownCt-Mean

x Reference value in %

Control Ct. Mean

14. Coefficient of variance — ________
C hi-Square

15. Point to point data reduction utilizes a least
square linear regression.
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CHAPTER?
HEMATOLOGY
Objectives
• Be able to provide a definition, including function and
purpose, of the following terms:
° erythocytes
° leukocytes
° thrombocytes
° specific gravity
° hematocrit
° plasma
• Understand the basic principles and methodology
needed for blood sample collection.
• Be able to demonstrate a basic understanding of blood
fluid precautions.
• Be able to demonstrate how to perform a blood volume
determination.
• Know the principle of dilution and its purpose.
o Understand the uses and basic procedure for plasma
volume and RBC volume determination.
• Know the basic procedure and purpose of red cell
survival testing and iron metabolism studies.
Blood is a part of the main transport system that delivers O2,
nutrients, hormones, and antibodies to the tissues.
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Blood makes up approximately 7-8% total body weight.
Fluid fraction—
• plasma
Formed elements —
• red cells (erythocytes) (RBC)
• white cells (leukocytes) (WBC)
• platelets (thrombocytes)
Specific gravity—Formed element which values are greater

than 1, the plasma cells tend to settle if allowed to stand.
• Because of abundance of red calls
5,000,000/mm3
• in relation to leukocytes
8,000/mm3
• Relative small size of the platelets
Volume of packed erythocytes expressed as percentage of
blood sample—hematocrit
• Normally averages 45%
• Supernatant plasma (plasmacrit) 55%
Plasma—Complex, watery fluid contain various ions as well

as inorganic and organic molecules.
Solid constitent by plasma proteins 7.5ym/100 ml
Plasma protein helps maintain the constancy of the blood
reactors.
Albumin factor together with the proteins concerned in blood
clotting are manufactured in the liver.
Globulins, the fibrogens, are formed by reticuloendothelial
systems, plasma cells, lymphid nodules.
RBC—Circular, non-nucleated, biconcave manufactured —
RB marrow—vertebrae, sternum, ribs. Hemoglobin con
tent —red cells carries 02. Red cells usually survive for about
120 days.
WBC —Leukocytes, are nucleated (50-70%).
• Granulocytes —formed in RB marrow - survive for less
than 2 weeks.
• Lymphoid tissue (lymphocytes) —20-40%, survive
2-200 days, essential for the development of immunity
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• Monocytes—2-8% phagocytic, play major role in
production of Abs.
Platelets—Small, non-nucleated, granulated bodies formed
in RB marrow, survive 10 days, provide support for en
dothelium of injured vessels and formation of hemostatis
plugs, particulaiy in blood coagulation and clot retraction.

| Blood Sample Collection
Quality control involves not only actual assay consideration,
but also the sample itself should be subjected to a similar
scrutiny. Because most assays are performed on blood com
ponents (plasma or serum), these samples are the most im
portant to consider. It should be emphasized, however, that
many other body fluids and organ structures may be analyzed
by the principles of radioimmunoassay and related techni
ques. For example, urine may be analyzed for its content of
insulin, thyroxine, etc. We will confine this discussion to
blood samples, bot other samples should have similar atten
tion when they are analyzed.

Patient Factors
Collection of samples must be preceded by a review of the
specific assay protocol. Several assays require special proce
dures for collection. For example, proper attention to timing
of collection of samples for HTSH and cortisol is necessary to
account for the circadian nature of the secretion of these
hormones. Posture may affect serum secretions, such as plas
ma renin, and food intake will obviously affect insulin levels.
Human growth hormone is markedly affected by the presence
of stress. These factors must be either known or controlled at
the time of specimen collection.

Sam ple Factors
Prompt handling of the specimen is desirable, and thorough
mixing of any anticoagulant material should prevent un
desirable clotting. Since many assays require serum, clotting
of the collected blood ollowed by centrifugation and freezing
(-20°C optimal) of the serum specimen should be expedited.
Some substances may be rapidly destroyed in whole blood
(such as ACTH), while others (such as angiotensin) may be
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inactivated by enzymes and require the addition of enzyme
inhibitors. Hemolysis causes increased enzyme release and
may accentuate enzymatic destmction of specific substances
being measured. Anticoagulant effects on the assay should be
evaluated prior to sample collection. The total amount of
sample available should be adequate for the specific assay.
zzmmmmmmmmss

Normal R ange
The statement has already been made that the normal range
for any assay should be established in each laboratory. This
section will review the concept of a normal range and how the
laboratory can approach its determination.
The normal range in medical terms usually refers to healthy
persons. It becomes rather difficult to relate a state of health
(or ill health) to natural phenomena such as aging, activity,
etc. Often the characteristics of healthy and ill persons over
lap, further complicating matters. Thus the simple estab
lishment of a “normal range” may entail serious arbitrary
decisions on the part of the laboratory, which may directly
affect the usefulness of the determination.
Many factors affect levels of assayable substances besides ill
health. Age has been mentioned. Other factors include al
terations by conditions unrelated to the substance being
measured, as occurs in unrelated diseases in the same in
dividual; lack of longitudinal study of the individuals; cir
cadian variations (as with ACIH); and effects of posture. To
establish a true “normal” population, these factors need to be
determined and standardized.
A typical application of statistical principles is to use the 95%
confidence limits to define the “normal” population or test
results in that population. Using these limits, the operator
would expect the measurement for one individual in 20 to fall
outside of the normal range ( one in 40 would exceed the upper
limit, and one in 40 would be below the lower limit). This
technique of looking at a population of values in a “normal”
population and forming a mean value and its standard devia
tion is the most frequently used method for deriving a normal
range for the determination.
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Blood and Body Fluid Precautions
Health care workers need to consider ALL patients as poten
tially infective and to adhere rigorously to infection control
precautions for minimizing the risk of exposure to blook or
body fluids of ALL patients. Body fluids include: urine, feces,
oral secretions, sputum, vomitus, saliva, semen, wound
drainage and all other moist body substances.
The Centers for Disease Control recommend using the fol
lowing precautions when caring for ALL patients:
1. Gloves should be worn when:
a. touching blood, body fluids, mucous membranes or
non-intact skin of all patients.
b. handling items or surfaces soiled with blood or other
body fluids.
c. performing venipuncture or other vascular access
procedures.
Gloves should be changed after contact with each patient and
hands should be washed, with particular attention to the area
around the nails and in between the fingers, immediately after
gloves are removed.
If a glove is tom or a needlestick injury occurs, the glove
should be removed, hands washed, and a new glove used as
promptly as patient safety allows.
2. Masks/protective eyewear or face shields should be
worn to prevent exposure to mucous membranes of the
mouth, nose or eyes during all procedures that are likely to
generate droplets of blood or other body fluids.
3. Gown or apron made of materials that provide an effec
tive barrier should be worn during procedures that are like
ly to generate blood or body fluid splashes.
4. Needles should not be recapped, bent or broken or
otherwise manipulated. Puncture-resistent containers
should be located as close as practical to the use area.
Special care should be taken to avoid needlestick injuries
when discontinuing IVs, IV meds or giving injections. Get
help when giving injections to uncooperative patients.
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5. Ventilation devices should be available for use in areas
in which the need for resusitation is predicted.
6. Health care workers with exudative lesions or weeping
dermatitis should refrain from all direct patient care and
from handling patient care equipment until the condition
resolves.
7. For all invasive procedures (surgical entry into tissues,
cavities, organs or repair of major traumatic injuries), car
diac caths and angios, vaginal and C-section delivery gloves,
surgical masks, protective eyewear or face shields and
aprons or gowns should be worn.
8. All specimens of blood and body fluids should be put in
well-constructed containers with a secure lid to prevent
leaking during transportation to the lab. Care should be
taken when collecting specimens to avoid contamination of
the outside of the container.
9. Soiled linen should be handled as little as possible with
minimum agitation to prevent gross microbial contamina
tion of the air and of the person handling the linen. All
soiled linen should be bagged at the location where it was
used.
10. Chemical germicides that are approved for use as a
hospital disinfectant can be used to clean up spills of blood
or body fluids.
11. Hands and other skin surfaces should be washed im
mediately and thoroughly if contamination with blood or
body fluids occurs.
Besides following the usual routine of completing an occur
rence report and seeking medical attention, the employee
that has had a blood or body fluid exposure should contact the
employee health nurse as soon as possible after the occur
rence.

Blood Volume Determination
Radioactive tracers used for volume measurements must be
non-toxic and completely safe for parenteral administration,
should mix rapidly and uniformly with the diluting fluid, and
remain for a reasonable time interval.
TVacer—easily detected and quantitated in high dilutions.
Ideally, accurate measurement of circulating blood volume
should be performed by simultaneous determination of the
volume of both plasma and blood cells. Two radioactive
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tracers of different energy are used to enable their differences
by means of PHA.
I - Human serum albumin - used measure plasma
51Cr - Tagged erythrocytes - used measure red cell volume

Problem s with m easuring b oth together:
• time consuming
• tedious calculations to correct for I measuring from
51Cr
® use of dual isotopes
• specific equipment
Single tracer can be used for determination of volume of
either plasma or red cells using principle of dilution!
V1C1 = V2C2 Q = V x C
V= Q
C

V = diluting volume
C = tracer concentration
in diluting fluid
Q = total quantity of tracer

Serum differs from plasma in that it contains no fibrinogen
plasma. Since of the volume of one component is determined,
the total blood volume can be calculated with the aid of
hematocrit.
Total blood = Plasma volume
Volume
Plasma crit

—R.G volume
Hematocrit ~ 45%

Average whole-body hematocrit is roughly 92% of venous
blood hematocrit.
Problems: different size vessels, different organs
Discrepancy exists: plasma trapped within cells
Hematocrit is multiplied by correction factor 0.90 (.92 x .98)

Plasma Volume Determination
1311 hum an seru m albumin (RISA o r IHSA)
• Venous blood sample is obtained to estimate
background radioacivity.
• Test dose of 5-30 uci RISA transferred into volumetric
container and diluted up to 1,000 ml to act as stand.
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• Exactly equal amount of tracer is injected in patient
(antecubital vein).
• After 15 minutes, a blood sample is withdrawn from
patient’s other arm in a heparinized syringe.
• Hematocrit is determined and plasma separated by
centrifugation.
• Radioactivity in equal volumes of stand, and plasma are
measured in canter.
• Background is subtracted.
Plasma volume (liters) = count rate of standard
net count rate of plasma
Normally 43 ml/kilogram of body weight
125

I —human serum albumin: main disadvantage is lower
cting efficiency

51Cr—tagged chromic chloride trivalent: 98% labels the
plasma protein
Remainder attached RBC

R ed Cell Volume Determination
Depends on labeled erythrocytes as the tracer. Sodium
chromate (5 lCr) radiochromate is most commonly utilized hexavalent compound - easily penetrated RC membrane and
establish firm tag with hemoglobin - tagged is done (invitro).
• Anticoagulated blood sample (10 ml) is obtained from
patient and mixed with 50 uci of radiochromate.
• Mixture left at room temperature 15 minutes (ACD
solution
added)
(stops
tagging
process).
Radiochromate should not be added to ACD solution
before use. ACD is going to hinder the chromate and
hinder tagging process.
• Aid 100 mg (ascorbin acid) (vitamin C) to mixture to
reduce radiochromate and thus prevent it from tagging
any other erythrocrytes.
• Accurate measured volume (0) of tagged mixture is
kept as a standard.
• Exact equal amount is injected back into patient.
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• After 15-30 minutes, blood sample is withdrawn from
patient’s other arm.
• Hematocrit of blood sample and standard one
determined
• 1 ml of standard, 1 ml of blood sample - counted in well
counter
RBC Volume = Cts of Standard V = O
Net Cts of RBC
C

P roblem s with this m ethod
• Errors encountered by the occurrence of extravasation
during intravenous injection of tagged cells
• Lack of tagging due to reducing agents
• Formation of clots in standard
• Hemolysis of tagged cells

Clinical Indications for Blood Volume Determination
• After acute blood loss
• After extensive burns
• Preoperatively in patients of extreme ages —children
and elderly—before major surgery
• Measure for degree of anemia of a patient
• Postoperatively - need for transfusion therapy

Red Cell Survival
Is measured by following a given group of erythrocytes to
determine the time required for their elimination from circultion. Specific erythrocytes easily identified from remainder
of RBC by a label or tag.

IWo m eth o d s
Selective labeling—uses glycine C-14, glycine N-15, glycine
H-3, Fe-59, Se-75. The RBC are tagged and followed for the
full life span which can extend over 4 months.
• Normal life span = 120 days
• Normal disappearance T 1/2 = 25-35 days
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Difficulties of this method include: radionuclide expense,
special preparation, specific equipment is required for count
ing (liquid scintillation).
Random labeling—uses Cr-51 sodium chromate tagged to
TBCs. This method is easier. The RBC survival time is
calculated from the percent of surviving tagged erythrocytes
as determined at period time intervals.
Procedure: Inject Cr-51, wait 24 hours, take sample, then take
sample every other day for 3 weeks.
It is preferable to rely on the results of the first 3 weeks and
express the survival in terms of time required for elimination
of 50% of the tagged erythrocytes. Since survival is computed
from % of surviving tagged cells as determine/volume, a wide
fluctuation in blood volume can invalidate results.
Disadvantage: inability to differentiate a short life span from
random destruction.
Clinical application: study cases of unexplained anemia and
helps determine the nature of defect causing shortened R.C.
survival.
Determine site of R.C. sequestration - choice of proper treat
ment
Iron metabolism studies - uses 10 uci of Fe-59 ferrous citrate.
After injection of Fe-59, external counting is performed peri
odically and simultaneously over the precardium, sacrum,
spleen and liver over a period of 2 weeks. Normally within
the first few hours, after injection. The tracer dose —ct rates
over the precardium—representing blood diminishes. Ct.
rates over spleen and liver decrease. Ct. rates over sacrum
increase - represent bone marrow - and peak for about two
days before rapidly decreasing.
Significant increases in spleenic cts.—denotes spleenic se
questration of red cells.
If radioactivity over liver/spleen behave similar to that over
sacrum —ex tram ed u lla ry ( form ation o f R B C ) —
erythropoiesis is suggested.
The main indication of ferrokenetic studies is the investiga
tion of obscure hematologic disorders.
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REVIEW
Section 1
1. What is
a. Plasma
b. Specific gravity
c. Hematocrit
d. Plasmacrit

2. Explain the different functions of RBC, WBC, platelets.

ViCi = V2C2
Initial volume = 15 ml
Initial concentration = .6 uCi
ml
New concentration = .007 uCi
ml

What is the new volume?
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Section 2
Multiple choice
1. The fluid portion of the blood is called____ .
a. serum
b. plasma
c. fibrogen
d. hematocrit
2. The three types of cellular elements present in the
blood are_____
a. fibrogen, semm and plasma
b. granulocytes, albumin, and monocytes
c. eoslinophils, globulin, and albumin
d. erythrocytes, leukocytes, and thrombocytes
3. The term used to describe the production of blood
cells is
.
a. nuclear maturation
b. hematopoieis
c. polyphyletic
d. Unitarian

4. The volume of packed erythrocytes expressed as a per
centage of the blood sample is defined a s_____
a. plasmacrit
b. hematocrit
c. albumin ffactia
d. all of the above
5. The normal hematocrit is approximately what percent
age of a given blood volume?
a. 10%
b. 25%
c. 45%
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d. 85%
6. Hematocrit obtained from blood sample is multiplied
by .91. This is done:
a. because 91% of the blood cells are erythrocytes
b. because 91% of blood is usually plasma
c. to correct for large vein sampling
d. all of the above
7. The following equation:
Q = V x C where V = volume of diluent,
Q = amount of tracer, C = concentration of tracer

— explains the relationship between volume and con
centration. This equation is based upon:
a. Starting’s Law
b. the dilution principle
c. law of concentration
d. none of the above
8. In blood volume measurements, the plasma portion of
the blood is most commonly labeled with_____
a. 51Na chromate
b. 125IHSA
c. m I HSA
d. 32p
9. The RBC survival test can be performed

.

a. by randomly labeling RBCs in the circulation with
sodium chromate
b. to estimate the RBC life span
c. to diagnose hemolytic anemia
d. all of the above
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10. Selective labeling of erythrocytes for RBC survival can
be achieved with
.
a. 75Se
b. 59Fe
c. 3H glycine
d. all of the above
11. In a red cell survival determination, samples are taken
from the patient:
a. every day for 1 week
b. every other day for 3 weeks
c. every other week for 1 month
d. every week for 1 month
12. If the specific gravity is less than 1, cells will
a. tend to settle if allowed to stand
b. recombine after a while
c. tend to remain in solution
d. form particles that will fragment into alpha, beta,
and gamma emitters.
13. Leukocytes are in abundance approximately ____
mm3 in the body while erythrocytes are
mm .
a. 8,000; 5,000,000
b. 8,000,000; 5,000,000
c. 5,000; 8,000,000
d. 7,000; 16,000,000
14. The supernatant is
a. the volume of packed erythrocytes expressed as per
centage of whole blood
b. approximately 55% of whole blood normally
c. approximately 45% of whole blood normally
d. a and b
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15. RBCsare
a. small, non-nucleated granulated bodies formed in
red bone marrow
b. granulocytes, nucleated formed in red or yellow mar
row
c. circular, non-nucleated, biconcave, manufactured in
red bone marrow
d. could b any of the above
16. The hematocrit value of a given blood sample repre
sents
a. the ratio between the plasma compartment and the
cellular compartment
b. the ratio between the serum compartment and the
cellular compartment
c. the percentage of the cellular components to the
whole blood
d. the ratio of the RBCs to WBCs
17. The dilution principle can be expressed as
a. QSVXC
b. V = QXC
c. V = QXC2
d. V = QXC2
18. Radionuclides used for blood volume determination
may either be tagged to plasma proteins or to the
a. serum
b. WBCs
c. platelets
d. erythrocytes
19. The form of Cr-51 which can permeate the red cell
membrane is
a. trivalent form
b. bivalent form
c. hexavalent form
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d. all of the above
20. All of the following are types of WBCs except
a. thrombocytes
b. granulocytes
c. lymphocytes
d. monocytes
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Chapter 8
SIGNIFICANT IN VITRO TESTING
PROCEDURES IN NUCLEAR
MEDICINE
Objectives
® Understand the functioning and metabolic effects of
the hypothalamus-pituitary-thyroid axiom.
• Be able to describe the function, clinical applications,
normal ranges and testing procedures for: TSH, T-3,
T-4, T-3 binding capacity.
• Understand the importance of Vitamin B-12 to the
human body.
• Demonstrate a knowledge of Vitamin B-12 absorption
testing methodology, including blood testing, hepatic
uptake testing, and Schilling test.
• Understand the function and methodology of folic acid.
• Demonstrate an overall understanding of tumor
testing, including HCG, CEA, and AFP.
• Understand the basic feedback system for
pituitary-gonadal axis and the hormones that are
involved.
• Demonstrate a knowledge of Indium-III WBC
labeling, including the basic tagging procedure.
• Develop an appreciation for the functional uses of
various other RIA tests.
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Thyroid Functioning and Testing
These tests are often used as a screening device for patients
suspected on clinical grounds of having thyroid dysfunction.
Do before radioactive iodine-uptake and invivo thyroid tests.
TSH - thyroid stimulating hormone
T4 - thyroxine
T3 - triothyronine
Uptake T3 - binding capacity

Hypothalamus-Pituitary-Thyroid Homeostasis
Normal thyroid function depends on effective function at 5
levels:
® Hypothalamus and its release of thyrotropin-releasing
hormone (TRH) or (TRF) - thyrotropin-releasing
factor
® Pituitary release of (TSH)
• Thyroid’s secretion of active hormone T4, T3
® Plasma space with its specific thyroid-binding plasma
protein
• Target organs and specific cell receptors
TRH is transported from hypothalamus via the portal system
of the pituitary region of adenohypophysis where it stimulates
basophilic cells to produce and release TSH.
TSH stimulates thyroid gland to increase production and
release of active thyroid hormones T3 and T4; therefore,
plasma T4 and T3 are increased. If plasma levels of T4 and T3
fall, TSH is secreted.
Thus, TSH is the prime regulator of the rate of function of the
thyroid gland and hence of thyroid hormone production and
secretion.
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’ituitary

Hypothalamus
T3T4

TSH
Thyroid
T4,T3

TSH—Thyroid Stimulating Hormone
TSH is a glycoprotein — molecule weight approximately
28,000. Protein contains one alpha and one beta polypeptide
subunit. Possible cross-reactivity (same alpha species as
HCG, LH, FSH).
It is the beta subunit of TSH that determines the specific
physiology of the hormone.
TSH is essential to normal thyroid function. Absence of TSH:
thyroid gland undergoes involution. It is involved in all levels
of thyroid function.
• Production of hormone is stimulated by increasing the
amount of thyroid iodide transported into gland and by
increasing organic binding of iodide— 12 (I- = Iodine)
• Increase
T4,T3
storage—iodotyrosines—into
thyroglobulin
• Release of T4/I 3
TSH is part of a sensitive control system that keeps the semm
concentration of thyroid hormones within fairly narrow limits.
TSH under direct control by TRH—via portal system.
TRH stimulates basophilic cells in the adenohypophysis to
produce TSH, TSH stimulating thyroid gland to release T4T3.
Increased blood levels inhibit release of TSH.
1/2 time of TSH turnover in plasma is approximately 1 hour.
Daily secretion rate is about 170 mU.
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Test is performed in 24 hours or less—long incubation.
Double-Ab precipitation and solid phase tech.—separation
tech. HCG is usually added to absorb out alpha chain.

Clinical Applications
Hypersecretion of TSH occurs when hypofunction of thyroid
due to decreased plasma levels of thyroid hormones.
Suspicion of hypothyroid disorders is a main clinical reason
for TSH assaying.
Primary TSH overproduction—pituitary tumors and in
creased TRH secretion.
Secondary TSH (pituitary level)
Hyposecretion of TSH
Secondary (pituitary level)—destruction in pituitary is the
cause —postpartum patient necrosis, pituitary tumors
Usually TSH deficiencies are associated with other trophic
hormones: gonadotropins, ADH.
Frozen samples —stable for years.
Samples of TSH —does not undergo marked diurnal variation
Pregnancy—TSH is unchanged
TRH stimulation test for hyposecretion of TSH
I.V. dose 200 ug TRH—normal patient prompt increase peak
in 30 minutes
Average increase: lOuU/ml
Normal levels: 0-10uU/ml
15 uU/ml

Interpretation of Results
Elevated TSH level—greatly elevated in primary hypothyroid
myxedema. Levels up to 100 uU/ml are frequently seen in
untreated hypothyroid.
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D ecreased TSH Levels
TSH levels are not measurable in hyperthyroid or
hypopituitarism and secondary myxedema. Most assays do
not permit difference between normal and decreased TSH
levels.
In hypothyroid, response of serumTSH to TRH infusion (I.V.)
is greatly increased.
Circulation of increased concentrations of T4,T3
Response of TSH to TRH (I.V.) is markedly reduced. Patient
with thyrotoxicosis: no effect is observed.
Thus, TRH may be used different diagnosis of thyrotoxicosis
(excessive activity of thyroid gland).
Normal response to TRH—good evidence of absence of hy
perthyroidism.

Thyroxine (T4)
Tetraiodothyronine
T4 is produced by the actinar epithelium of the thyroid gland.
A large reserve of T4 is stored in the thyroid gland within
thyroid follicle—sufficient supply for body’s needs for 2
weeks.
In bloodstream T4 is bound to plasma protein.
99.9% of plasma T4 is bound to TBG.
Protein-bound thyroid hormone is metabolically inactive—
free (T4) that exerts metabolic effects.
T4 -1/2 life = 8 days
60 ug T4 - extracted daily from blood by target tissues

Performance of Test
Serum absorbed with charcoal to remove thyroid (T4-free
serum) is frequently added to standard curve samples.
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Separation Technique (Absorption Technique)
Absorption of unbound thyroxine to activated charcoal
predominates—also may use double-Ab method.
Time needed for test usually 2 hours.

Clinical Application
Hyperfunction of thyroid gland—thyroxicosis: excessive
amount of thyroid hormone is present in peripheral tissues.
Denominates in every organ system—accelerated metabo- lism.
Disease states cause hyperthyroid: diffuse toxic goiter.
Most common: toxic multinodules (Graves disease), goiter
(Plummer’s disease) and toxic adenoma (epithelial tumor).
In these disorders, thyroid loses its normal responsiveness to
inhibition of falling TSH level.
Its automous or “nonresponsive” (independent of TSH).

Thyrotoxicosis Factitin
Excessive ingestion of T4 or T3.
Hypofunction—thyroid tissue fails to provide enough thyroid
hormone to peripheral tissues—reduction on metabolism to
activity.
Absence of thyroid hormone—ultimately leads to coma,
progressive falling body temperature of organ systems and
death.
Not commonly—idiopathic (self-originated, spontaneous) —
last manifestation of autoimmune thyroiditis.
Hypothy—end stage of treating hyperthyroid may occur at
birth leading to cretinism from low levels of circulating TSH.
T4 sample—stable in serum for several days at room tempera
ture little diurnal variation unaffected by fasting acute febrile
illness (pertain to fever).
• Reference Values
normal - 45 to 120 ng/ml
hypo - 5 to 50 ng/ml
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hyper -120-460 ng/ml

Interpretation of Results
Elevated levels —patient has hyperthyroidism.
Decreased levels—hypothyroidism of both primary and
secondary types different diagnosis of these disorders is best
made using TSH.
Elevated TSH - Decreased T4 - primary hypothyroidism
Decreased TSH - Decreased T4 - secondary hypothyroidism
Increase T4 concentration in blood may be wrongly thought
to be due to thyroid overactivity when real cause is increase
in binding protein concentration (TBG).
T4 - along with T3 binding capacity may be affected by the
following conditions:
Increased

Decreased

TBG—estrogen, pregnancy

hyperthyroidism

hypothyroidism

acromegaly

hepatitis

Down’s syndrome

cirrhosis

major illness
androgens
corticosteroid

C om petes with T4 for binding
• Phenytoin (Dilantin)
• T3
• Dicumanol

T3 Tridothyronine
13 Tridothyronine—like T4, T3 is produced with thyroid
gland by the Acinar epithelium. Thyroid secretes T3 in mass
amounts that are less than 10% of T4 secreted.
Thyroid secretion of T3 is only a minor source of T3 produced.
The majority is produced by monodeiodination of T4 in the
peripheral tissues.
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T3 concentration is influenced by TBG concentration - same
as T4. T3 -1/2 life in plasma 2.0 days.
Daily turnover: 30ug/day.

Perform ance of T est
Charcoal absorption is most frequently used separation
method. Also solid phase method.
Highly specific antiserum is required for T3. T4 concentra
tion in serum 80 - lOQx. T3 serum close structure - makes for
some degree of cross-reactivity.

Clinical Applications
Hypersecretion of 13 is always found in hypothyroidism as far
as is now known.
Frequently T3 levels are much more elevated thanT4, indicat
ing T3 is being produced directly from the thyroid in greater
abundance than T4. Some patients’ hyperthyroidism may be
manifested only by T3 elevation. T3 Thyrotoxicosis—before
T4 begins to elevate T3 thyrotoxicosis is very common hyper
thyroidism patients are in iodine deficient areas.
Hyposecretion of T3—accompanies hypothyroidism, may
occur in euthyroid patient with acute febrile illness.
Reference Values —normal 1.5 +1-1 ng/ml
hyper 3.0 ng/ml

Interpretation of Results
Elevated T3 - single best indicator of hyperthyroidism. If T3
is normal, what seems to be hyperthyroid state should be
carefully scrutinized.
D ecreased Values T3 —do not n ecessa rily imply
hypothyroidism. May be low euthyroid or acute illness. Tend
to decrease in hypothyroidism. Normal T3 - is not infrequent
in hypothyroid state, therefore, T3-RIA is not particularly
usefiil for diagnosis of hypothyroidism.
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T3 Binding Capacity or T3 Uptake
Since most thyroid hormone circulates bound to protein in
plasma, changes in concentration markedly influence thyroid
hormone concentration.
An indirect estimate of capacity of plasma protein to bind
thyroid hormone is the T3 uptake test. It measures the ability
of patient’s plasma proteins to compete with a secondary
binder such as a resin bed, red cells or rubber sponge matrix.
Technique gives an estimate of unoccupied binding sites of
transporting proteins, chiefly TBG.
Adding I-125-T3 to free binding sites of TBG and by the resin.
If free binding sites TBG decrease because of TBG deficiency
or because sites are occupied by increase T4 production,
I-125-T3 will be greater degree take-up by resin. If free
binding capacity TBG increases, example is extremely lowT4
levels, or increase (example pregnancy).
Resin will bind less to I-125-T3. Resin uptake should be
interpreted in light of total T4 serum concentration.
Free T4 Index—estimate of the amount of free thyroxine
hormone present in plasma.
Value from T3 uptake x total T4 have been combined into a
free T4 index.
Free T4 index has been shown to be closely related to the
actual concentration of free T4 in serum.
Since resin T3 uptake reflects the number of TBG binding
sites present and since total T4 concentration indicates total
hormone, the product should be proportional to free T4.

Vitamin B-12
Vitamin B-12 is a very potent, cobalt-containing, dietary fac
tor available in many foods such as liver, kidney, muscle, milk,
and eggs. It plays a major role in the synthesis of nucleic acids
and therefore, is particularly important in the process of cell
maturation. The first cells to suffer from its deficiency are
the rapidly dividing cells such as bone marrow and
gastrointestinal tract cells.
Proper absorption of vitamin B-12 depends upon adequate
secretion of intrinsic factor by glands in the stomach. Vitamin
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B-12 intrinsic factor complex mainly absorbs in the termal
ileum. After absorption vitamin B-12 is carried in blood by
plasma protein. Then goes to liver as a storage depot. It stays
in the liver for months to even years and is slowly released,
carried out by normal cellular metabolism. Vitamin B-12 is
excreted through urine.
The presence if cobalt atom in each molecule of vitamin B-12
makes it possible to synthesize a radioactive cobalt labeled
vitamin B-12 using 57Co, 58Co, 6OC0 . 57Co is preferred
because of its efficiency and absence of beta radiation.
This is called cyanocobalamin. It is essential to a variety of
enzymatic reactions, normal growth, hematopoiesis, func
tional states of nervous system.
Intrinsic factor is produced by gastric parietal cells found in
the stomach. .1 ug of vitamin B-12 daily, recommended in
take 2 ug/day.
Radioisotope of cobalt (57Co,58Co) are easily substituted for
natural cobalt, used for highly specific receptors in RIA.
The binding of cyanocobalamin to exogenous binders must
not disrupt vitamin B-12 reactivity.
In the lower normal and lower levels substitution may crossreact giving falsely high levels of measure for vitamin B-12.
Most assay give sensitivity in the order of 10-30 pg/ml.

Clinical Applications
Vitamin B-12 deficiency—A characteristic defect develops in
cells of many different tissues. The nucleus is unable to
mature normally and does not divide appropriately. Affects
organ systems with rapidly dividing cells such as hemopoietic
cells. Prolong deficiency causes central nervous system
problems. Most deficiencies are due to malabsorption of
vitamin B-12.

Possible C auses
• Inability of gastric parietal cells to secrete intrinsic
factor.
• Gastric resection.
• Inflammatory disease of ileum.
• Bacterial growth in stomach.
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• Diet deficiency such as seen in strict vegetarian dieters
and their breast fed infants.
The normal ranges in blood serum is 200-900 pg/ml.

Interpretation of Results
Values less than 100 pg/ml are almost always associated with
vitamin B-12 deficiency.
Falsely low levels have been reported in patients taking very
large doses of ascorbic acid and high concentrations of
fluoride in serum.
Elevated values are values greater than 1,000 pg/ml which can
be found in hepatic disorders such as hepatitis and leukemia
patients in which there is a release of cyanocobalamin.
Folates—Generic term used to describe folic acid. In adults
the dietary requirement is about 50 ug/day. The requirement
in children is considerably greater at about 100 ug/day.
During pregnancy the requirement is 400 ug/day and during
lactation (period of secretion of milk) 300 ug/day.
Folates are found in all foodstuffs. Examples are liver, yeast,
vegetables and fruits. Folates in food are in the form of
polyglutamate. They are broken down within the stomach
into monoglutamate form and is rapidly absorbed primarily
through the proximal small intestine. Folic acid is rapidly
absorbed into the blood and converted into a variety of active
folate forms and stored in the liver.
Two isotopes have been utilized to evaluate levels;
• 3H —triton was first used
• 1251 - is now more common.
Clinical Applications —Malabsorption of folate may occur in
intestinal disorders.
Most common is folate deficiency in diet. In certain disease
states, hyperutilization of folate may occur and result in
deficiencies found in pregnant patients, hemolytic anemia,
malignancies, and lactation. Some drugs such as oral con
traceptives, phenytoin, and ethanol impair absorption of fo
late.
Like vitamin B-12, folate is essential in rapidly dividing cel
lular systems.
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Sampling Blood —fasting serum should be used, folate levels
vary significantly after eating.
The normal ranges 3-20 ng/ml.

Interpretation of Results
Elevated levels are not uncommon in patients with vitamin
B-12 deficiency. Ranges less than 3 ng/ml is common in
malabsorption states, pregnancy, alcoholism and a malignan
cy

Other Methods to Measure Vitamin B-12
Absorption_______________________
Fecal Excretion Method —Stools collected at least 72 hours
after the administered dose of radiation, the net amount of
radiation in stools is expressed as % of administered dose.
This represents the amount of vitamin B-12 not absorbed.
Remainder is absorbed normally in stools at 30%-70% of
administered dose with defective absorption, stool % is
higher.
Hepatic Uptake Test—days after oral ingestion subject is
given a laxative to clear alimentary tract. Two days later,
radiation accumulates in four different areas over the liver,
left iliac fossa, and thighs (considered background). The ratio
between hepatic count rate and that over iliac fossa is then
calculated. Normal patient’s count over liver and over left
iliac fossa is at least 2.5 to 1.
Urine Radioactivity Collection—Schilling Test—most com
monly used. The patient is given an oral dose of .5 uci of
vitamin B-12. Patient is then given nonradioactive vitamin
B-12 which will reach and block specific binding sites before
absorbed radioactive vitamin B-12. This non-radioactive B12 is given intramuscularly. Consequently the absorbed un
bound radioactive vitamin B-12 is excreted in the urine. The
1,000 ugofstable vitamin B-12 is injected within 2 hours after
oral administration of tracer dose. Urine is collected over the
next 24 hours. Radioactivity is estimated and expressed as a
percentage of the administered oral dose. Percentage of dose
that is absorbed and consequently recovered in urine by flush
ing with stable vitamin B-12 is normally 1% or more. The
main source of error is in the collection of urine, measure
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ment of radiation, and results may also be affected by renal
disease. (For preparation procedure, calculations and diag
nostic values see Laboratory Exercises.)

In Vitro Testing for Tumors in Body
Measurement of tumor-specific products in body fluids may
in the future offer a selective way to detect human neoplasms
at a curable stage. Some tumors produce hormones that call
attention to their presence, such as gynecomaastia (excessive
developm ent o f mammary glands in m ales), Cushings
Syndrome (overproduction of adrenocortisol from the
pituitary effecting the adrenal cortex), and certain trophoblas
tic (uterus) tumors for examples.
The ideal method for detecting tumor products would be
extremely sensitive and specific for neoplasia. The level of
the tumor product in the blood should correlate with the total
mass of the tumor present.
Such methods would be useful for:
o
•
•
•

Screening for cancer in high risk patient populations.
Assisting in establishing a specific diagnosis of cancer.
Helping to localize tumors.
Monitoring tumor response to therapy.

The three most common blood testing methods for tumor
detection are:
• CEA - carcinoembryonic antigen
• AFP - alpha-fetoprotein
• HCG - human chorionic gonadotropin

CEA - carcinoem bryonic antigen
CEA is a normal product o f human development and occurs
in the fetal colon. CEA may also be found as a normal
constituent of adult tissues, such as the glycocalyx of the adult
large intestine.
Gold and Freedman found a tumor-specific antigen (CEA)
that was present in perchloric acid extracts of cancer of the
colon and fetal intestine, but not the adult intestine. This
developm ent showed great prom ise for diagnosis of
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gastrointestinal m alignancies. CEA has becom e a
widespread evaluator of patients with a variety of neoplasm.
A double-antibody measurement used to extract perchloric
acid, CEA is located in the luminal surface of the mucosal cell.
Two factors appear to be important as a cause for increased
serum levels of CEA in malignancies:
e Tumor cells produce a greater quantity of this antigen.
• Rapidly growing tissue results in disruption of
blood-tissue barriers, what is produced in tissues is
more accessible to the blood.
A variety of malignant tumors produce CEA in abundance
some examples include: pancreas, colon, rectum, lung,
breast, cirrhosis and gastrointestinal.
Reference Values:
• normal - 2.5 ng/ml
• m a l i g n a n t . - 40 n g / m l
Modest elevation occurs in pancreatitis, cirrhosis, chronic
bronchitis and inflammatory bowel diseases.
Increased levels - disseminated malignancies, main utilization
of measuring CEA is evaluating patients who have already
been documented to have tumors checking on effects of
therapy. CEA is often utilized as an indicator of recurrence
of tumor after surgical treatment of colon cancer.

AFP - alpha-fetoprotein
Associated with liver malignancies, hepatoma, teratocarcinoma (malignant neoplasm in testes), and metastic tumors
to liver AFP is a normal constituent of the fetus and plays a
similar role in fetal life that serum albumin plays in adults.
The normal transition from AFP to serum albumin as the
dominant serum protein begins at about 13 weeks of gesta
tion, peak concentrations in AFP in fetus is 3 to 4 ng/ml. In
pregnancy and adults it is 100 ng/ml.
AFP is found as a normal constituent of human serum but in
diseases of the liver massive elevations may be noted.
Elevated values of AFP are seen in both benign and malignant
liver diseases.
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Reference values:
3-25 ng/ml - normal adult
up to 120 ng/ml - pregnant women

Values above 1,000 ng/ml in an adult are always associated
with primary liver malignancies.

HCG—human chorionic gonadotropin
Certain trophoblastic tumors (uterus) which produce HCG
can be detected since this hormone is not present in nonpreg
nant individuals. Its presence in serum indicates a neoplastic
state significant HCG levels are associated with tumors of
1mm in size.
HCG levels are virtually always present with patients with
choriocarcinoma and chorioadenomas.
HCG-B is a common testing method to rule out pregnancy.
It can be either qualitative or quantitative in value.
Pituitary—Gonadal Axis
The reproductive system’s regulated by three distinct classes
of hormones.
• The hypothalamic releasing hormones.
• Gonadotropins which exert no target organ effect
except stimulate release of other hormones (anterior
pituitary hormones).
0 follicle stimulating hormone (FSH)
° luteinizing hormone (LH)
° placental hormone
° human chorionic gonadotropin (HCG)
• Gonadal steroids—Hypothes. releasing hormone
known to be of importance in reproductive physiology
is gonadotropin releasing hormone (Gon RH)
migrates within the portal venous system to the
pituitary where it stimulates production of LH and
FSH.
FSH and LH stimulate the gonads to produce a number of sex
steroids principally estradiol and progesterone from the
ovaries and testosterone from the testes.
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Complex interactions between the gonadotropins and the sex
steroids that produce the cyclic changes of ovary such as
maturation of the follicle ovulation and formation of the
corpus luteum are only partially understood.
Estrogen and testosterone exert an inhibiting feedback on the
secretion of FSH and LH. Increased plasma levels of sex
steroids will inhibit release of gonadotropins and decrease
levels stimulate release of gonadotropins and decrease levels
stimulate release of gonadotropins.
C astration, oophorectom y (rem oval o f ovaries) and
menopause are followed by an increase of the release of
gonadotropins.
During pregnancy HCG intervenes in this regulatory system
and secretion of FSH and LH is suppressed.
Feedback inhibition is directed against anterior pituitary.
Pituitary—Gonadal Negative Feedback System
Hypothalamus
Gonadotropin
Feedback

(GonRH)
Pituitary

System
LH, FSH
Estradiol

Placental hormones

Progesterone

HCG

Testosterone
Sex Steroids

INDIUM-111 LEUKOCYTES TESTING
PROCEDURE AND TECHNIQUE
Introduction:
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The clinical use of Indium-111 oxine labeled white blood cells
for detection and localization of abscesses and other inflam
matory disease is a valuable diagnostic tool.

Physiological Principle:
Leukocytes function primarily in the localization, destruction,
and removal of micro-organisms and damaged cells. The
leukocytes chemotactic, phagocytic, and microbial destruc
tion functions all play a role in the body defense mechanisms.
With the introduction of Indium-111 oxine as a radiolabel for
cellular blood elements, it became possible to image the
distribution of leukocytes. The lipid soluble oxine carries the
Indium-111 across the cell membrane where the Indium
separates from the oxine and preferentially binds to
cytosolular proteins. The labeled cells retain viability and
function. When labeled cells are intravenously administered
to the patient they will normally distribute to the liver, spleen
and functioning bone marrow, but some will continue to
circulate in the blood. Any collection of labeled white cells
outside of these areas indicates an area of abnormality to
which the patient’s blood cells are being attracted.

Description of Technique:
Forty cc’s of patient blood are collected with five cc’s of
acid-citrate-dextrose (ACD) as an anticoagulant. Donor
blood may also be used. The blood components are separated
by centrifugation. The white blood cell layer is removed,
suspended in saline and incubated at room temperature with
Indium-111 oxine for 15 minutes. All white blood cells will
be labeled unless more sophisticated procedures (generally
not available) are used to separate the granulocyte from
mononuclear and lymphoid cells. The cells are washed to
remove non-incorporated Indium and oxine from the labeled
white blood cells which are resuspended in the patient’s plas
ma and returned to the patient via intravenous injection.
Imaging may be started as early as four hours after injection;
however, the quality and diagnostic value of the images will
be superior in the day after (18-24 hours) the labeling and
injection of the white blood cells. Anterior and posterior
whole body images along with spot views of the anterior upper
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and lower abdomen are routinely obtained along with addi
tional images as indicated. Occasionally, delayed imaging at
48 hours is useful.
m m m m m m m m m m m m m m m m m ssm m m ii

Indium-111 oxine - d o se 500 uci
• Energy levels 171 kev (primary)
• 252 kev
® T 1/2 67.2 hours

Basic Invitro Labeling Technique
© 40 cc of patient blood is collected with 5 cc’s of
acid-citrate-dextrose (ACD) anticoagulant
© blood components are separated by centrifugation
• WBC layer is removed - suspended in saline (1%
albumin)
• incubate at room temperature for 15 minutes
• WBC’s are labeled
• cells are washed
• labeled In-111 WBC are reinjected into patients (for
step by step procedure see lab exercise)

Indications for In-111
Useful for spectrum of inflammatory diseases. Abscess
localization, acute and chronic osteomyelitis. Activity in in
flammatory bowel disease, Crohn’s disease, ulcerative colitis,
fever of unknown origin, study of choice.
CT and ultrasound has better resolution in abdominal absces
ses. When one does not know specific area of abscess, use
In-111.
m m m m m m sm

Limitations
Technically demanding, false negatives if chemostatic func
tion has been altered, long-term antibiotic therapy may fail to
attract WBC’s, gallium scan is preferred, false positives,
gastrointestinal bleeding, upper respiratory infection.
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Hepatitis
RIA TEST Antibody to Hepatitis B Surface Antigen 1-125
Ausria 1-125

Introduction
Three forms of viral hepatitis are currently recognized.
Hepatitis A, Hepatitis B which can be differentiated by
Serologic Tests. A third form called non A, non B is diagnosed
by exclusion.
Hepatitis B causes greatest concern in terms of it spreading
from patient specimens to laboratory personnel. As little as
0.0004 ml of blood contaminated with hepatitis B can transmit
the disease. Transmission can also occur by oral route,
mucous membrane and through minor cuts or scratches in the
skin.

Clinical Differences
T^pe A
Incubation
Symptoms

TypeB
28-120 days Avg. 45 days

15-45 days Avg. 28 days
2040% (in patients)

4060%

usually abrupt

usually insidious

1-3weeks

1-4 weeks sporadic

Onset of Symptoms

Duration
Jaundice

3035% (of patients)

3040%

Major Difference —Type Bhas a tendency to evolve to chronic
carrier state in 5 to 10% of cases.
Structural Components & Physiology
Electron Microscopy has shown that in the serum Hepatitis B
Surface Antigen (HBsAg) is constantly associated with
spherical particles, ubular forms, and the Dane particle
(larger). Hepatitis B virus (HBV) production in the body is
characterized by the disproportionate manufacture if HBsAg
as compared with the production of whole virus particles. The
complete HBV (Dane particle) consists of a core component
enveloped by a lipoprotein Surface matrix (HBsAg). HBsAg
is produced in vast unassembled amounts in tubular and
spherical forms. The number of such incomplete virus par-
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tides in the circulation of a typical H B sA g carriers is immense
and may range up to 100 billion to a trillion particles per
milliliter of blood.

Principle
The Ausria 11-125 system uses the “Sandwich principle”. It is
a solid phase radioimmunoassay technique to measure
HBsAg levels in serum. Plastic beads coated with guinea pig
antibody are supplied. Patient semm or plasma is added and
during incubation Hepatitis B Antigen, if present is fixed to
the antibody. When antibody tagged with Iodine-125 is added
if binds to any Hepatitis B Antigen on the bead creating an
antibody-antigen-antibody sandwich.

Indications
• Testing should be done on a routine basis particularly
on patients admitted to the hospital.
• Medical and health care staff that have a high risk of
exposure.
• Determine the type of viral hepatitis and type of
prevention and prognosis.
• For studies of epidemics.
• Diagnosing of liver disease.
• Screening of blood donors.
Implications: H B sA g presence is the earliest indicator of the
presence of acute infection. Also indicative of chronic infec
tion.

Interpretation of Results
The presence or absence of HBsAg is determined by relating
net cpm of the unknown to the “cut off value”. The cut off
value is the net cpm of negative control mean (NCX) times a
correlation factor.
Specimens with net cpm equal to or greater than the cut off
value established with NCX are to be considered reactive for
H B sA g which should be evaluated further.
For the run to be valid, the mean value for the positive
controls (PCX) specimens should be at 4 times the NCX.
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D isease S tates and Patient Problem s
• The chances of detecting H B sA g in patients with
hepatitis B relate directly to the time of testing,
frequency of testing, sensitivity of the method.
• The detection of H B sA g in a patient with acute viral
hepatitis is strong presumptive evidence that the
patient has hepatitis B .
• The persistence of H B sA g for 3 or more months
following the onset of acute viral hepatitis suggests that
the patient is becoming a chronic carrier or is
developing chronic active hepatitis.
• Positive results may be first evidence that the patient
has underlying liver disease.

Infrequently Utilized Nuclear Medicine—In Vitro
RBATests
Cortisol Levels—useful in the diagnosis of Cushing’s
syndrome (hyperadenocorticolism) and Addison’s disease
primary adrenal insufficiency.
Secreted by adrenal cortex called zona fasciculata.
Pituitary secretion of ACTH stimulates adrenal cortex to
secrete cortisol.
Diurnal variation—diff. am and pm values.
Dexamethasone used to suppress overactive ACTH stimula
tion.
Hepatitis Testing—used to evaluate viral hepatitis, type A and
B at different stages.
• Hepatitis A —transmitted by oral-fecal rates.
• Hepatitis B —spread by contaminated blood or blood
products.
• Hepatitis A —positive for acute and recovery period.
A-AB, A-B-M.
• Hepatitis B —known as Australia Antigen (positive for
forms of Hep-B complex). BS-Ag, Bc-Ab, BS-Ab,
Be-Ag.
RIA tests for hepatitis will give qualitative results - not quan
titative.
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Calcitonin—useful for differential diagnosis of medullary
thyroid carcinoma and to monitor therapy.
Produced in parafollicular or C-cells of thyroid gland.
Important in calcium metabolism.
HGH Levels (Human Growth Hormone) —Important in diag
nosis of growth retardation.
Pituitary insufficiency—lack of hypothalamic stimulation.
Hypersection in adults (acromegaly).
Hypersection in children (giantism).
PTH (Parathyroid Hormone)—Useful in differential diag
nosis and management of hypercalcemia and hypocalcemia,
tumors of parathyroid gland.
Regulation of calcium—by regulating the calcium—ion con
centration in body fluids.
Gastrin—useful in diagnosis of peptic ulcers, pernicious
anemia, Zollinger-Ellison syndrome (extreme gastric hyper
activity).
Functions in body and stimulate gastric acid secretion.
Collected sample should be fasting.
Digoxin—useful in treatment of congestive heart failure,
atrial fibrillation, atrial flutter and supraventricular tachycar
dias.
Blood drawn 8 hours after last dose.
Must be monitored closely—proper therapeutic range .5-2
ng/ml.
Ck-B (Creatinine-Kinase-B Isoenzyme)—Is most specific
and sensitive for acute myocardial infarctions.
Test should be done with N.M. scan evaluating heart infarct.
Myoglobin—elevated levels following myocardial infarction
and usually peaks 5-18 hours after onset of chest pain.
Found in skeletal and cardiac striated muscles.
HCG-B Levels (Human Chorionic Gonadotropin - Beta) —
Useful in detection of choriocarcinoma, ectopic pregnancy
and threatened abortion. Can be detected within first 10 days
of pregnancy.
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Useful in diagnosis of tumors of ovaries, testes, breast, pros
tate.
Maximum levels of HCG-B during second-third month.
Can be used for quantitative or qualitative results.
Renin Levels (Plasma PRA) —Useful in diagnosis of primary
and secondary aldosteronism in hypertensive and renin-angiotensin system disease states.
Usually measuring angiotensin 1—rate of angiotensin formdirectly related to renin level.
Collected in EDTA—coated tubes (usually purple tops) and
early morning draw, and after letting patient walk around.
Gentamicin - used as a aminoglycosole antibiotic with narrow
therapeutic range.
IgE—immunaglobin class responsible for allergic reactions
and is elevated in most patients with asthma, hay fever, ec
zema, and other allergies.
Phenytoin or Dilantin—Is an anticonvulsant drug used to
treat epilepsy.
Theophylline—Bronchodilator useful in the treatment of
asthma. Must be drawn two hours after dose.
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REVIEW
Section 1
Draw and explain the feedback system of the hypothalamuspituitary-thyroid axiom including the process, function, and
type of hormones released at each level.

Thyroid Functioning
Match the organ with the substance it releases.
_

1. pituitary

a. T3, T4

_

2.thyroid

b. TSH

_

3.

hypothalamusc. TRH
d. thyroglobulin
e. barium
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Section 2
1. Secondary hyperthyroidism refers to disorders of the
a. thyroid
b. pituitary
c. hypothalamus
d. adrenal gland
2. T4 (thyroxine) is stored in the

.

a. acinar epithelium
b. thyroid follicles
c. adenophysis
d. colon
3. Hyperfunction of T4 or thyroid gland is called
thyrotoxicosis this is when __ .
a. there is accelerated metabolism throughout the body
b. decreased metabolism
c. unknown etiology
d. too much TBG in system
4. When there is an increase in TSH levels and a decrease
in T4 levels it is probably_________ .
a. primary hyperthyroidism
b. primary hypothyroidism
c. secondary hyperthyroidism
d. secondary hypothyroidism
5. Elevated T3 testing is _____
a. the single best indication of hyperthyroidism
b. doesn’t necessarily imply hyperthyroidism
c. must be elevated with TRF stimulation test
d. none of the above

„
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6. In T3 uptake testing, the greater the number of binding
sites, the (lower) or (higher) the uptake on the resin of I125-T3.
7. The pituitary release of TSH is influenced by___
a. amount of TRH
b. amount of thyroid hormone in plasma
c. amount of cortisol simultaneously stimulated
d. all of the above
e. a. and b. only
8. TSH help stimulate thyroid to

.

a. increase the amount of thyroid iodide transported
into the gland
b. increase T4, T3 storage
c. release T4, T3
d. a. and b. only
e. all of the above
9. The hormones which the thyroid gland produces in
clude all of the following except .
a. calcitonin
b. thyroxine
c. triiodothyronine
d. TSH
10. After synthesis, the thyroid hormones T3 and T4 are
stored in th e
until needed for use in the body.
a. acinar epithelium of the thyroid
b. parathyroid glands
c. adenohypophysis
d. colloidal thyroid follicles
11. The thyroid hormone which is in the greatest abun
dance in the bloodstream is ___
a. triiodothyronine
b. thyroxine
c. calcitonin
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d. TSH
12. The more metabolically active of the thyroid hor
mones T3 and T4 is
.
a. triiodothyronine
b. thyroxine
13. The bulk of circulating thyroid hormone is

.

a. free, unbound
b. TBG bound
c. TBPA bound
d. albumin bound
14. TSH is secreted by th e___
a. hypothalamus
b. pituitary gland
c. parathyroid glands
d. thyroid glands
15. The element which is essential for normal thyroid
function is
.
a. iron
b. iodine
c. chlorine
d. fluorine
16. Isotopes of iodine which have been used to evaluate
thyroid function include all the following except .
a. 1-127
b. 1-123
c. 1-131
d. 1-132
17. Euthyroidism refers to the condition of the thyroid as
b ein g
.
a. overactive
b. normal
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c. underactive
d. oversecreting
18. Which of the following conditions occurs as a result of
thyroid deficiency in infancy?
a. Down’s syndrome
b. mongolism
c. cretinism
d. myxedens
19. Primary hypothyroidism is due to

.

a. failure of the pituitary to secret TSH
b. failure of the hypothalamus to secrete TSH
c. failure of the gland itself
d. all of the above
20. Secondary hypothyroidism is due to ___
a. failure of the pituitary to secret TSH
b. failure of the hypothalamus to secret TRH
c. failure of the gland itself
d. none of the above
21. T3 by RIA is most helpful in the diagnosis o f___
a. hypothyroidism
b. hyperthyroidism
c. thyroiditis
d. thyroid carcinoma
22. The greatest clinical utility of measuring TSH by RIA
is in differentiating .
a. primary from secondary hypothyroidism
b. Graves from Plummers disease
c. Hashimoto’s thyroiditis from Reidel’s struma
d. thyroid adenoma from cyst
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23. Serum TSH levels are Generally
in the
hypothyroidism and
in hyperthyroidism.
a. decreased, elevated
b. decreased, normal
c. normal, elevated
d. elevated, decreased
24. Calcitonin, a hormone involved in calcium metabo
lism, is produced in th e___
a. parathyroid glands
b. thyroid gland
c. pancreas
d. anterior pituitary
25. A person with clinical features of acromegaly is likely
to be tested for which hormonal aberration?
a. elevated TSH levels
b. depressed TSH levels
c. elevated HGH levels
d. depressed HGH levels
26. PTH, which is produced by the parathyroid glands, is
important in the regulation o f___
a. iodine
b. calcium
c. tyrosine
d. thyrotropin
27. Plummer’s disease is another name for

.

a. toxic diffuse goiter
b. toxic nodular goiter
c. hypothyroid goiter
d. Grave’s disease
28. Free thyroxine index (H I) was developed to ade
quately reflect thyroid status; the formula used is
.
a. 1-131 uptake

1

APPENDIX C-118

IN VITRO NUCLEAR MEDICINE LABORATORY M A N U A L

T4
b.

T4
T3 uptake

c. T3 uptake x T4
d. T3 uptake xTBG
29. If a patient is tested for vitamin B-12 deficiency and
received a value less than 7% in phase I and phase II, but
urine values above 7% after antibiotics are given, then the
most probable disease state is
.
a. pernicious anemia
b. gastrectomy
c. blind loop
d. disease of the ileum
30. Cyanocobalamin is

.

a. important in cell maturation
b. absorbed in stomach with intrinsic factor
c. same as folates
d. both a. and b.
e. all of the above
31. Which is not needed for a Schillings test?
a. blood sample
b. urine sample
c. standard
d. cyanocobalamin injection
32. If a phase I Schillings test provided a 17% uptake on a
patient, one should .
a. begin phase II using intrinsic factor
b. consider patient normal and end testing
c. administer antibiotics to make sure patient does not
have sprue or gastro-colic fistula
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33. The first procedure performed dining Schillings test is
a. inject 1 cc (1000 micrograms) of non-radioactive
vitamin B-12 (flushing dose)
b. administer cobalt-labeled cyanocobalamin capsule
to patient
c. instruct patient to remain fasting for four hours
d. collect blood sample of patient
34. Which does not belong when evaluating vitamin B-12
deficiency?
a. inability of gastric parietal cells to secrete intrinsic
factor
b. gastrointestinal reflux and esophagal pain
c. gastric resection
d. inflammatory disease of ileum
e. all need to be evaluated
35. When evaluating B-12 by RIA, the isotope used is
whereas folic acid utilizes__

,

a. cobalt, Tc-99m
b. 1-125, cobalt
c. cobalt, 1-125
d. 1-125, cobalt
36. Normal ranges for vitamin B-12 are
while values
less than
are almost always associated with vitamin B-12
deficiency.
a. 200-900 pg/ml, 100 pg/ml
b. 200-800 pg/ml, 200 pg/ml
c. 3-20 ng/ml, 3 ng/ml
d. 100-500 ng/ml, 100 pg/ml
37. The most common test utilized for vitamin B-12 ab
sorption after blood testing is __
a. hepatic uptake test
b. fecal excretion method
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c. Schillings test
d. depends upon the type of absorption one desires
38. CEA testing is most commonly associated with what
type of carcinoma?

a. liver
b. uterus
c. fetal intestine
d. colon
39. Elevated levels of AFP between 25-100 pg/ml are as
sociated with___

a. primary liver malignancies
b. an indeterminate range that no diagnostic value is as
sessable
c. either benign or malignant liver diseases
40. Vitamin B12, which is not stored in the body, is ex
creted primarily via the
.
a. feces
b. urine
c. bile
d. all of the above
41. Intrinsic factor is a glycoprotein secreted by th e
a. jejunum
b. stomach
c. duodenum
d. ileum
42. Absorption of vitamin B12 can be studied by one
more of the following tests
.
a. fecal excretion
b. hepatic uptake
c. urinary excretion
d. all of the above
e. b. and d. only

.
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43. The dose of Co-57 vitamin B12 given for a Schilling
test is generally
.
a. 0.5 uci
b. 5.0 uci
c. 50 uci
d. 500 uci
44. The most common cause of vitamin B12 malabsorp
tion is
.
a. drug therapy
b. small bowel blind loop
c. pancreatic insufficiency
d. deficiency in intrinsic factor
45. Failure to absorb dietary vitamin B12 will eventually
lead to
.
a. pernicious anemia
b. microcytic anemia
c. leukemia
d. hyperchromic anemia
46. Choose one that does not belong—Possible causes of
malabsorption of Vitamin B12 include___
a. inability of stomach to secrete intrinsic factor
b. gastric resection
c. inflammatoiy disease of ileum
d. Down’s syndrome
e. bacterial growth in stomach
47. High levels of HCG-B hormone in the blood cor
responds highly with
.
a. patient with abdomen cancer
b. patient is pregnant
c. patient has fever of unknown origin
d. impossible to diagnose without correlation to bone
or liver scan
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48. Rtuitaiy-Gonadal negative feedback system means
that___
a. low levels of estradiol or testosterone stimulate
hypothalamus to release gonadotropin
b. high levels of estradiol or testosterone stimulate
hypothalamus to release gonadotropin
c. L H and F S H (low levels) stimulate sex hormone
production
d. pituitary stimulates hypothalamic release of hor
mones at certain time intervals
49. L H and F S H are released by th e

.

a. gonads
b. anterior pituitary
c. hypothalamus
d. a. and b. only
50. The Australia antigen, discovered in 1963 by Blumberg is also known as the antigen o f___
a. hepatitis A
b. hepatitis B
c. hepatitis C
d. hepatitis D
51. The effect of the hormone gastrin, secreted by the
gastric antrum, is to
.
a. stimulate gastric acid secretion
b. suppress gastric acid secretion
c. increase gastric motility
d. decrease gastric motility
52. The standard time when blood for digoxin concentra
tion measurements should be drawn is approximately__
hours after the last digoxin dose was taken.
a. 2 hours
b. 4 hours
c. 6 hours
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d. 8 hours
53. The serum Ck-B is elevated in cases o f___
a. acute myocardial infarctions
b. chronic liver disease
c. ischemic heart disease
d. digoxin toxicity
54. The radiolabel used in Vitamin B12 RIA testing is ___
a. 1-125
b. Se-75
c. Co-57
d. 1-131
55. The subunit which is immunologically identical for the
glycoprotein hormones FSH, LH, TSH, and HCG is the
a. Alpha subunit
b. Beta subunit
c. Gamma subunit
d. Delta subunit
56. Theophylline, which may be measured RIA, belongs
to the class of drugs known a s___
a. anticonvulsants
b. bronchodilators
c. antibiotics
d. vasodilators

Section 3
True o r False
_
1. Acid-citrate-dextrose (ACD) is used to clot blood
when making up Indium-111 labeled WBC’s.
_
2 Lipid soluble oxine carries the In-111 across the
cell membrane where In-111 separates from oxine.
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3. Labeled WBC will not distribute to liver, spleen,
and functioning bone marrow in normalpatients.
4. In-111 is the isotope and technique o f choice
(WBC labeling) when investigating abdominal absces
ses.
5. As little as .0004 ml o f blood contaminated with
hepatitis B can transmit the disease.
6. Incubation o f hepatitis B is approximately 3-4 days.
7. Digoxin is used to treat congestive heartfailure.
8. IgE is an immunoglobulin class responsible for al
lergic reactions.
9. The normal range is 3-250 nglml in adults for CEA
testing.
10. Alpha-fetoprotein plays a similar role in fetal life
that serum albumin plays in adults.
11. One reason for high levels o f CEA is the rapid
growth o f tissue resulting in disruption of blood tissue
barriers.
12. Pancreas, colon, rectum, and lung carcinomas are
associated with AFP.
13. Blood testing o f carcinoma are useful in evaluating
response to tumor therapy.
14. Liver disease and Cushing syndrome are as
sociated with high levels ofHCG.
15. The recommended intake of vitamin B12 is 2
ug/day.
16. Folates is a generic term for vitamin B12.
17. Folic acid is found in liver, yeast, and vegetables.
18. Vitamin B12 and folates are stored in small intes
tines until needed by the body.
19. Decreased levels of TSH with decreased levels of
T4 is indicative of secondary hypothyroidism.
20. T3 uptake is an indirect estimate o f capacity of
plasma protein to bind thyroid hormone.
21. CEA levels become increased in pancreas, rectum
and lung malignant cancers.
22. Alpha-fetoprotein is most commonly associated
with liver malignancies such as hepatomas.
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Chapter 9
ALTERNATIVE METHODS TO RIA
TESTING
Objectives
• Understand
the
basic differences between
heterogenous and homogeneous immunoassay testing.
© Be able to distinguish the advantages and
disadvantages of heterogeneous and homogeneous
testing.
• Demonstrate an overall understanding of EIA, FLA,
FPIA and monoclonal antibody testing including their
function and methodology.

Alternative Methods to RIA Testing
All of the discussion within this manual thus far has centered
on radioimmunoassay testing. This type of testing is called
heterogeneous immunoassay. That is when there is no dif
ference between the signals produced by bound or free
labeled substances, therefore it is necessary to separate the
two before measurement.

H om ogeneous Im m unoassay
In these types of testing procedures there is a difference
between the signals generated by the free and the bound
labeled substances. Separation is therefore unnecessary.
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Example: EIA, FIA (optical) testing, FPIA testing. Dif
ference between signals arise because the signal is either
produced or altered upon binding.
Heterogeneous

Advantages

Homogeneous

more sensitive

no separation technique

more specific

easier, faster to perform

less matrix interference

Three common homogeneous immunoassay testing proce
dures will be briefly discussed:
© Enzyme immunoassay (EIA)
• (FIA or LIA) fluorescence and luminescence
immunoassays
• Fluorescence polarization immunoassay (FPIA)
• Monoclonal antibodies

Enzyme Immunoassay (EIA)
Substance is labelled with an enzyme rather than I . This
enzyme catalyzes another reaction within reaction matrix.
This other reaction produces an optical signal.

EMIT (Enzyme Multiplied Im m unoassay Test)
Enzyme GGPDH (Glucose-G-Phosphate Dehydrogenase)
C atalyzes N A D
Dinucleotide

NADH

N icotinam ide A denine

But GGPDH is deactivated when bound to antibody
measures change of absorbance at 340 nm produced by con
version of NAD to NADH.
When large amount of natural Ag, little Ab remaining to
deactivate enzyme. Rate of conversion of NAD to NADH
high as measured by increase of absorbance at 340 nm. Con
versely low natural Ag high Ab to deactive enzyme, rate NAD
NADH low.
Direct Relationship

Advantages
• Less expensive to run, can be automated.
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© No separation.
• Not labor intensive like heterogeneous.
Disadvantages
• Not as specific as RIA.
• Reaction medium critical.
• pH, ionic, temperature, other enzyme like lysozyme
interfere 95 % confidence level false negatives and false
positives.

FIA or LIA Luminescence Immunoassays
Ag labeled with fluorophore but not active and an enzyme that
release fluorophore - active but enzyme is ineffective when
Ag is bound to Ab.
Ag + Ag* + Ab < — > AgAb + Ag Ab
What happens to fluorescence when large Ag - goes up direct
ly proportional.
Fluorescein - fluoresces when light added to system luminol
produces light on own - no light to system.

Fluorescence Polarization Immunoassay (FPIA)
Ag + Ag* + Ab < — > AgAb + Ag* Ab
Ag* fluorescent labeled with a fluorophore when light at 485
nm (blue) hits fluorophore - raises it to an excited state (eouter shell) when returning to ground level (e- come back), a
different is emitted 525 - 550 hm (green).
How does it tell difference? B/W Ag* and Ag*Ab
Polarize the 485 nm blue light, THerefore absorption of the
blue light takes place on a single plane. But during emission
of green light, a rotation occurs or a depolarization and the
525 - 550 nm light is emitted on different plane.
But Ag* Ab hinders rotation B/W absorption and emission
preventing depolarization of green light. Green light emits
on the polarized plane so higher natural Ag, Lower the Ag*
Ab and lower the degree of polarized (green) light (inversely
proportional) degree of polarized light akin to radioactivity.
Advantages
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• Specificity, stability like RIA
• Can be automated, not labor intensive
Disadvantages
• Cost

Monoclonal Antibodies
Generally when inject antigen, animal immune system ac
tivates broad range of antibody secreting cells each cell
releases one molecular configuration antibody against an
tigen. Wind up with a mixed population of antibodies that
bind with differing affinities—call polyclonal antibodies.
Binding is also at different locations. This increases possible
cross reactions to substances with similar configurations to a
particular locations. To produce monoclonal antibodies, an
tibody secreting cells are fused with myeloma cells purpose:
faster division genetic material of myeloma cells—provides
the rapid division. Resulting “hybridomas” are separated
with special techniques into separate cell colonies which
produce only one antibody population.
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REVIEW
Section 1
1. List and describe the four types of homogeneous test
ing methodologies described in the chapter.

2. List and describe the advantages and disadvantages of
heterogeneous and homogeneous tests.

Section 2
1. Which blood testing technique os considered
heterogeneous?
a. florescence
b. enzyme
c. sandwich
d. RIA
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2. Enzyme immnno testing is the most common form of
blood sample testing because .
a. it’s cheap and not labor intense
b. of it’s sensitivity
c. of it’s reliability
d. it produces the fewest false negative results
e. all of the above
3. Enzyme testing

and

. RIA testing

and

.

a. results are a direct relationship between counts and
Ag
b. results are presented an indirect between counts and
Ag
c. high sensitivity, high specificity
d. not labor intensive
4. Two substances that may interfere with analysis of drug
testing are___
a. opiates, free T4
b. chlorine, salts
c. iodine and morphine
d. any of the two above
5. Which is not true of florescence blood sample testing?
a. absorbed florescence is polarized in blue light,
emitted in green light
b. emission of light is due to rotation of plane or
depolarization
c. high specificity, sensitivity and high cost
d. all of the above are true

IN VITRO N U C L E A R MEDICINE LABORATORY M A N U A L

APPENDIX C-131

Laboratory #1
Lab Safety & Pipetting Laboratory
SELECTING RADIOISOTOPE COUNTERS
In equipping a radioimmunoassay laboratory probably the most important piece
of equipment is the auto-gamma scintillation spectrometer. All of the assays per
formed will depend upon the reliability and efficiency of this instrument. Con
siderations involving the selection of a gamma counter include: (1) the number
of assays to be performed, (2) availability of service for the instrument, (3)
capability of the instrument (e.g., does it have a single pulse height analyzer or
more than one; does it have a rapid, clear printing system, etc.), and (4) the finan
cial resources of the laboratory. If beta counting is to be performed, a high
quality liquid scintillation system is mandatory.

THE LABORATORY FACILITY
As in any good laboratory, the RIA facility includes many components: adequate
lighting and counter space, abundant cabinet storage for chemicals and
glassware, convenient electrical outlets, a hood with an outside air escape (espe
cially working with volatile chemicals or pathogenic antigens), vacuum, air, and
gas sources, and a place for disposing of all radioactive waste.

G eneral Laboratory Equipment
An assortment of glassware consisting of beakers, graduated cylinders, and Erlenmeyer flasks, should be on hand. Additional equipment includes graduated
serologic pipettes (1,5, and 10 ml); Pasteur pipettes; test tubes, both glass and
plastic (polypropylene or polystyrene); and test tube racks.
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A triple beam balance is necessary for weighing chemicals and balancing tubes
for centrifugation. An analytical balance is occasionally required for certain as
says for more accurate weight determination. Three or four timers capable of
timing up to two hours are also useful. Magnetic stirrers and magnetic stirring
bars are necessary for complete mixing of the many different solutions in the as
says. A vortex mixer for test tube or vial mixing should also be available.
Many assays require careful regulation of the temperature; consequently, a water
bath capable of maintaining temperatures from 37° to 100°C should be available.
In addition to heat, ice is needed for a number of applications. Distilled water in
plentiful supply represents an integral part of preparing any buffer or solutions
needed in the assays.
A pH meter should be used to check the pH of many assay solutions. We recom
mend a pH meter with an expanded scale and single electrode.
A refrigerated centrifuge equipped with a horizontal head is the centrifuge of
choice.
A refrigerator and freezer must also be available for storage of reagents, sera, etc.

Specific RIA Equipment
Automatic pipettes with disposable tips capable of delivering accurate volumes
are required for all procedures (including commercial kits). The pipettes should
be available in the following sizes: 5,10,20,50,100,200,500,1,00 ul. Also
needed is an automatic jar type pipette that can deliver volumes of 1 to 10 ml.
This device allows the rapid delivery of known volumes of solutions used in the
assays. A relatively new type pipette is the automatic pipetting station. This in
strument was designed for high volume laboratories that perform very large num
bers of studies. While expensive, this type of instrument promotes a greater
degree of efficiency and reliability for the larger laboratory than is possible with
conventional pipettes.
A calculator is needed to compute the results of the different assays. Also, a
good bookkeeping system is critical. The receipt of the sample, the date of the
assay, and the result must be carefully recorded and available for immediate
retrieval.
Laboratory Safety and Pipetting problems with radiation safety include:
Personnel, monitoring, loss of data validity, and environmental pollution Of
these factors, the most prominent is lab contamination with radioactivity.
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Lab Facility & Selection of Equipment in R.I.A.
1.

2.
3.
4.
5.
6.
7.
8.
9.
10.

Gamma scintillation spectrometer (counter). All of the assays per
formed will depend upon the reliability and efficiency of this instru
ment.
Adequate lighting and counter space.
Adequate cabinet storage for chemicals and glassware.
Beakers, graduated cylinders and flasks.
Graduated serologic pipettes (1,5,10 ml), tubes, test racks.
Triple beam balance for weighing and balancing tubes in centrifuge.
Magnetic stirrers, vortex mixers.
Temperature controls — water baths, distilled H2O.
pH meter — check pH of many assay solutions.
Refrigerated centrifuge, refrigerator, and freezer to store reagents.

Specific R.I.A. Equipment
• Pipettes — 5 — 1,000 ul size.
• Automatic pipettes with huge volumes.
• Calculator to compute the results of different assays.

Contamination Control
1.
2.
3.
4.
5.*
6.

Limit amount of radioactive material to just amount needed.
Surfacing materials should be chosen with contamination control in
mind.
Areas designated for opening, transferring and handling radioactive
materials.
Removable absorbent material or non-absorbent easy to clean
material.
Wear lab coats.
No eating or drinking.

Personnel Monitoring—film badge or TLD may be required depending upon
type and amount of radioactive used.
Radioactive Material—Inventory, Storage, Disposal — all radioactive materials
require legal documentation of each isotope - received and disposed - monitor
ing of expiration date.

Storage of radioactive expired kits may become prohibitive due to long half lifes.
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The amount of activity that may be discharged into the sewage is restricted by the
amount per unit volume and by the total amount of activity per year. Each
isotope has its own specific limit.

Pipetting Laboratory
The purpose of this laboratory exercise is to allow students the opportunity to
practice with a variety of different pipettes. Students will be able to demonstrate
competence in their pipetting technique by the end of this lab.
1.
2.
3.
4.
5.

6.
7.
8.

Have students set-up racks of test tubes and number them 1-10.
Using various pipette sizes 10 ul - 200 ul students will practice pipet
ting H2O into various test tubes 1-10.
Students will visually inspect the test tubes to see if the amounts dis
pensed were similar from tube to tube.
Using tracer 1-125 from any R.I.A. test kit, have students set-up at
least 2 different sets of test tubes and number them 1-10 and 11-20
respectively.
Students will choose any two pipettes from the variety available size 10
ul - 200 ul and attempt to pipette equal amounts into each set of ten
then change pipette and dispense into next tubes 11-20.
Calculate C.V. for tubes 1-10.
Calculate C.V. for tubes 11-20.
Repeat until C.V. values are less than +/-10% .

Ex: Using pipettes 20 ul and 1-125 tracer and counting tubes in Gamma well
counter the follows counts are recorded;
•—

~ —

----- —

—

-------- - ' " - ' - 7

1.

10,551

coefficient of variance

2.

10,392

%C.V. = SD x 100

3.

11,001

4.

10,845

5.

10,782

6.

10,615

7.

10,432

8.

10,444

9.

10,681

10.

10,532

X
S.D. = (Xi- X)2
n- 1
n = total number of tubes used
X = X = 106,275 = 10,627.5 round to 10,628
n

10
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)2

10,551 - 10,628 = { - l l ) 2 = 5929
10,392- 10,628 = (-236)2 = 55,696
11,001 - 10,628 = (373)2 = 138,384
10,845 - 10,628 = (217)2 = 47,084
10,782-10,628 = (154)2 = 23,716
10,615 - 10,628 = (-13)2 = 169
10,432-10,628 = (-196)2 = 38,416
10,444 - 10,628 = (-184)2 = 33,856
10,681 - 10,628 = (53)2 = 2,809
10,532-10,628 = (-96)2 = 9216
355,275
S.D. = 355,275 = 198.6
9
Calculate C.V. % = 198.6 x 100 = 1.86%
10,628
This is the percent variance or deviation for all ten test tubes that were pipetted.
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Student Worksheet
1.

After pipetting a known volume into the first ten tubes 1-10, count in
gamma counter and record results.

2.

Calculate X =e X
n

3.

Calculate e (Xi - X)2

1.

2.
3.
4.
5.
6.

7.
8.

9.
10.
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4.

Calculate S.D. =

/J 2 & i2 Or
v
n -1

5.

Calculate % C.V. = _SyD. x 100
X
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Laboratory 2
Normal Distribution, Confidence
Intervals and Percent Error Laboratory
Data Given: 20 individual counts
1.

15,505 11.

17,981

2.

14,90112.

18,002

3.

13,876 13.

16,544

4.

19,351 14.

16,994

5.

18,41115.

15,456

6.

18,302 16.

17,893

7.

16,451 17.

16,543

8.

17,339 18.

15,988

9.

16,272 19.

16,901

10.

14,98120.

17,042

1.

Calculate X = e X =
n
2.
3.

Calculate +1-1 S.D. =
What is the range in counts for 68% confidence
Calculate + /-2 S .D . =
What is the range in counts for 95% confidence
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4.
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Calculate+ /-3 S.D . = ______
What Is the range in counts for 99% confidence_____

5.
6.

Is ct. number (3) 13.876 outside 3 S.D . = _______
Is ct. number (4) 19,351 outside 3 S.D . = ______
Why or why not?__________________________________

7.

How many cts. would be needed to be 99% confident and + /- 2%
error?
Show work_______________________________________

8.

If a source is counted provides 100 ct/sec, how long will you need to
count this source to be within 95% confidence and + /- 8% error?
Show work_____________________________________

9.

A source is counted in a nuclear medicine department during a
routine liver scan gives us 17,500 counts what is the % error?
Show all work_______________________________

10.

What percent confidence is necessary for research?
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Laboratory 3
Examining Principles and Procedures
for Reagents
The purpose of this laboratory exercise is to have students become familiar with
the component parts of a typical R.I.A booklet used in Nuclear Medicine.
In this laboratory, the student will use a booklet on an R.I.A. procedure common
ly performed in your lab (ex.: T4, T3, digoxin, Haa, Cortisol, etc.).
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.

What is the intended use of this kit?
Why is it important to know the level (quantity) in samples?
How does this blood level (T4, Digoxin, CEA, FSH, etc.) function in
the body?
What is the basic principle of this assay? Competitive or non-competi
tive?
List and describe each component in this test.
What supplies and materials are needed?
How do you prepare reagents?
Explain and describe the protocol used in this test?
What precautions (if any) need to be noted?
What are the quality control measures?
Limitations of test?
What is the (Ag), (Ab), standards, sample in test?
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Laboratory 4
Typical R.I.A. Testing
Competitive Protein Binding in most R.I.A. analysis testing is
considered to be competitive because the antigen (Ag), which is
either the patient unknown, standards, or controls, compete for
binding sites on the antibodies (Ab). This reaction takes place
in each test tube.
Let’s give an example of a typical R.I.A. test, outlining each
step and then, upon gaining an understanding of the process, the
student will attempt to develop a typical test and plot the
results obtained.

ffismsmsmss&ixsmimsi

P roced u re 1
Using the appropriate test tubes for a given test, label each tube 1 through 20
with a dark magic marker and place tubes into a test tube rack sets of two.
Tubes are set up in sets of two because each component is run in duplicate.
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Procedure 2
Set up a worksheet explaining which tubes correspond to which item or com
ponent, allowing space for values obtained after running the test.
For example:
Test tube # ’s

Component
*

I,2

total counts (Ag only)

3,4

NSB (non-specific binder from
manufacturer plus standard “0")

5,6

standard - “0" concentration

7,8

standard - 2.5 concentration

9,10

standard - 5.0 concentration

II,12

standard - 10.0 concentration

13,14

standard - 15.0 concentration

15,16

standard - 30.0 concentration

17,18

patient unknown (Mary Smith)

19,20

control A (high count rates)

21,22

control B - (low count rates)
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Resultant values:

The purpose of any R.I.A. test is to ascertain the value of the unknown or
patient, or Mary Smith in this case.

Procedure 3
Adding appropriate reagents: assume we are testing Mary Smith
for a T4 blood concentration level.
Pipette into test tubes 1 and 2 the appropriate amount of total counts from the
kit, let’s say 20ul.
Follow your worksheet and add the specified amounts of each standard (20ul) to
their corresponding tubes.
Add patient serum (20ul) to the appropriate tubes (15 and 16).
Add control A to tubes 17 and 18, and add control B to tubes 19 and 20.
*

Pipette Ag (radioactive antigen) to each test tube (1-20) in a given amount (100
ul for our purposes).
Now, pipette the Ab into each test tube (1-20) in a given amount (let’s say
200ul).
At this point, competition for binding sites on the Ab begins between either nonradioactive Ag, the NSB, standards, patient unknown, control and the radioactive
(usually 1-125), labeled ligand (Ag).
♦

Ag Ab

Ag

Ab
(either standard,
patient or control)

Ag

AgAb
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The higher the concentration of NSB, standards, patient or
control, the less the binding of 1-125 to the Ab binding sites.
Thus, when counting the radioactivity, there is an inverse
relationship between counts and concentration, which will be demonstrated
shortly.

Procedure 4
Incubation of reagents: allow the reaction to reach a state of
equilibrium (Ki - K2). Depending on the type of test performed,
this incubation may be at room temperature or may require heating
in water baths from, typically, 10 minutes to 2 hours.

Procedure 5
Centrifugation: this allows for binding to be completed and aids
in separation.
Procedure 6
Separation of bound from free: the results of the test are
obtained from counting the bound portion only. This is typically
done by decanting the reagents nor bound into a sink or toilet.

m^mmmmssssmsssm

Procedure 7
Count tubes in gamma well counter.
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P rocedure 8
Analyze resultant values: refer back to Mary Smith’s T4 test.
The manufacturer has sent known concentrations on components
refered to as the standards at various values and have also
supplied us with controls of known values.
If the normal values for a T4 patient is known, let’s say 5-20ug/dl, we can analyze
the results. After running the test,
assume the following data were obtained:
TEST TUBE COUNTS
1

25,404

2

24,355

3

21,456

4

20,596

5

19,347

6

19,562

7

16,322

8

16,848

9

13,471

10

13,484

11

10,958

12

11,651

13

8,945

14

8,886

15

6,842

16

6,731

17

1,785

18

1,698

19

15,421

20

15,822

COMPONENTS
total counts
rr
NSB
it
"0" concentration
tt
2.5 concentration
It
5.0 concentration
it
10.0 concentration
II
15.0 concentration
It
30.0 concentration
it
patient-Mary Smith
II
Control A (low)
tt
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21

7,345

22

7,269

Control B (high)

Plot the standard curve for the above:

concentration

counts
Interpolate the values for Mary Smith and controls A and B.
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Laboratory 5
R.LA. LABORATORY
Running and Analyzing Resultant Values for
Common R.LA. Tests
1.

This lab should be run at least 2 different times by stu
dents.
Set up worksheet including all components in assay listed in packet in
sert, such as: (see typical R.I.A. testing LAB for example)
total counts, NSB, B0, all standards, controls and patient unknowns
Do all test tubes in duplicates. For example:
COMPONENT

TEST TUBE #

total counts

1,2

NSB

3,4

Bo

5,6

standard 1

7,8

etc ...
2.

Perform test as described in packet insert in test kit.

3.

Count tubes in gamma well counter.
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4.

Plot counts received vs. known concentration of standard on graph
paper.

counts
received
in test

concentration of assay
5.

Interpolate resultant values for controls and patient unknowns in
graph on original worksheet.
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WORKSHEET
TUBE #

1

2
3
4
5
6
7
8
9
10

11
12
13
14
15
16
17
18
19
20
21

22
23
24
25
26

COMPONENT

COUNTS

INTERPOLATED RESULTS
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A Typical R.I.A. Procedure Protocol
T H C used as an example

Details of th e P rocedure
A standard curve must be constructed for each set of unknowns assayed. Follow
the order of the steps exactly.
1.
2.

3.
4.
5.
6.
7.
8.
9.
10.

11.
12.

Label and arrange the assay tubes according to the assay protocol
shown in Table 2.
Dilute the 125I-THC derivative with BSA buffer (1:50) according to the
instructions for dilution of tracer. Add 200ul working tracer to the
total count tubes, stopper and set them aside for counting at the com
pletion of the assay.
Add 50ul cannabinoid standard to the correspondingly numbered
tubes. Note that the Ong/ml standard is dispensed into the NSB and
zero standard tubes.
Add 50ul of the urine low control and high control to the correspond
ingly numbered tubes.
Add 50ul of the urine samples to their correspondingly numbered
tubes.
Add lOOul of the BSA buffer to the NSB tubes.
Add lOOul of the THC antibody to all assay tubes (do not addantibody
to NSB tubes).
To each assay tube add 200ul of the working tracer solution.
Add 200ul of second antibody complex to all tubes (mix the second an
tibody well before use).
Gently vortex mix all tubes and incubate the entire assay for 15
minutes at room temperature (25°C). The assay rack may be covered
with Parafilm (optional). Avoid incubating in direct sunlight.
Centrifuge the assay tubes at 2500g for 15 minutes.
Replace the assay tubes in their rack. Aspirate the supernatant fluid
taking care not to disturb the pellet (See Note 3). Count all assay
tubes in a gamma counter for at least one minute per tube.
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Laboratory 6
Equipment Performance Evaluation
Laboratory
There are three basic ways of analyzing your gamma counter’s effectiveness and
unbiasness of results.
1.
2.
3.

Chi-square test (checks for reliability of counter)
Efficiency (checks for sensitivity of instrument)
Background check (rules out contamination)

A test that is performed to ensure that variation from a series of individual
counts are likely to be due to random nature of radioactive decay and not by
other influences.

Parti
Using a single source (T-l/2 many wks) 1-125
1.
2.
3.
4.
5.

count a series of 1 min cts
count this same sample 20X
Place values in appropriate spaces
Calculate Chi-square value
Compare to tabulated results
Is instrument reliable?
Why or why not?

This set of data of different counts are compared to the theoretical variation that
one would expect from random sampling.
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Chi-square test*2 = e ( X - X ) 2
X
compared calculated result to tabulated (P) values
(P) value should be around (.5) must fell between .1-.9 or equipment is considered faulty.

DATA FROM COUNTING 1-123 SOURCE 20 TIMES
1.

11.

2.

12.

3.

13.

4.

14.

5.

15.

6.

16.

7.

17.

8.

18.

9.

19.

10.

20.

Part 2
Another way to analyze equipment is by calculating the efficiency.
This is performed by comparing the number of counts registered to the number
of potentially effective emissions from the source.
CPM
DPM

1.

=

Counts per/min
disintegrations per/min

Take a known NBS standard source CS-137,50-60, calculate the DPM
based on its decay.
1 curie = 3.7 x 101°dps

1 curie = 22 x 1012dpm
show all work
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2.

3.
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Count the source in the well-counter 10 times for 1 min each and
record data.
1.

6.

2.

7.

3.

8.

4.

9.

5.

10,

Based on the average X of these count rates/min calculate:
CPM for this gamma well counter
DPM
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Laboratory 7
Laboratory Worksheet for Indium-111
Labeled for Leukocytes
I.
Patient information: (Patient should not be dehydrated)
Date:___________________
Hospital:_____________________
Patient Name:_________________
Indium Rx #:
WBC Count:

n.
Radiopharmaceutical preparation: Check off each step as completed.
1. Time blood was drawn:_____ Volume of blood drawn:_____mis 50ml.
2. Plasma volume after separation: ____ mis (Approx. 251m, Need at
least 15ml)(10cc HESPAN if needed after 30min, Doctors Cons.)
3. Centrifugation for 5 minutes at 400-450g (setting 70
WBC button from supemate.
4. Draw off platelet-rich plasma (PRP) and save.
5. Saline wash: Wash button with 3mls of saline. Centrifuge for ap
proximately 5 minutes at 400-45Og. Draw off wash and discard.

) and separate
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6. Reconstitute the WBC button using approximately 3mls of saline.
Break up button with needle.
7. Activity added to button:

uci Assay time__

8. Total incubation time:______
9. Centrifuge PRP for 10 minutes at lOOOg (setting_____ 90 ) Yielding
PPP top layer.
10. Plasma wash 2-5mis of PPP from top layer. Let stand for 5 minutes.
11. Centrifugation at 400-450g for five minutes. Draw off hot supemate
and save.
12. Resuspend button with 4mls of plasma (PPP top).
13. Assay of hot supemate and discard:_____ uci.
14. Assay of WBC button:_____uci.
15. Labeling efficiency of In-111 labeled WBC:
(14)________ / (7)________ x 100 = ________
____________ time
____________uci
ml
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Laboratory 8
Linearity Testing in R.I.A. Procedures
RIA/THC LAB
*
note this lab exercise utilizes a THC kit, which is commonly used in RIA labs,
but any other kit can be substituted.
sm&m&mmsmm

Introduction
The basic purpose of this lab is to study serial dilution linearity of natural human
urine containing cannabinoid metabolites (primarily 11-NOR-D -THC-9-CARBOXYLIC ACID). There is evidence showing that some urine specimens con
taining cannabinoid metabolites do not maintain a linear response to RIA
activity upon serial dilution, while others do. The reason for this is unclear. Pos
sible explanations include solubility changes influenced by the amount of protein
present, or the presence of an interfering substance which becomes more
pronounced with decreasing concentrations of antigen. As this lab develops,
depending on results, these, and other possible influences, will be explored.
m m m m m m m m ztm m

Basic Procedure
Dilute a urine specimen containing between 100 and 200 ng/ml THC metabolite:
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URINE

DILUTANT

TOTAL VOLUME

1:2

200ul

200ul

400ul

1:4

lOOul

300ul

400ul

1:6

lOOul

500ul

600ul

1:9

50ul

400ul

450ul

1:11

50ul

500ul

550ul

1:16

20ul

300ul

320ul

1:21

20ul

400ul

420ul

Using (1) water, (2) negative natural urine, (3) negative synthetic urine. Com
pare results. This needs to be preformed on several different urine samples.
For values between 200 and 400 ng/ml
URINE

DILUTANT TOTAL VOLUME

20ul

600ul

4
6
9
11

16
21
31

For values between 400 and 800 ng/ml
9
11

16
21
31
42

dilute

1:21, 1:2

62

dilute

1:31, 1:2

620ul
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Construct curves to determine linearity. In particular, point where linearity
begins to deviate should be noted. In addition, any consistency in holding to, or
deviating from linearity should be recorded.
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Laboratory 9
Effects of Time on R.IA . Testing
Procedures
RIA/THC LAB II
Introduction
It is well known in RIA testing that time is a critical parameter in the outcome of
the analysis. This fact becomes crucial when considering the workup itself involv
ing adding reagents in a sequential fashion. The purpose of this lab is to deter
mine the total effect of time difference between the front and end of the assay
on the final results. Only the calibrators and controls contained in the THC kit
are needed.

Basic Procedure
The high and low controls are to be compared by running two sets (everything in
duplicate including calibrators, therefore one set of high and low controls equals
4 tubes) per assay - one before and one after the calibrators. Since there are
seven calibrators, each assay will have 18 tubes (19 with total tube). One high
and low control set will assume the positions for unknown samples during count
ing.
Following package insert, add all reagents as readily as possible recording time.
Repeat, but doubling the time for adding reagents. Repeat again doubling once
more. Compare values calculated for the high and low controls at the beginning
and end of the assay.
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Repeat the above procedure adding isotope first, 2nd antibody second, and 1st
antibody last. Compare.
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Laboratory 10
Altering the Standard Curve
RIA/THC LAB III
Introduction
The proportions of reagents added in the THC assay according to the package in
sert are calculated to provide the most beneficial curve between the highest
(100) and lowest (0) calibrators. It is possible, however, to alter the curve by
changing reagent and sample ratios. Occasionally, it is desirable to make such an
alteration. For instance, when assaying a sample containing THC metabolite
above the range of the curve, you could dilute the sample to fit the curve, or you
could alter the curve to fit the sample.
msmmmmmsmststmsmsst

Basic P ro ced u re
Using calibrators only, using the package insert proportions as a base, run the fol
lowing assays with the indicated changes in reagents or calibrators. You should
have already ran a normal curve for comparison. Everything in duplicate. P =
package insert.

Page 162

IN VITRO NUCLEAR MEDICINE LABORATORY M A N U A L

CALIBRATOR

1ST ANTIBODY

ISOTOPE

2ND ANTIBODY

X2

P

P

P

X4

P

P

P

P

X2

P

P

P

X2

X2

P

P

P

X2

P

P

X4

X4

P

P

P

P

X2

P

X4

X4

X4

Additional changes may be tried as stimulated by above results.
Compare and explain variations of curves. Which assay could be used to deter
mine a higher level which normally would have to be diluted? Which assay
would be more sensitive to low levels?
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Laboratory 11
Plasma Volume
S -S SS S53& 838S8K S 8

P urpo se
Plasma volume studies are a great asset in treating patients suffering from con
gestive heart failure, nephrosis, cirrhosis, polycythemia, and the anemias. It is
especially useful when doing serial studies on patients in whom large blood los
ses and blood replacements are apt to occur.

Rationale
The radioiodinated human serum albumin being a protein, travels solely with the
proteins in the plasma.

D osage and Radiation
The dosage of 10 c of ratioiodinated human serum albumin is so small that the
total radiation dose is approximately 0.2 rads. In the case of a daily serial study,
the doses run 10 uc on the first day, with 20 uc on the second day, and 40 uc on
the third day. The increased dosage is necessary because it is essential that the
patient’s sample count be at least twice background. This dosage increase in
sures adequate counting statistics.

Patient Preparation
None.
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Material and Equipment
1.
2.

Human semm albumin
Syringes
a.

I'll

I (IHSA) — 15 microcuries

= 20ml. (1)

b. 10ml. (3)
3.
4.
5.
6.
7.
8.

Needles - 20 gauge
Timer
Microhematocrit and capillary tubes
Centrifuge - capable of spinning 10 ml.samples at 2000 rpm.
Pipettes - 3 ml. (3)
Test Tubes
a. glass (3) 13 mm
b. plastic (3) 13 mm

9.

Scintillation well counter

PROCEDURE
1.
2.
3.
4.

5.
6.
7.
8.
.9.

Obtain patient’s weight and height.
Dilute 15 uc ^ I IHSA in a 30 ml. saline vial to which has been added
1 ml. or 0.5 mg. human semm albumin.
Withdraw 20 ml. and count the activity in the syringe at a fixed dis
tance above the well with the analyzer set at 150 Kev to infinity.
If the patient had any previous isotope procedure, draw 10 ml. of
whole blood in a heparinized tube as a control. Inject 20 ml. of diluted
IHSA into the patient.
Withdraw 10 ml. of venous blood at 10 and 15 minutes post injection
from opposite arm not receiving transfusion.
Count the empty m I IHSA syringe.
Do hematocrit on both patient samples.
Centrifuge the samples for 15 minutes at 2000 rpm.
Pipette 3 ml. of plasma from both 10 and 15 minute samples and count
the radioactivity in the well using setting in step. Record the back
ground.
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CALCULATIONS
Total plasma activity is equal to counts before injection minus counts after injec
tion times the distance factor. NOTE: (Distance factor utilizes the inverse
square law whereby the syringe is counted a certain distance from the crystal and
the counts are decreased by a fixed and known amount). If a distance factor is
not extablished, simply dilute 1 ml. of the remaining 10 ml. saline solution mix
ture to 100 ml. Pipette 1 ml. of the dilution and count in the well.
Plasma volume = Net Standard Count x Dilution
Net Sample Count/ml
Whole Blood volume = Plasma Volume
l-(H ct x 0.91)
Red cell mass - Whole Blood volume - Plasma volume
Express all values as cc per wt. in kg.
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Laboratory 11
51Cr RED CELL MASS
PURPOSE
Blood volume studies are a great asset in treating patients suffering from conges
tive heart failure, nephrosis, cirrhosis, polycythemia and anemias. It is also used
to follow the status of the patient who has had open heart surgery and other
major surgery with associated large blood loss and replacement.

RATIONALE
51

Cr as sodium chromate is present in the hexavalent ( + 6) state and readily
penetrates the red cell to attach to the hemoglobin where it is reduced to the
trivalent (+ 3 ) state.

MATERIAL AND EQUIPMENT
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.

A-C-D (Strumia formula) solution
Socium chromate (51Cr) - 60 microcuries
Syringes - 50 cc (2), 10 cc (2)
Needles - 18 gauge, 20 gauge
Hematocrit tubes
Test tubes (8)
Volumetric flasks - 100 cc (2)
Heparin solution - 1000 USP units per cc
Timer
Centrifuge
Tourniquet
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12.
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Scintillation well counter

PROCEDURE
1.
2.
3.
4.

5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.

Obtain patient’s weight and height.
Withdraw the 10 ml. of Strumia formula ACD solution into a 50 ml.
syringe.
Into the same syringe, draw 40 ml. of whole blood to make a total
volume of 50 ml.
Expel the entire syringe contents back into the tagging vial. U se an 18
gauge needle to avoid hemolysis and have a 20 guage needle for an air
way.
Add 60 uc Na2 51Cr 0 4 to the vial and let stand at room temperature
for 15 minutes with occasional mixing every 2-3 minutes.
Withdraw 40 ml. from the mixture and weigh the capped syringe. The
remaining 10 ml. will be used as the standard.
If the patient had any previous isotope procedure, withdraw 15 ml. of
whole blood as a background control.
Have physician inject the tagged blood back into the patient.
At 10 and 15 minutes post injection, withdraw 15 ml. whole blood from
the contralateral arm into a heparinized syringe.
Do hematocrit on both patient and sample and on standard.
Pipette 3 ml. whole blood from each patient sample.
Pipette 1 ml. of whole blood standard and dilute to 100 ml. with dis
tilled water. Pipette 3 ml. of this dilution for counting.
Centrifuge standard and both patient’s samples for 15 minutes at 2000
rpm.
Pipette 3 ml. plasma from each patient sample.
Pipette 1 ml. of plasma standard and dilute to 100 ml. with distilled
water. Pipette 3 ml. of this dilution for counting.
Count all samples in a scintillation well-type counter and record the
background.

CALCULATIONS
Red Cell Mass =
Where:
a. Standard whole blood count
b. Standard plasma count
c. Hematocrit of the standard
d. Patient’s whole blood count
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e. Patient’s plasma count
f. Patient’s hematocrit
Vwbi. Volume of whole blood injected
Whole Blood Volume = Red Cell Mass
Pt. hct x 0.9.18
Plasma volume = Whole Blood volume - Red Cell Mass.

IN VITRO NUCLEAR MEDICINE LABORATORY M A N U A L

APPENDIX C-169

Laboratory 11
Principle of Dilution Laboratory Exercise
Q = VxC_or V = Q/C
Q = total quantity of tracer
Formulas

C = tracer concentration in diluting fluid
V = diluting volume
V1C1 = V2C2

In calculating blood volumes if either plasma volume or red cell volume is deter
mined, the total blood volume can be calculated with the aid of hematocrit.

PLASMA VOLUME = Net standard counts x dilution
Net sample counts/ml
WHOLE BLOOD VOLUME = Plasma volume
(1-HcL x 0.91)
OR
Red blood cell volume
(hematocrit x 0.01)
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EXAMPLE:

15uCi of 1-125 HSA in a 10ml syringe = 15uCi
10ml

This material is then tagged to patient’s plasma and reinjected into the
individual’s arm. Fifteen minutes later, 10ml of blood is withdrawn from patient.
Activity is calculated as:
0.023uCi
10ml
Substitute known values into dilution equation:
V1C1 = V2C2
0.023uCi

15uCi

V2( 10ml )

(10ml)( 10ml)

15uCi = 0.0023V2
So, patient’s plasma volume = 6521ml (this is V2)
Normal plasma volum = 43 ml/kilogram of body weight
Calculated hematocrit = 49%
Whole blood volume = 6.5 liters = 11.81 liters of blood
(1 - .49 x 0.91)
Students will calculate blood volumes on the following patients:
1.

patient’s weight = 92kg
VI = 15ml
C l = lOuCi (use 1-131 HSA for plasma determination)
15ml
C2 = 0.035uCi
15ml
hematocrit = 0.41
PATIENT’S BLOOD VOLUME________ Is patient normal?
Why or why not? SHOW ALL WORK...

2.

patient’s weight = 117kg
VI = 10ml
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C l = lOuCi
10ml
C2 = 0.078uCi
10ml
hematocrit = 0.56
PATIENT’S BLOOD VOLUME
Why or why not? SHOW ALL WORK.

Is patient normal?
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Laboratory 12
SCHILLING
Purpose
To determine the ability to absorb Vitamin B12.

Rationale
Oral Vitamin B 12 combines with a small polypeptide in the gastric juice. This
polypeptide is secreted by the parietal cells of the gastric mucosa, and usually is
referred to as Intrinsic Factor. The Intrinsic Factor combines with Vitamin B 12,
the complex is later absorbed as it passes into the ileum portion of the small in
testine. Diseases such as Pernicious Anemia, total Gastrectomy, and even some
subtotal gastrectomized patients have a deficient Intrinsic Factor secretion and
will fail to absorb Vitamin B 12 in the ileum. Other gastrointestinal disease such
as spme, tuberculosis of the ileum, regional ileitis, lymphomatous infiltration of
the ileum, may also show failure to absorb Vitamin B 12. Blind loops caused by
Billroth I procedure or multiple small intestinal diverticuli absorb Vitamin B 12
because of preutilization by resident blind loop bacteria. Administration of
broad spectrum antibiotics will kill the bacteria and correct this condition there
by causing normal Vitamin B 12 absorption. Short circuiting procedures or fistula
formation causing bypassing of the ileum as well as severe diarrheal states will
also have defective Vitamin B12 absorption.
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Oral Vitamin B12 Absorption
B12 with
State_______ B12 alone_________ Int. Factor
Normal

+

P.A.; Gastrectomy

-

Blind Loop

-

Disease of Ileum

-

Sprue

+ /-

After
Antibiotics

+
-

+

Gastro-colic Fistula

Patient Preparation
The patient is to be in an overnight fasting state from solid food, liquids are al
lowable. He is then instructed to abstain from solid foods for the next four
hours, coffee and water are permissible. In the case of diabetics, coffee, toast,
and jelly are allowable one hour after the onset of the procedure.

Material and Equipment
1.
2.
3.
4.

Cyanocobalamin Injection (Vitamin B 12) — 1000 ugm/cc
Cyanocobalamin (5 Co or Co) — 0.5 microcuries
Reference Standard (57Co or ^C o) — 1:50 dilution of 0.5 microcuries.
Gallon jug

Procedure
1.
2.
3.

Administer the cobalt-labeled cyanocobalamin capsule to the fasting
patient with water.
Inject 1 cc. (1000 micrograms) of non-radioactive Vitamin B 12 in
tramuscularly immediately following the ingestion of the capsule.
Instruct the patient to remain fasting for four hours and to collect all
of the urine excreted during the following 24 hours.
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Urine Calculations
1.

Measure the 24-hour urine volume and pipette a 20 cc. aliquot for
counting.
Pipette 1 cc. of standard and dilute to 20 cc. This is equal to 2% of the
administered dose, or 1/50 of the standard.
Count the urine aliquot and standard in the well for three minutes.
Determine a background count.

2.
3.

Total volume
% = (cpm in patient’s sample - Bkgd) x
20
x 100
(cpm in standard sample - Bkgd) x 50

SCHILLINGS TEST FOR VITAMIN B-12
EXCRETION
Using the formula:
Vitamin B-12 % uptake

=
CPM in pt.
CPM in standard
sample

total vol.
- bkgd. x 20
bkgd.x 50

Normal value = greater than 7%
Example:
CPM in pt.

= 65,360

Bkgd.

= 9,520

Total volume = 1600 cc.
CPM in standard
sample = 62,335
CPM in
pt.
CPM in
std.

% Excretion = 14.5%
Pt. is normal for B-12

65,360

62,335

-

bkgd. 9,521

total volume
x 1600 cc.
20
X100

bkgd. 9,526

X

50

x 100
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LABORATORY EXERCISE FOR SCHILLING
TEST EVALUATION
1.
2.

Each student will properly calculate the % of Vitamin B -12 from the
two (2) sets of data given.
Each student will then provide a diagnosis based on values obtained
from each pt’s data.

P t #1

P h ase II

Data collected using Intrinsic Factor

Vitamin B-12 % uptake

=
CPM in p t
CPM in standard
sample

CPM in pt. 1 = 10,351
Bkgd.

=

105

Total volume = 1200 cc.
CPMinstd.

= 140052

% ofvitam inB-12is =
Diagnosis

=

total vol.
- bkgd. x 20
- bkgd. x 50

x 100
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Pt. # 2
Data collected in Phase I using Intrinsic Factor
CPM in pt. 2 =

1,005

Total volume =

1800 cc.

CPM in std.

= 37,562 cc.

Bkgd.

= 501

% of vitamin B-12 is =
Diagnosis

=

IN VITRO NUCLEAR MEDICINE LABORATORY M A N U A L

Answer Key to Questions
Chapter 1
Section 1
1.
J
2.
F
3.
H
4.
I
5.
E
6.
G
7.
B
8. C
9.
D
10. A

Section 3
1.
C
2.
D
C
3.
D
4.
5.
D
6.
C
C
7.
8. D
9.
D
10 C
11. D
12. A
13. A
14. A
15. B
16. C
17. C

Section^
1.
2.
3.
4.
5.
6.
7.

F
F
T
T
F
T
F

.

Chapter 2
Section l Section 2
F
1.
B
1.
D
2. T
2.
3.
A
3. T
4.
F
4.
A
F
5.
D
5.
6. T
7.
F
Chapter 4
Section 2
1.
C
2.
B
3.
11.1 Sec
4.
B
5.
C
Chapter 6
7.
F
1.
F
8.
F
2.
E
9.
F
3.
B
10. F
4.
T
5.
T
11. T
6.
T

T
8.
9.
F
10. T
11. F
12. F
13. F
14. F
Chapter 5
Section 2
D
1.
2.
E
C
3.
D
4.

12.
13.
14.
15.

Chapter 3
Section 2
SSCCtionJl
C
T
1.
1.
2.
D
2.
T
3.
C
3.
F
4.
F
E
4.
5.
D
5.
F
6.
D
7.
B

Section 3
1.
F
F
2.
T
3.
F
4.
5.
F
Chapter 7
B
6.
F
1.
7.
2.
D
T
8.
F ' 3.
B
9.
4.
B
T
10.
5.
C

C
B
C
D
D

11.
12.
13.
14.
15.

B
C
A
B
C

16.C
17A.
18.D
19.C
20.A
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Chapter 8
Section 1 Section.2
1.
B
1.
B
A
2.
B
2.
3.
C 3.
A
4.
B
14.
15.
5. A
6. A
16.
17.
7.
E
8.
E
18.
19.
9.
D
10. A
20.
Section-2
1.
F
11. T
T
12. F
2.
13. T
3.
T
14. F
4.
F
5.
T
15. T
6.
F
16. F
7.
17. T
T
8.
T
18. F
19. T
9.
F
10. T
20. T
Chatper 9
1.
2.
3.
4.
5.

D
A
A,B
B
D

11.
12.
13.
B
B
A
B
C
C
A

B
A
B
24.
25.
26.
27.
28.
29.
30.

21.
22.

T
T

21.
22.
23.
B
C
B
B
C
C
D

B
A
D
34.
35.
36.
37.
38.
39.
40.

31.
32.
33.
B
C
A
C
D
C
B

A
B
B
44.
45.
46.
47.
48.
49.
50.

41.
42.
43.
D
A
D
B
A
A
B

B S1.A
D 52.D
A 53.A
54.C
55-A
56.B
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BASIC RIA VOCABULARY LIST
ACCURACY

H Closeness to true or real value.

AFFINITY

H Strength (energy) of binding to the receptor.

ANALYTE

a The patient sample.

ANTIGEN (Ab)

a A protein formed as part of an immunologic
response to foreign substance.

ANTIGEN (Ag)

h

ANTISERUM

H Serum form an im m une animal (contains various
antibodies).

AVIDITY

n Measure of the strength of the bound Ag.

CONTROLS

** May be a standard or any known concentration
of testing material that serves as a comparison
between successive test runs.

CROSS
REACTIVITY

53 Similar structured Ag that interfere with analysis
of a given assay.

EQUILIBRIUM
SATURATION

H Competition between labeled and unlabeled
ligand is allowed to occur simultaneously until
equilibrium is reached between the ligand and
the binder.

FREUD’S
ADJUVANT

** An emulsifier that enhances the immune
response and allows for slow absorption into an
animals system when producing antiserum.

HAPTEN

a A substance that is not immunogenic in itself,
but becomes immunogenic when complexed
with another compound.

HEMATOCRIT

b

IMMUNOGEN

H A substance capable of inducing an immune
response.

IMMUNO
GLOBULINS

H A group of serum proteins (antibodies) that
specifically bind the antigens (Ag).

A substance capable of including formation of
antibodies.

formed elements
whole blood
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LIGAND

a The substance that is bound.

NON-SPECIFIC
BINDING

a

When labeled Ag and Ag free serum (without
Ab’s) are put into the same test tubes.

PRECISION

a

Degree of agreement of repeated measurement
of a quantity (usually expressed as coefficient of
variance).

QUALITY
CONTROL

a

Ensure that the results of assays are reliable and
representative of true concentrations.

RADIOIMMUNOASSAY

a

Radioligand assay in which the receptor is an an
tibody.

RECEPTOR

«

A substance (protein) that specifically binds a
certain compound (ligand).

SENSITIVITY

a

Minimum quantity detectable.

SPECIFIC ACTIVITY «

Activity, usually expressed as uci
mass
g

SPECIFIC GRAVITY «

Materials whose weights are being compared to
that of water.

SPECIFICITY

a

Capacity to discriminate antigens of similar struc
ture.

STANDARD

a

A substance that is added to certain reference
tubes to serve as a yardstick for quantitation of
the contents.

STANDARD CURVE a A curve of dilutions of known amounts of sub
stances to which the unknown may be compared.
TITER

a

Measurement of antibody concentration - the
dilution of antiserum that will bind 50% of
added radioligand.

